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Abstract
RNA interference (RNAi) provides a specific and efficient way to silence gene expression; 
therefore, it is an attractive tool to be used in basic research on gene function as well as 
gene therapy. Despite the enormous potential of RNAi, delivering the  small interfering 
RNA (siRNA) to the cells is one of the main hurdles. Previously there have been reports 
showing effective plasmid DNA delivery to cells and such systems could be used to deliver 
siRNA to cells due to the similarity of the delivery criteria between plasmid DNA and 
siRNA. Therefore, I hypothesise that a successful siRNA delivery system will have similar 
biophysical characteristics as a successful DNA delivery system. The aim of this study is to 
identify  the  important  criteria  to  establish  a  promising  siRNA  delivery  system  by 
comparing the criteria of successful DNA delivery systems such as linear and branched 
polylysines and linear and branched PEIs.
In order to deliver nucleic acid to a cell, a vector system should be able to bind and form a 
positively surface-charged nano-sized complex with the nucleic acid for cellular binding 
and uptake. Inside the cell, the vector should be able to dissociate from the nucleic acid for 
gene expression or silencing. Therefore, the important parameters to investigate are the 
binding and dissociation properties of the vector components to the nucleic acid and the 
size and surface charge of the complex. From the results, generally all the polylysines and 
PEIs can bind, dissociate and form a positively charged nano-particle with plasmid DNA, 
which can mediate gene expression. Despite the ability of all the polylysines and PEIs to 
bind to and dissociate from siRNA, only branched polylysines, linear and branched PEI, 4
but not linear polylysines can form positively charged nano-particles with siRNA. Indeed, 
branched PEI behaves similarly towards siRNA and DNA biophysically. Interestingly, only 
branched  PEI  and  siRNA  complexes  can  mediate  cellular uptake  and  60%  target  gene 
knockdown. Branched polylysines or linear PEI siRNA complexes cannot mediate gene 
silencing in spite of the formation of positively charged nano-particles. This could be due to 
poor cellular uptake of these complexes or degradation of siRNA upon uptake. Therefore, 
to improve the design of the siRNA vector system, there is a need to research the cellular 
binding and uptake of siRNA complexes in the future.     5
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Chapter 1
Introduction33
1.1 Gene silencing technology
Gene  silencing  technology  provides  an  attractive  route  for  disease  associated  gene 
identification and treatment. Since the completion of the Human Genome Project, many
potential new drug targets await discovery (Hopkins & Groom 2002). However, it is a main 
hurdle to the translation of genomic information into drug development. To validate gene 
products which are functionally involved in a disease and the therapeutic effect of silencing 
these gene products, ribozymes and antisense oligonucleotides have been used to target 
specific mRNA (Leung & Whittaker 2005). So far, only a single antisense oligonucleotide
has  been  developed  to  a  therapeutic  product,  Vitravene®,  for  the  treatment  of
cytomegalovirus-induced retinitis (Winkler 2004). RNA interference (RNAi) is the latest 
discovery in this field. Since the discovery of double stranded RNA mediated sequence 
specific gene silencing, RNAi was named as the greatest scientific breakthrough in 2002 by 
Science magazine (Couzin 2002). The original discovery of this mechanism was awarded 
with  the Nobel  Prize  in  Physiology  or  Medicine  in  2006,  reflecting  its  importance  in 
scientific and medical research. In this section, the background, biology and application of 
RNAi  are  discussed.  The  antisense  oligonucleotide  and  ribozyme  technologies  are  also 
discussed, and are compared with RNAi.34
1.1.1 RNA interference
1.1.1.1 History of the RNA mediated gene silencing discovery
RNA mediated gene silencing was first reported in the early 1990s in a study to improve 
the  colouring  of  petunia  flowers.  Researchers  introduced  mRNA  encoding  chalcone 
synthase  (CHS),  an  enzyme  for  petunia  pigmentation,  into  normal  petunia  flower  to 
enhance the colouring. Unexpectedly, the petunias became either fully or partially white. It 
was observed that the mRNA expression of CHS was reduced when both the endogenous 
and introduced CHS genes were present. The mechanism was unknown and the observation 
was  termed  “co-suppression” (Napoli  et  al.  1990).  Further  study  found  that  the  co-
suppression effect was associated with an increased mRNA turnover (van Blokland et al.  
1994). Similar phenomena were observed in the fungus Neurospora crassa (Romano & 
Macino 1992) and in Drosophila (Pal-Bhadra et al. 1997).
A similar paradoxical  phenomenon was observed in a study on par-1  gene function in 
Caenorhabditis elegans (C. elegans). In this study, antisense RNA was used to silence the 
par-1  gene  expression;  interestingly,  the  sense  RNA  control  produced  an  identical 
phenotype  as  the  antisense  RNA.  The  entire  mechanism  of  this  silencing  remained 
unknown (Guo & Kemphues 1995).   
In 1997,  research  on viral disease resistance  in plants  showed a  similar gene silencing 
observation. It was found that plants containing short and non-coding regions of viral RNA 35
sequences mediated enhanced resistance to viral infection (Covey et al. 1997). In a related 
study, it  was shown that viral gene  expression was suppressed in infected plants when 
viruses were engineered to carry short sequences of plant genes. This phenomenon was 
termed “virus-induced  gene  silencing” (Ratcliff  et  al.  1997).  All  of  the  gene  silencing 
observations were named “post transcriptional gene silencing” (Cogoni & Macino 2000;
Hammond et al. 2001). 
In 1998, the mechanism of the RNA induced gene silencing was discovered in a C. elegans
model by Craig Mello, Andrew Fire and co-workers. In this study, it was observed that 
either sense mRNA or antisense mRNA induced modest gene silencing effects; however, 
double  stranded  RNA  mediated  potent  gene  target  silencing (Fire  et  al.  1998).  This 
phenomenon  was  termed  “RNAi”  and  this  study  was  awarded  the  Nobel  Prize  in 
Physiology or Medicine in 2006.
1.1.1.2 RNAi mechanism 
RNAi is observed to occur in most of the eukaryotic cells, from protists to plants and 
animals.  The RNAi mechanism is a highly evolutionary conserved pathway. This pathway 
has  been  identified  to  play  an  important  in  regulating  gene  expression  and  defence 
responses against transposable elements and viruses (Cerutti & Casas-Mollano 2006).   
RNAi commences when a double stranded RNA is firstly cleaved into a small interfering 
RNA  (siRNA),  a  double  stranded  21-23  nucleotide  product  with  two-nucleotide  3’ 36
overhangs and 5'-phosphorylated ends, by a Dicer complex in the cytoplasm (Figure 1.1)
(Bernstein  et  al.  2001;Vermeulen  et  al.  2005;Zamore  et  al.  2000). The  siRNA  is  then 
incorporated into a mutlicomponent nuclease complex to form the RNA-induced silencing 
complex  (RISC).  In  RISC,  a  catalytically  active  endonuclease  called  argonaute  protein
binds to siRNA and degrades one strand of the siRNA, the anti-guide stand or passenger 
strand, leaving the guide strand intact to direct gene silencing (Gregory et al. 2005). The 
guide strand tends to have a less stable 5’ end than the passenger strand (Preall et al. 2006). 
The more stable 5’ end of the passenger strand may be bound by R2D2 protein, a protein 
that aids siRNA binding into the RISC, differentiating it from the guide strand (Tomari et 
al. 2004). 
To mediate target mRNA cleavage, it was found that the phosphorylated 5' end of the guide 
RNA binds to a conserved basic pocket in the PIWI domain of the argonaute protein. The 
first nucleotide  at the 5'  end of  the  guide RNA binds  to  a  conserved  tyrosine  residue, 
leaving the successive nucleotides of the guide strand available as a nucleation site for 
pairing with target mRNA for cleavage (Ma  et al. 2005). Target mRNA cleavage then 
occurs at a position between nucleotides 10 and 11 relative to the 5’ end of the guide strand
(Rand et al. 2005). The activated RISC complex is then recycled and targets other mRNA 
(Hutvagner & Zamore 2002).
There is evidence that the target mRNA cleavage initiated by siRNA could occur in a 
specific  region  of  the  cytoplasm  called  the  processing  body  (P-body)  where  argonaute 
proteins and siRNA are located (Jagannath &  Wood 2009; Sen  & Blau  2005). A high 
turnover rate of mRNA is observed in P-bodies (Sen & Blau 2005) and disruption of P-37
bodies decreases the efficiency of RNAi (Jakymiw et al. 2005), implicating the importance 
of P-bodies for RNAi.38
Figure  1.1 RNAi  mechanism  in  mammalian  cells.  In  the  cytoplasm,  double  stranded  RNA 
(dsRNA) is bound and cleaved into siRNA by the Dicer complex consisting of a Dicer, double 
stranded RNA binding proteins such as the TAR RNA-binding protein (TRBP), and the protein 
activator of protein kinase PKR (PACT). The siRNA is then bound to the RNA induced silencing 
complex  (RISC).  The  siRNA  guide  strand  recognises  the  target  site  on  the  target  mRNA  and 
cleavage is mediated through the catalytic activated domain of argonaute 2 protein (AGO2). 39
1.1.1.2.1 mRNA degradation mechanism
The P-body is an important site within the cytoplasm for mRNA degradation after cleavage 
(Eulalio et al. 2007). Following target mRNA cleavage by the RISC, the mRNA fragments 
can be degraded through the mRNA degradation mechanism in the P-body (Figure 1.2). 
During mRNA degradation, the poly(A) tail of the mRNA is removed by poly(A)-specific 
exoribonucleases. The deadenylated mRNA can  then be degraded through two possible 
pathways. In one pathway, the 5’ cap of the deadenylated mRNA is removed by Dcp1 and 
the Dcp2. Subsequently, the mRNA is degraded by Xrn1 exonuclease from the 5’ end to 
the  3’  end  of  the  mRNA  (Valencia-Sanchez  et  al.  2006).  In  the  other  pathway,  the
deadenylated  mRNA  is  degraded  from  the  3’  end  to  the  5’  end  of  the  mRNA  by  the 
exosome. The 5’ cap is then cleaved by the DcpS (Wilusz & Wilusz 2004). 40
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Figure  1.2  General  pathway  for  mRNA  degradation.  Following  deadenylation  of  the  target 
mRNA  by  poly(A)-specific  exoribonucleases  such  as  CCR4,  CAF1  and  PARN,  the  mRNA  is 
decapped by Dcp1 and Dcp2 and degraded from 5’ to 3’ by Xrn1 (left hand side of the figure). 
Degradation  of  the  mRNA  from  3’  end  can  be  mediated  by  exosome,  a  large  complex  of 
exonucleases. The remaining 5’ cap is then broken down by DcpS (right hand side of the figure). 41
1.1.1.3 Other forms of small molecules for RNAi
Apart from siRNA, there are other classes of RNA molecules such as microRNA (miRNA), 
short  hairpin  RNA (shRNA),  Piwi-interacting  RNA  (piRNA)  and  endogenous  siRNA 
(endo-siRNA) that can induce gene silencing. The biology of these RNA is discussed in 
this section.
1.1.1.3.1 miRNA
miRNA refers to single stranded RNA of 21-25 nucleotides. It is expressed endogenously 
in cells and induces RNAi to regulate gene expression. Recent studies have demonstrated 
that one single miRNA can interact with one hundred targets. miRNA plays an important 
role  in  various  cellular  pathways,  particularly  vital  in  controlling  developmental  and 
oncogenic processes (Gregory et al. 2006; Winter et al. 2009). 
There are several steps for a cell to produce mature miRNA (Figure 1.3). Firstly, a long 
RNA molecule of around 70 nucleotides is produced in the nucleus of the cell. The RNA is 
then folded to form a long hairpin structure called “primary miRNA” (pri-miRNA). Most of 
the pri-miRNA is processed by a multicomponent complex consisting of the RNase III 
enzyme Drosha and a dsRNA-binding protein Pasha into a 70 nucleotide hairpin structure 
called  “precursor  miRNA”  (pre-miRNA).  However,  small  potions  of  pre-miRNAs  are 
generated  from  introns,  referred  as  mitrons,  during  transcript  splicing  rather  than  the 
Drosha dependent pathway (Berezikov et al. 2007; Okamura et al. 2007; Ruby et al. 2007).42
Pre-miRNA is then exported from the nucleus into the cytoplasm by 5’ exportin. The pre-
miRNA is then bound and cleaved by a Dicer complex into a 21-25 double strand miRNA. 
The miRNA binds to RISC and is then guided to the 3’ untranslated region of the target 
mRNA by a seed sequence (2 to 8 nucleotides from the 5’ end) to mediate gene silencing 
mainly  by  translational  repression  (Gregory  et  al.  2006;  Pillai  et  al.  2007).  However,
mRNA  degradation  can  occur  in  P-bodies  where  miRNA  activity  clusters  (Lian  et  al. 
2006).  43
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Figure 1.3 miRNA silencing pathway in mammalian cells. In the nucleus, endogenous primary 
microRNA (pri-miRNA) is transcribed by RNA polymerase II (Pol II). Precursor miRNA (Pre-
miRNA)  is  then  generated  by  Drosha-DGCR8  (DiGeorge  syndrome  critical  region  gene  8). 
Following export from the nucleus to the cytoplasm by 5’ exportin, the pre-miRNA is then bound to 
the Dicer-TRBP-PACT complex which processes the pre-miRNA into miRNA. After associating
with RISC, the mature miRNA mediates translational repression by recognising the target mRNA 3’
untranslated  region  (3’UTR). mRNA  degradation  occurs  in  the  P-body which  contains  the 
decapping enzymes DCP1 and DCP2. 44
1.1.1.3.1.1 Regulation  processes  for  mRNA  degradation—AU-rich 
elements regulation
Apart from the general mRNA degradation pathway (Section 1.1.1.2.1), AU-rich elements 
(AREs) at the 3’UTR of mRNA can regulate miRNA mediated mRNA cleavage. AREs 
enhance the mRNA turnover rates by interacting with subunits of the exosome or proteins 
that interact with the exosome such as KSRP (KH-type splicing regulatory protein) and/or
tristetrapolin  (TTP).  AREs also  function  with  other  proteins  such  as  the  urokinase 
plasminogen activator (UPA) associated RNA helicase to manipulate the decapping and 
deadenylation processes for the mRNA turnover (Wilusz & Wilusz 2004). 
A recent study suggested that the miRNA-RISC complex targets ARE sequences in mRNA 
through  interactions  with  TTP,  a  sequence  specific  RNA  binding  protein.  However, 
downstream  mRNA  cleavage  is  not  mediated  by  the  exosome  as  knockdown  of  the 
exosome by RNAi does not abrogate the target mRNA degradation, suggesting that the 
mRNA  is  degraded  through  the  5’  to  3’  end  pathway  (Figure  1.2)  or  other  unknown 
pathway(s) (Jing et al. 2005)
1.1.1.3.2 Differences in siRNA and miRNA mediated gene silencing 
siRNA and miRNA share a similar cellular machinery for their initial processing; however, 
their  gene silencing  mechanisms  may differ (John  et  al.  2007).  siRNA  mediates  target 
mRNA cleavage through perfect base-pairing of the guide strand to the target mRNA while 45
perfect base-paring is not required in miRNA induced RNAi. It was found that the seed 
sequence (2 to 8 nucleotides from the 5’ end) of miRNA needs an almost perfect pairing to 
its mRNA target, usually in the 3’ untranslated region of the mRNA, while the 3’ end of the 
miRNA can tolerate suboptimal pairing (Pillai et al. 2007). Therefore, a miRNA can silence 
various genes with similar sequences whereas an siRNA can only mediate cleavage of a 
specific gene. 
1.1.1.3.3 Short hairpin RNA (shRNA)
RNAi can be mediated by plasmid expression of a single stranded RNA able to form a 
double stranded hairpin structure called shRNA. shRNA are a short double stranded RNA 
with a stem-loop, often 6-8 nucleotides, on one side. They are exported from the nucleus 
and  processed  into  siRNA  to  mediate  gene  silencing  via  the  RNAi  machinery.  The 
silencing effect of shRNA generally lasts longer than the siRNA (Paddison et al. 2002). 
1.1.1.3.4  Piwi-interacting  RNA (piRNA) and  endogenous siRNA (endo-
siRNA)
There  are  other  endogenous  small  RNAs  which  are  found  to  be  able  to  mediate  gene 
silencing.  Such  RNAs  include  Piwi-interacting  RNA  (piRNA)  and  endogenous  RNA 
(endo-siRNA). piRNA, which is around 24-31 nucleotide long, is found to be expressed in 
the germline, implying that it would be important for the germline development. This small 
RNA  does  not  required  Dicer  for  processing,  and  some  piRNAs  involved  in  silencing 46
transposon through RNA destabilisation or heterchromatin formation. Endo-siRNAs can be 
derived from transposing transcripts, sense-antisense transcript pairs and long stem-loop 
structures. Different to miRNA, endo-siRNAs are dependent on Dicer but not on Drosha. 
Endo-siRNA (~21 nucleotide long) is shorter than miRNA. Some of the endo-siRNAs have 
been found to block retrotransposition (Kim et al. 2009; Weinberg & Wood 2009). 47
siRNA miRNA shRNA
Size  A  19-21  nucleotide  double 
stranded  RNA  with  a  2 
nucleotide  overhang  at  the 
3’ end
A  single  stranded  RNA 
with 21-25 nucleotides.
A  short  double  stranded 
RNA  with  a  stem-loop, 
often  6-8  nucleotides,  on 
one side.
Origin Introduced exogenously Endogenously expressed Introduced exogenously
Processing siRNA  is  loaded  in  the 
RISC  and  mediated  target 
cleavage. 
Pre-miRNA  is  generated 
from  the  cleavage  of  pri-
miRNA  by  the  Drosha 
complex or introns during a 
splicing  process.  The  Pre-
miRNA is transported from 
the  nucleus  to  the 
cytoplasm  through  5’ 
exportin  and  processed  by 
Dicer to miRNA. miRNA is 
loaded  to  RISC  for 
translation repression.  
shRNA is expressed from a 
plasmid  and  transported 
from  the  nucleus  to  the 
cytoplasm  by  5’  exportin. 
shRNA is cleaved by Dicer 
to an siRNA and is loaded 
to  RISC  for  target  mRNA 
cleavage.
Target 
identification 
siRNA  mediates  target 
mRNA  cleavage  through 
perfect  base-pairing  of  the 
guide  strand  to  the  target 
mRNA.
Only the  seed  sequence  (2 
to 8 nucleotides from the 5’ 
end)  of  miRNA  needs  an 
almost perfect pairing to its 
mRNA target, usually in the 
3’ untranslated region of the 
mRNA.
The siRNA processed from 
the shRNA mediates target 
mRNA  cleavage  through 
perfect  base-pairing  of  the 
guide  strand  to  the  target 
mRNA.
Specificity An siRNA usually designed 
to  mediate  cleavage  of  a 
specific gene. 
A miRNA can silence up to 
100  genes  with  similar 
sequences.
An  shRNA  usually 
designed  to  mediate 
cleavage of a specific gene. 
Table. 1.1 A summary of siRNA, miRNA and shRNA.48
1.1.1.4 Hurdles and improvements of siRNA technology
Although RNAi allows potent and specific gene silencing in cells, there are major hurdles 
to overcome in order to develop this technology for clinical use. For shRNA, the major 
hurdle is the side effects caused by overexpressing shRNA within cells. For siRNA, the 
main hurdles are in vivo delivery, stability and specificity of the delivered RNA molecules,
and interferon activation induced by siRNA molecules. However, recent improvements in 
shRNA and siRNA design and modification of siRNA have shed light on the development
of RNAi as a therapeutic. 
1.1.1.4.1 shRNA design
Grimm and co-workers found that over-expression of shRNA in vivo could be fatal to mice. 
They found that high doses of shRNA and certain shRNA sequences caused mortality by 
downregulating liver-derived  miRNA.  Over-expression  of shRNA  with  these  sequences
resulted  in  competition  of  exportin-5’  with  miRNA,  leading  to  mortality;  however, 
optimising the shRNA dose and sequence can minimise the toxicity effect causing by over-
saturating the endogenous small RNA pathway (Grimm et al. 2006).   
To address the toxicity effect induced by shRNA, Giering and co-workers demonstrated 
that an incorporation of a tissue specific polymerase II promoter in a plasmid for shRNA 
expression minimised the toxicity effect without compromising the gene silencing efficacy 
(Giering et al. 2008). They showed that a liver-specific apolipoprotein and human α-1-49
antitrypsin fusion promoter driven plasmid can yield shRNA silencing the envelope surface 
antigen of hepatitis B virus (HBV) in mouse liver without major toxicity. McBride and co-
workers also  showed that  modifying the shRNA  to  an  “artificial  miRNA”, in  which it 
contains a  hairpin,  mRNA  targeting  region  and  a  tail  region  as  a substrate  for Drosha 
processing, improved the safety of the shRNA without compromising the gene silencing 
efficacy (McBride et al. 2008).
1.1.1.4.2 Stability and specificity of siRNA
Unmodified siRNA is susceptible to nuclease mediated degradation. Modifications of the 
siRNA  backbone  with  boranophosphate  (Hall  et  al.  2004),  2’-fluoro  and  2’-O-methyl 
modified  siRNA  can  increase  the  half  life  of  siRNA  relative  to  unmodified  siRNA 
(Allerson  et  al.  2005).  Interestingly,  these  modifications  can  also  improve  the  gene 
silencing potency and specificity of the siRNA significantly (Allerson et al. 2005; Hall et 
al. 2004). In terms of the 2’O-methyl modification, Jackson and co-workers demonstrated 
that this modification specifically at position 2 on the guide strand further improves siRNA 
specificity (Jackson et al. 2006). These modifications are believed to improve the siRNA 
specificity by decreasing the free energy for hybridisation between the guide strand and its 
non-specific targets. As a result, binding between the guide strand and the non-specific 
targets becomes suboptimal and therefore target cleavage is not initiated (Jackson et al. 
2006).50
Off-target or non-specific gene silencing has been observed in some siRNA applications. 
However, recent studies on a better sequence design may help to improve the specificity of 
siRNA. It was found that siRNA with characteristics such as low C/G content and low 
internal stability at the 3’end of the passenger strand are more specific in gene silencing
(Reynolds et al. 2004). Absence of inverted repeats or palindromes within the siRNA can 
also  improve  gene  silencing potency.  This  may  be  due  to  the  fact  that  a  guide  strand
containing an inverted repeat would form an internal fold-back structure which reduces the 
effective concentration and silencing potential of the siRNA (Reynolds et al. 2004).  It was 
also observed that there is a base preference in certain positions of siRNA for more specific 
gene silencing. For instance, siRNA with an A at position 3 and 19, U at position 10, the 
absence of a G at position 13 and the absence of a G or U at position 19 of the sense strand 
are proven to be more specific in gene silencing (Reynolds et al. 2004). As non-specific 
gene  silencing  effects  are  associated  with  the  perfect  pairing  of  the  guide  strand  from 
positions 2-7 or 2-8 (the seed sequence) to the 3’UTR of mRNA, but not to the 5’UTR or 
ORF (Birmingham et al. 2006), siRNA sequences should preferentially be designed not to 
target the 3’UTR.  
1.1.1.4.3 Interferon activation
Interferon activation has been a problem of siRNA mediated gene silencing for in vivo or 
clinical  use.  It  was  demonstrated  that  certain  siRNA  sequence  induced  interferon-α 
(Hornung et al. 2005; Judge et al. 2005). On the other hand, it was shown that 2’O-methyl 
modifications  on  uridine  or  guanosine  nucleosides  in  the  passenger  strand  can  prevent 51
immunostimulation.  The  exact  molecular  mechanism  is  not  known;  it  could  be that 
modification of the GU in the passenger strand sterically hinders the interaction between 
the siRNA and the toll-like  receptor 7 and 8 (Judge et al. 2006), a receptor located in 
endosomal membrane which recognises the GU content of RNA (Heil et al. 2003; Lee et al. 
2003).
1.1.1.4.4 Delivery of siRNA
Delivery efficiency  of  siRNA  in  vivo is  a  main problem for  the  applications  of  RNAi 
technology. siRNA is a negatively charged molecules and often require a carrier for cellular 
delivery.  The  delivery  of  siRNA  is  improved  by  complex  formation  of  siRNA  with 
polyethyleneimine  (PEI) (Urban-Klein  et  al.  2005)  or  atelocollagen  (Minakuchi  et  al. 
2004), or conjugation of siRNA with cholesterol (Soutschek et al. 2004). Urban-Klein and 
co-workers were  able  to  deliver  siRNA  into  subcutaneous tumors in  mice  by systemic 
(intraperitoneal, i.p.) administration of PEI siRNA complexes targeting the c-erbB2/neu 
(HER-2)  receptor (Urban-Klein  et  al.  2005).  Minakuchi  and  co-workers  showed  that 
atelocollagen  siRNA  complexes  targeting  fibroblast  growth  factor  4  (FGF-4)  injected 
intratesticularly  reduced testicular  tumour  growth  in  mice (Minakuchi  et  al.  2004).
Soutschek  and  co-workers  demonstrated  that  siRNA  conjugated  with  cholesterol  could
silence an endogenous apolipoprotein B (apoB) messenger RNA in liver and jejunum after 
intravenous injection in mice (Soutschek et al. 2004). 52
Although these systems improve the efficiency of siRNA delivery, these systems are not 
cell type specific. Delivery of siRNA to non-disease cells would be harmful (Toub et al. 
2006). Therefore, there is a need to further develop a robust, safe and clinically suitable 
siRNA delivery system (Whitehead et al. 2009). Strategies developed for plasmid delivery 
could be applicable for the further improvements of siRNA delivery. These strategies are 
discussed in Section 1.2.
1.1.1.5 RNAi based human trials
Despite the delivery hurdle, there are several RNAi-based human trials have been reported, 
showing the proof of concept of using siRNA or shRNA as a therapeutic. A trial on human 
immunodeficiency virus (HIV) infection utilised shRNA expressed by a lentiviral vector to 
target rev and tat mRNA of HIV-1, alongside a nucleolar-localising TAR RNA decoy and 
an anti-CCR5 ribozyme to inhibit HIV-1 infection in primary hematopoietic cells (Li et al. 
2005;  Benitec  Limited 2009).  This  study  showed  that  the  primary  hematopoietic  cells 
treated with the lentiviral vector had the potential to limit HIV infection. Although this trial 
also included other silencing technology, it demonstrated the possibility of using shRNA as 
a medical treatment. 
Other trials are conducted for the treatments of diseases in which the disease causing cells 
such as the epithelial cells can take up naked siRNA. For instance, there was a trial on 
prevention of respiratory syncytial virus (RSV) infection by intranasal delivery of naked
siRNA  targeting  the  P  protein,  an  essential  subunit  of  viral  RNA-dependent  RNA 53
polymerase,  to  inhibit  viral  gene  expression  (Alnylam  Pharmaceuticals  2008).  It  was 
observed  that  this  siRNA  was  well  tolerated  in  healthy  adults  and  induced  significant 
antiviral efficacy in patients. Two other trials were on the age-related macular degeneration 
(AMD), an ocular disease which leads to blindness due to excessive blood vessel growth 
and rupture within the cornea. Naked siRNA targeting vascular endothelial growth factor 
(VEGF) or its receptor (VEGFR1) was delivered by direct intravitreal injection into the eye 
to test the safety and efficacy for the AMD treatment (Opko Health 2007; ClinicalTrial.gov 
2009). It was reported that the siRNA induced minimal side effects and improved vision in 
some of the patients initially. However, the phase III trial was terminated because it was 
deemed that the trial was unlikely to meet its primary end point (Opko Health 2009).
Despite the initial success of some of these trials, the outcomes of the therapeutic values are 
remained to be seen. Clearly, there is a need to develop a better siRNA delivery system for 
disease treatments because delivering siRNA to most of the cell types has proven to be a 
major  hurdle  to  transfer  this  technology  into  the  clinic  (Whitehead  et  al.  2009). 
Nevertheless, those trials and pre-clinical studies to date have shown that RNAi can provide 
an attractive way to target disease causing genes as a therapeutic. Further applications of 
the siRNA technology will probably require the development of a robust and safe siRNA 
delivery system for systemic application in the clinic. It is likely that synthetic carriers will 
play a key role in siRNA delivery in the future.
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1.1.2 Other gene silencing technologies
Apart from RNAi, there are other different types of gene silencing techniques including the 
use  of  antisense  olignucleotides  and  ribozymes  to  down-regulate  target  mRNA.  These 
methods have been used to treat diseases such as cancers and retinitis (Leung & Whittaker 
2005). 
1.1.2.1 Antisense oligonucleotides
Antisense  oligonucleotides  can  base  pair  with  target  mRNA  and  mediate  mRNA 
degradation by RNase H, which cleaves the RNA in a DNA-RNA duplex (Sazani & Kole, 
2003),  or  by  double  stranded  RNase  which  degrades  double  stranded  RNA (Lima  & 
Crooke, 1997) (Figure 1.4A). However, some of the oligonucletides do not silence a gene 
by RNase H, instead they decrease gene expression by translational repression (Sazani & 
Kole, 2003; Juliano et al. 2008) (Figure 1.4B). Since oligonuclotides are unstable in the 
biological  environment,  there  are  several  improvements  to  increase  their  stability.  For 
instance, the oligonucleotide backbone can be modified into locked nucleic acids (LNAs), 
peptide nucleic acids (PNAs) and hexitol nucleic acids (HNAs). However, these modified 
oligonucleotides are not able to mediate RHase H based mRNA degradation (Manoharan 
2002;  Kurreck  2003;  Crooke  2004).  It  was  found  that  introduction  of  several 
phosphodiester residues within the central parts of these modified oligonuleotides allowed 
RNase H mediated target mRNA degradation while the stability of the oligonucleotides was 
still retained (Crooke 2004).  55
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Figure 1.4 A schematic diagram showing the mechanisms of antisense induced gene silencing.
(A) RNase H cleavage mediated by antisense oligonucleotides. (B) Translational suppression of 
gene expression.56
1.1.2.2 Ribozyme
Since the discovery of catalytically active RNA molecules known as ribozyme (Kruger et 
al. 1982; Guerrier-Takada et al. 1983), there has been much researches on developing these 
gene  silencing  molecules  for  therapeutic  uses.  Ribozymes  are  capable  of  binding  in  a 
sequence  specific  manner  to  substrate  mRNA  through  base-pairing  interactions,  and 
cleaving the bound RNA (Figure 1.5). Ribozymes then release the cleaved RNA and bind 
to other target RNA to mediate further RNA cleavage. Repeated cleavage cycles lead to 
target gene silencing (Sullenger & Gilboa 2002).57
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Figure 1.5 A schematic diagram of ribozyme mediated target RNA cleavage. The ribozyme can 
bind to target RNA through base-pairing interactions. The target RNA is then cleaved and released. 
The ribozyme is then free to bind to other target RNA. 58
1.1.3 A comparison of the antisense oligonucleotides, ribozymes and RNAi
The  antisense  oligonucleotides,  ribozymes  and  RNAi  share  similar  advantages  such  as 
target specificity and problems such as poor stability to be used as therapeutics. Some of 
the problems can be addressed by the improvement of the synthetic technology. 
Gene silencing potency: Both of these technologies can be designed to cleave virtually 
any target mRNA. However, to mediate potent gene silencing, it appears that less amount 
of  siRNA  is  required  whereas  relatively high  amount  of  antisense  oligonucleotides  are 
needed (Grunweller et al. 2003; Vickers et al. 2003). There are no direct comparisons of the 
dose effect between siRNA or antisense oligonucleotides and ribozymes (Scherer & Rossi 
2003).
Target sequence selection: Although potential target sequences can be estimated by 
certain design rationales, the antisense oligonucleotide or siRNA sequence still needs to be 
verified  by  systemic  testing  of  various  potential  targets  which  is  proven  to  be  time 
consuming  (Scherer  &  Rossi  2003).  There  are  also  limitations  for  the  design  of  the 
ribozyme sequences. For example, ribozymes are required to contain specific sequences 
such as GUC  triplet  to  mediate target  RNA  cleavage (Kurreck  2003;  Scherer  & Rossi 
2003). This limits the choices of RNA target site for ribozymes. 
Non-specific gene silencing: There is  potential that  these molecules  could  mediate 
non-specific gene silencing. It was shown that antisense oligonucleotides directed RNase H 59
to mediate non-specific RNA cleavage (Scherer & Rossi 2003). There was also a report 
about non-specific effect by siRNA (Jackson et al. 2003). However, a better understanding 
of  the  sequence  selection  criteria  enables  non-specific  gene  silencing  to  be  minimised 
(Reynolds et al. 2004; Scherer & Rossi 2003). Ribozymes appear to be very specific for 
target  cleavage;  however,  they  may  bind  to  other  proteins  in  the  cells,  affecting  the 
functions of the bound proteins and resulting in unwanted side effects (Scherer & Rossi 
2003).    
Stability: All those molecules are susceptible to nucleases. However, as mentioned in 
Section  1.1.1.4.2  and  1.1.2.1,  modifications  of  the  backbone  of  siRNA  or  antisense 
oligonucleotides improve their stability. By contrast, modifications of ribozymes may not 
be available because these would change the conformation of a ribozyme which affects the 
gene silencing effect (Kurreck 2003).
Effective gene silencing molecules should be able to mediate specific gene silencing with 
minimal side effects such as off target silencing. They should be stable enough to exert 
their effect to achieve gene silencing phenotypes. At the moment, RNAi appears to be more 
effective than  antisense  oligonuclotides  for potent  gene silencing  and  more  stable  than 
ribozymes for achieving the gene silencing phenotypes. The potential of siRNA to mediate 
non-specific gene silencing and immunostimulation can be minimised by better sequence 
design  and  backbone  modifications  (Section  1.1.1.4.3).  A  better  understanding  of  the 
biology  of  antisense  oligonucleotides  and  ribozymes  may  lead  to  improvements in  the 
silencing potency, stability and side effects of these molecules.      60
Today, RNAi is widely used for basic research, target validation and disease treatments. As 
previously mentioned, RNAi can be delivered using an siRNA or a plasmid expressing an 
shRNA.  However,  RNAi  delivery in  vivo has  proven  to  be  challenging,  restricting  the 
development of RNAi-based therapies (Li et al. 2006). The next section will discuss in vivo
plasmid delivery techniques and how these methods can be modified for siRNA delivery.61
1.2 Methods used for delivering RNAi
To mediate RNAi, either an shRNA encoding plasmid, an pri-miRNA expressing plasmid, 
siRNA or other small RNAs need(s) to be delivered to cells. Generally, methods for nucleic 
acid delivery can be divided into two main types, namely viral and non-viral methods. Each 
method has its own advantages and disadvantages and these are discussed in this section.
1.2.1 Viral methods
    
The choice of vectors for a specific therapeutic use should be determined on the basis of its
biological properties. In this section, the most commonly used viral vectors such as the 
adenoviral and retroviral vectors (Figure 1.6) and the adeno-associated viral vector which 
is used for a recent clinical trial for treating blindness and failing eyesight (Bainbridge et al. 
2008; Maguire et al. 2008) are discussed.62
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Figure 1.6 A chart showing percentage of different vectors used in gene therapy clinical trials
(modified from Edelstein 2008).
1.2.1.1 Adenoviral vector
The adenoviral vector is one of the most efficient vectors for gene delivery (Thomas et al. 
2003). Adenovirus is a double stranded DNA virus which infects the human respiratory 
tract and eyes (El Aneed 2004). It can carry a relatively large transgene compared to other 
viral vectors due to its large genomic size (36kb), and can infect both dividing and non-
dividing cells (Goverdhana et al. 2005). Transduction of tissues including muscle, brain,
lung,  liver, hematopoietic  stem  and cancer  cells  have  been  demonstrated.  This  broad 
tropism gives the adenoviral vectors the potential to treat a wide range of diseases.63
Adenoviral  vector  transgene  expression  may  be  transient (5-10  days  post-infection)  in 
dividing tissues because it does not integrate the therapeutic gene into the host cell genome
(Marshall 2000; Selkirk 2004). The therapeutic gene persists as a non-integrated episome
inside the nucleus (Thomas et al. 2003). The non-integrating property means the vector
should not pose a risk of insertional mutagenesis (Marshall 2000). 
Some studies reported long-term gene expression following adenovirus-mediated transfer. 
This can be done by injecting vectors into cells of nude mice or mice in which both the 
vectors  and  immunosuppressing  agents  are  injected  (Verma  &  Somia  1997).  The  gene 
transfer  is  more  efficient  in  immunodeficient  animals  (El  Aneed  2004),  implying  that
transient expression may also be caused by an immune response.
One of the main drawbacks of adenoviral vectors is that the viral proteins stimulate a strong 
immune  reaction  (Marshall  2000).  At  high  doses  the  vector  may  induce  a  lethal 
inflammatory reaction (El Aneed 2004). The viral gene products can elicit a cytotoxic T-
lymphocyte response while the viral caspid can induce humoral virus-neutralising antibody 
responses  and  cytokine-mediated  inflammatory  responses, resulting  in  inflammation
(Thomas et al. 2003). Inflammation caused by a high vector dose is believed to have caused 
the death of a young patient involved in a clinical trial using an adenoviral vector which 
was conducted at the  University of  Pennsylvania in  Philadelphia (Ferber  2001; Selkirk 
2004).
The immunogenic problem  must be solved  to  make the  adenoviral vectors suitable  for 
therapeutic applications. A “gutless” adenoviral vector, which lacks immunogenic factors, 64
has  been  generated  to  serve  this  purpose  (Selkirk  2004).  The  vector  has  a  lower 
immunogenicity as all viral genes, except the elements that define the beginning and the 
end of the genome, and the viral packaging sequence, are deleted (Goverdhana et al. 2005). 
It has also been observed that adenoviral vectors coated with lipids (Singh et al. 2008) or 
polymers (Green et al. 2008) show reduced immunogenicity, probably due to masking of
the immunogenic adenoviral capsid proteins (Kreppel & Kochanek 2008).
The use of adenoviral vector for shRNA delivery in vivo has been reported. Uchida and co-
workers  demonstrated  that  silencing  of  survivin,  an  antiapoptotic  molecule  widely 
overexpressed in malignancies but not detected in terminally differentiated adult tissues, 
induced apoptosis cancer cells and led to remarkably attenuated tumour  growth in vivo
following intratumuoral injection of the adenoviral vector (Uchida et al. 2004). Recently, 
Zhang  and  co-workers  silenced  Ki-67,  a  nuclear  protein  which  is  associated  with  cell 
proliferation, to induce apoptosis of tumour cells and efficiently suppress tumour growth in 
nude  mice  following  an  intratumoural  injection  of  the  adenoviral  vector  (Zhang  et  al. 
2009). These reports showed that adenoviral vectors can be good candidates for shRNA 
delivery, provided that side effects such as immunogenicity are minimised. 
1.2.1.2 Adeno-associated viral vector 
The adeno-associated virus (AAV) is a single stranded DNA virus (Verma & Somia 1997)
which is non-pathogenic in humans (Check 2003). Vectors derived from AAV have shown 
low immunogenicity and stable gene expression (Monahan et al. 2002). Most preclinical 65
and clinical studies show that the vector is non-pathogenic to the human immune system
(Marshall 2000; Monahan et al. 2002). 
As  with  adenoviral  vectors,  AAV  vectors are  able  to  transfer  genes in  vivo  with  high 
efficiency and infect both dividing and non-dividing cells (Marshall 2000). However, it has 
a limited gene-carrying capacity due to its small genomic size (5kb) (Goverdhana et al. 
2005; Marshall 2000). This restricts the length of therapeutic DNA sequence that it can 
carry.
One of the drawbacks of the AAV vector is that the viral genome integrates itself into the 
host genome (Marshall 2000) preferentially at chromosome 19 (Verma & Somia 1997). 
This poses a risk of insertional mutagenesis (Check 2003). However, more than 90% of the 
vector genome appears as the episomes (Thomas et al. 2003). Therefore, the chances of 
mutagenesis  are  not  as  high  as  retroviral  vector  (Section  1.2.1.3).  Despite  the  low 
frequency of integration, AAV vector was observed to cause liver tumour in mice in a 
recent study (Donsante et al. 2007).
There are studies showed some successes using AAV to deliver shRNA in vivo. Xia and co-
workers  delivered  shRNA  to  target  ataxin-1  in  spinocerebellar  ataxia  type  1  (SCA1) 
transgenic mice by injecting the AAV intracerebellarly. Following the shRNA treatment, 
the  authors  observed  a profound  decrease  of  ataxin-1  expression  in  the  Purkinje  cells, 
neural cells located in the cerebellar cortex. The SCA1 mice showed an improvement in 
motor coordination and a restoration of cerebellar morphology (Xia et al. 2004). On the 
other hand, Chen and co-workers demonstrated persistent HBV inhibition up to 22 weeks 66
in HBV transgenic mice using shRNA targeting  the HBV surface antigen delivered by 
intravenous injection of AAV (Chen et al. 2009). These reports indicated that AAV can be 
an option for RNAi delivery. However, as AVV poses a risk of insertional mutagenesis, 
there is a need to study the long term safety of AAV mediated gene silencing.
1.2.1.3 Retroviral vector
The retroviral vector is the most common class of gene transfer vector in clinical studies 
and was among the first class of viral vectors to be developed for clinical use. It is now the
vector of choice for ex vivo gene delivery to hematopoietic cells (Thomas et al. 2003). 
The vector has a plus strand RNA with a small genomic size (7-10 kb) and only infects 
dividing cells (Marshall 2000) as the vector genome can only gain access to the cell nucleus 
when the nuclear envelope breaks down (Thomas et al. 2003). It is efficient in gene transfer 
and does not produce a strong immune response (Marshall 2000), but it does not express 
genes  in  cell  stably even  though  it  integrates  itself  into  the  host  genome  as  a  double
stranded DNA provirus as a result of reverse transcription (Marshall 2000). One possible 
explanation is that large portions of the vectors integrate themselves in the transcriptionally 
silent heterochromatin, which hinders gene expression. This is called the position effects
(Emery et al. 2000). The integration property indeed is unsafe for patients as it poses the 
risk of insertional mutagenesis. The T cell leukemia development of the X-SCID patients in 
the clinical trials in France and United Kindgom is due to the insertion of the therapeutic 
gene near proto-oncogene such as LIM domain only 2 (LMO2), leading to transcription and 67
expression of the oncogene (Cavazzana-Calvo et al. 2004; Thrasher et al. 2005; Williams & 
Baum  2003). However,  more  recently  developed  self-inactivating  retroviral  vectors  are 
believed to be less likely to cause such events (Thornhill et al. 2008).
Nevertheless, retroviral vector was among the first viral vectors to infect cells for in vivo
shRNA expression. In this  study, Brummelkamp  and co-workers effectively suppressed 
tumour growth in nude mice by targeting the oncogene K-RASV12 gene, which is essential 
for tumour viability (Brummelkamp et al. 2002). This demonstrated the specificity of RNAi 
and highlighted the possibility of using shRNA as therapeutics.68
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Adenovirus dsDNA 36 kb Broad High Episomal
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Transduces 
dividing cells
Table 1.2 A summary of the characteristics of the adenoviral, adeno-associated and retroviral 
vectors.69
1.2.2 Non-viral vector systems
It is generally accepted that non-viral vector delivery systems are less efficient for gene 
transfer in vivo compared to viral vectors. However, they are less immunogenic, low risks 
of insertional mutagenesis, are flexible in delivering different kinds of nucleic acids such as 
antisense  oligonucleotides,  ribozymes  and  siRNA  and  are  generally  easier  for  mass-
production and quality control than the viral vectors; therefore, they are an attractive tool 
for nucleic acid transfer (Li & Huang 2000). A number of physical and chemical methods 
for non-viral gene transfer have been developed for nucleic acid delivery to improve the 
gene transfer efficiency and time period of gene expression. 
1.2.2.1 Physical methods
Physical  methods  for  gene  delivery  include  electroporation,  hydrodynamic  delivery, 
ultrasound  delivery, laser  beam  gene  transduction (LBGT) and  ballistic  gene  delivery.
These methods have  been  shown to  mediate effective  in  vivo  gene delivery,  and these 
methods are discussed in this section.
1.2.2.1.1 Electroporation
One  of  the  most  powerful  physical  methods  is  electroporation,  which  improves  gene
transfer efficiency by 100-fold relative to naked DNA injection. This method involves the 
use of electrodes to apply an electric field across the target tissue to facilitate gene delivery. 70
The mechanism behind this remains unknown, but it is believed that under the influence of 
an electric field, temporary pores are formed on the cell membrane and this allows DNA to 
enter the cells (Wells 2004).
Indeed,  electroporation  has  been  used  recently  to  deliver  siRNA  into solid  tumours  to 
mediate effective gene silencing (Golzio et al. 2007). Golzio and co-workers generated a 
mouse tumour model in which the tumour expressed enhanced green fluorescent protein 
(eGFP) stably. They found that eletroporation following a single injection of the siRNA 
targeting eGFP into the tumour led to eGFP silencing for three days.   
1.2.2.1.2 Hydrodynamic delivery
The hydrodynamic delivery can increase gene transfer efficiency and the duration of gene 
expression  without  integration of  transgenes  into  the  host  genome  (Ferber  2001). 
Experiments on mice showed that the plasmid can persist in liver cells for a year, which is
half of a typical mouse lifetime (Stoll et al. 2001).
The procedure of the method involves quickly injecting the tail vein of a mouse with naked 
DNA in a relatively large volume of saline  solution,  roughly equal to the entire blood 
volume  of  the  mouse.  A  high  pressure  will  be  generated  in  the  blood  after  injection, 
allowing creation of temporarily pores in the cell membrane of the mouse liver cells. As a 
result, plasmids can enter the cells and be expressed (Kobayashi et al. 2004; Zhang et al.
2004). Though it is impossible to inject humans with solutions that are half the volume of 71
human blood, hydrodynamic delivery has been shown to improve gene transfer efficiency
in large animal models. For example, DNA was injected into rhesus monkeys via arteries 
that feed the arm and leg muscles by using a blood-pressure cuff to temporarily increase 
blood pressure. Gene expression was detected in about 30% of muscle cells, similar to the 
efficiency of viral delivery (Ferber 2001).
A recent study has shown that hydrodynamic delivery can mediate effective in vivo siRNA 
transfer in various mouse organs such as liver, kidney, pancreas, spleen and bone marrow. 
The siRNA remained in these organs for at least 24 hours following the hydrodynamic 
delivery (Larson et al. 2007). Other studies showed that delivering siRNA targeting the 
surface antigen region of HBV by hydrodynamic injection in mice resulted in 70% - 80% 
silencing of the antigen, effectively preventing HBV replication (Giladi et al. 2003; Klein et 
al. 2003).
1.2.2.1.3 Ultrasound gene delivery
Though electroporation and hydrodynamic delivery are effective in gene transfer, they are
invasive to tissues. As a result, other less invasive methods have been examined for their
ability to  transfer DNA  and siRNA.  One such method is  ultrasound,    which works by 
transiently disrupting the cell membrane to increase cell permeability to DNA (Newman &
Bettinger  2007).  A  recent  study  has  shown  that  delivery  of  unmodified  siRNA  to  the 
synovium of the knee joints of rats can be achieved by ultrasound sonication (Saito et al. 
2007).  In  this  study,  delivery  of  siRNA  targeting  luciferase  mediated  70%  luciferase 72
knockdown in luciferase expressing synovium in rats. Suzuki and co-workers showed that 
ultrasound delivery of siRNA targeting luciferase silenced 80% of luciferase expression for 
24 weeks in luciferase expressing intervertebral discs in mice. They also demonstrated that 
ultrasound delivery of siRNA targeting the FasL gene inhibited 53% of endogenous FasL 
expression in intervertebral discs for 20 weeks (Suzuki et al. 2009).
1.2.2.1.4 Other physical methods
Laser beam gene transduction (LBGT) is one of the methods to transfer genes into cells. It 
is highly effective and has similar efficiency as electroporation. The mechanism behind the 
improvement of gene transfer is not clear, but it is believed that the laser beam creates 
transient holes in the cell membrane to facilitate DNA uptake (Zeira et al. 2003). On the 
other hand, ballistic gene delivery can also enhance gene transfer by “shooting” plasmids 
coated in microparticles  into  cells or tissues  by using a  machine called  gene  gun. The
machine can increase the velocity of the microparticles so that they can bombard into the 
target cells or tissues. However, this technique is limited to superficial tissues such as skin
(Dileo et al. 2003). To date there are no publications reporting the use of these methods for 
in vivo siRNA delivery, though this may be a possibility of transferring these techniques for 
siRNA delivery in the future.73
1.2.2.1.5 Disadvantages of physical methods 
Physical delivery of nucleic acids does not allow targeting to specific cell types; therefore, 
the uses of these methods are usually limited to local administration to the body such as 
skin, muscle, lung or tumour (Ferber 2004; Well 2004). To mediate cell targeting nucleic 
acid delivery, a synthetic vector system containing a cell targeting ligand can be used for 
nucleic acid transfer.   
1.2.2.2 Synthetic vector systems
Generally, synthetic vector systems can be classified into a lipid based (lipoplex), polymer 
based  (polyplex)  and  lipid  polymer  hybrid  (lipopolyplex)  system.  These  systems  are 
described in this section. 
1.2.2.2.1 Lipoplex 
DNA  delivery  using  the  cationic  lipid N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trime-
thylammonium  chloride  (DOTMA) as  a  carrier  was  first  reported  by  Felgner  and  co-
workers  (Felgner  et  al.  1987).  Since  then,  a  number  of  cationic  lipids have  been 
investigated for DNA transfer (Bennett et al. 1997; Felgner & Ringold 1989; Gao & Huang 
1991; Sternberg et al. 1998). It has been shown that cationic lipid DNA complexes, or 
lipoplexes,  can  be  efficient  for  gene  delivery  for  many  cell  types,  and  some  of the 
lipoplexes are currently being evaluated in clinical trials (Figure 1.6).74
Cationic lipids can bind to and condense DNA through electrostatic interactions (Felgner et 
al.  1987).  As  a  result,  nano-sized  lipoplexes  are  formed  which  can  enter  cells  by 
endocytosis (Farhood et al. 1995; McLachlan et al. 1995; Wrobel & Collins 1995). Within 
the cells, DNA must escape from the endosome and traffick to the nucleus for transcription. 
To  enhance  the  endosomal  escape  capability,  helper  lipids  such  as  dioleyl 
phosphatidylethanolamine (DOPE), cholesterol or dioleoyl phosphatidyl choline (DOPC)
can be added to lipoplexes (Farhood et al. 1995; Zuhorn et al. 2005).
Although lipoplexes can improve gene delivery, they are not cell type specific. To improve 
cell type specificity, receptor ligands including transferrin (Simoes et al. 1999), monoclonal 
antibodies  (Wang  and  Huang 1987),  or  folate  receptors  (Lee and  Huang  1996) can  be 
covalently attached to the vector to allow internalisation of the lipoplexes through receptor-
mediated endocytosis. 
Cationic lipids have been studied for siRNA delivery. Cardoso and co-workers found that 
cationic  lipids,  which  were  formulated  with  N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP) and cholesterol, associated with transferrin 
can deliver  siRNA (Cardoso  et al. 2008).  In this  study,  they  observed  40% of in  vivo
luciferase and c-Jun gene silencing without adverse cytotoxic effects. However, a contrary 
study  showed  that  although DOTAP/cholesterol  can  be  used  for  siRNA  delivery,  this 
complex may induce an immune response (Ma et al. 2005b). Sioud and Soensen also found
that liposomes could be used for in vivo siRNA delivery, but there may also be an immune 
response caused by the lipid-siRNA complex (Sioud & Soensen 2003). The difference in 
the cytotoxicity induced by the siRNA complexes could be due to the different siRNA 75
molecules that were used in these two studies. It has been shown that the cytotoxic effect of 
an siRNA complex is dependent on the siRNA sequence (Robbins et al. 2008).
As well as cationic lipids, Landen and co-workers showed that a neutral liposome, DOPC,
can be  used  for  in  vivo  siRNA  delivery.  With  the  combination  of  siRNA  complexes 
targeting a tyrosine kinase receptor, EphA2, and a conventional chemotherapeutic drug, 
paclitaxel, ovarian tumour growth was inhibited (Landen et al. 2005). 
Clearly, the understanding of lipid based siRNA delivery systems is evolving. There is still 
a need to further improve the nucleic acid transfer efficacy and study the cytotoxic effect. 
More researches into the mechanism of lipid based siRNA delivery may allow the problems 
of lipoplex delivery to be addressed, helping to develop this system for clinical applications
in the future.
  
1.2.2.2.2 Polyplex 
Polyplex refers to a complex using a polymer as a carrier to deliver nucleic acids to a cell. 
Cationic polymers such as polyethylenimine (PEI) (Gautam et al. 2000; Godbey et al. 1999; 
Goula et al. 1998), polyarginine (Kim et al. 2007), histidylated polylysine peptides (Read et 
al. 2005), chitosan (Koping-Hoggard et al. 2001; Lee et al. 1998), polylysine (Dash et al. 
1999; Ramsay et al. 2000; Wu & Wu 1987; Zauner et al. 1997) and dendrimers (Bielinska 
et al. 1999; Kukowska-Latallo et al. 1999) have been widely used to condense plasmid 
DNA and form nanoparticles. It has been reported that the polyplexes are taken up by cells 76
through  endocytosis  (Khalil  et  al.  2006).  To  further  improve  cellular  uptake  and  cell 
specificity of the polyplexes, the polymers can be conjugated with a ligand or antibody that 
binds to a cell surface receptor. For example, polylysine linked to an asialoorosomucoid 
ligand, a liver-specific asialoglycoprotein receptor, has been used to deliver plasmid DNA 
to  the  liver  in  vivo  (Kwoh  et  al.  1999;  Perales  et  al.  1997).  Other  targeting  systems 
including transferrin linked PEI (Kircheis et al. 1999), polylysine conjugated epidermal 
growth factor (Schaffer & Lauffenburger, 1998; Schaffer et al. 2000; Xu et al. 1998) and 
polylysine associated with an integrin targeting peptide (Hart et al. 1998; Jenkins et al. 
2003) have been shown to improve gene delivery. 
One of the main hurdles for effective gene delivery with the majority of polyplexes is 
degradation  of  the  vectors  within  cells,  usually  in  the  acidic  late  endosomes  (Section 
1.3.1.1) (Erbacher  et al.  1996;  Meyer &  Wagner 2006). However,  it  was reported  that 
polymer systems which have a high buffer capacity such as the histidylated polylysine 
peptides and PEI can mediate endosomal escape by increasing the osmotic pressure of the 
late endosome, leading to endosomal destabilisation and release of DNA (Kichler et al. 
2001;  Read  et  al.  2005).    For  polyplexes  that  cannot  mediate  endosomal  escape,  the 
addition of an endosomal destabilising peptide including the influenza virus hemagglutinin 
HA-2 (Wagner et al. 1992) can enhance transfection efficiency. Also, it has been found that 
an addition of endosomal buffering agents such as chloroquine can improve endosomal 
escape  by  increasing  the  osmotic  pressure  in  the  late  endosome,  resulting  endosomal 
destabilisation and release of DNA (Erbacher et al. 1996).77
Since plasmid DNA must be transcribed in the nucleus, an addition of a nuclear localising 
signal (NLS) peptide to vector systems can further improve the transfection efficiency. For 
example, it has been shown that vector systems containing an NLS peptide such as simian 
virus 40 (SV40) large-T antigen (Kaneda et al. 1989), protamine (Wienhues et al. 1987), 
histone H2 (Balicki et al. 2002) or melittin-derived peptides (Ogris et al. 2001) showed 
enhanced transfection efficiency. 
A number of polymers have been used to improve the in vitro siRNA delivery efficiency 
such as PEI (Grayson et al. 2006), polyarginine (El-Sayed et al. 2008; Kumar et al. 2007), 
histidylated  polylysine  peptides  (Leng  et  al.  2008),  chitosan  (Katas  &  Alpar  2006), 
polylysine (El-Sayed et al. 2008) and dendrimers (Patil et al. 2008). For in vivo siRNA 
delivery, some studies have demonstrated that these polymers can also be used. Ge and co-
workers showed that a PEI-siRNA complex could deliver siRNA targeting the influenza 
viral nucleocapsid protein or a component of influenza virus RNA transcriptase into lung 
tissue to treat and prevent influenza infections in mice (Ge et al. 2004). On the other hand, 
Urban-Klein and co-workers demonstrated that a PEI-siRNA complex could silence HER-2 
expression  in  SKOV-3  ovarian  cancer  xenografts,  leading  to  tumour  growth  inhibition 
(Urban-Klein et al. 2005). These early studies demonstrated the principle of using polymers 
to form nanoparticle with siRNA for in vivo siRNA delivery. 
Howard  and  co-workers  showed  that  a  chitosan-siRNA  complex  could  reduce  eGFP 
expression by 40% in bronchiole epithelial cells in transgenic eGFP mice (Howard et al. 
2006). In  another  study,  Kumar  and  co-workers  showed  that  oligoarginine  peptides
conjugated with a ligand targeting the acetylcholine receptor expressed by neuronal cells78
could form complexes with siRNA and deliver it to neuronal cells in vitro. Moreover, they 
observed that this siRNA complex could by pass the blood brain barrier and deliver siRNA 
to the brain in vivo (Kumar et al. 2007). Recently, Leng and co-workers demonstrated that 
histidylated polylysine peptides could carry siRNA to tumour xenografts for tumour growth
inhibition.  Their strategy  was  to use  siRNA targeting  Raf-1  mRNA in  tumour  cells  to 
induce apoptosis. However, there are concerns related to the cytotoxicity of this polyplex 
system (Leng et al. 2008).
Although  polymer  based  siRNA  delivery  systems  are  still  in  the  early  stages  of 
development, some reports have already shown promising siRNA delivery, highlighting the 
potential of these systems. However, more efforts are still needed to further improve the 
siRNA delivery efficiency and address the cytotoxicity of polyplexes. A systematic study 
of the polyplex properties and siRNA delivery efficacy may help address these issues and 
improve these systems for clinical applications in the future.    
1.2.2.2.3 Lipopolyplex
A lipopolyplex is composed of cationic lipids, cationic polymers and nucleic acids. It is a 
hybrid of the lipoplex and polyplex system. In the lipopolyplex system, cationic polymers 
condense nucleic acids into nanoparticles by electrostatic interaction. Lipids are added to 
the system to improve  gene delivery  efficiency  by enhancing endosomal  escape of  the 
complex.  With  the  addition  of  the  lipid,  lipopolyplexes  mediate  100-fold  higher  gene 
delivery efficiency than polyplexes (Hart et al. 1998).79
To further improve gene delivery efficiency, the polymer in the lipopolyplex can conjugate 
with a ligand or NLS to enhance cellular uptake and nuclear localisation of the lipopolyplex 
as described in Section 1.2.2.2.2.   
Lipopolyplexes have been used to deliver siRNA in vivo. Li and co-workers demonstrated 
that  a  lipopolyplex  system  containing  DOTAP/cholesterol,  polyethylene  glycol  (PEG)-
conjugated anisamide ligand, protamine, calf thymus DNA and siRNA against MDM2, c-
myc, and VEGF could mediate specific gene silencing. In this system, calf thymus DNA is 
believed  to  act  as  a  carrier  to  help  siRNA  condensation  with  protamine  to  form  a 
nanoparticle. It was found that this lipopolyplex mediated oncogene silencing and led to 
tumour growth suppression (Li et al. 2008). Despite this promising result, so far this is the 
only report using a lipopolyplex containing genomic DNA for siRNA delivery. Therefore, 
more studies are needed to demonstrate the efficacy and safety of siRNA delivery by this 
system.80
1.3 Barriers to nucleic acid delivery using synthetic vector systems
Although different methods for plasmid DNA or siRNA delivery are available, there is a 
need to improve the in vivo nucleic acid delivery efficiency, especially for siRNA (Li et al. 
2006). Several  key areas  must be  addressed, including  cellular  uptake  of  the  complex, 
release  of  nucleic  acids  within  cells  and  trafficking  of nucleic  acids  to  the  correct 
subcellular compartment, to improve nucleic acid delivery.
1.3.1 Cellular internalisation of vector complexes
Synthetic  nucleic  acid  complexes  can  enter  cells  through  either  the  endocytic  or  non-
endocytic routes (Khalil et al. 2006). There are two main types of endocytosis including 
phagocytosis  and  pinocytosis.  Phagocytosis  occurs  only  in  specialised  cells  such  as 
macrophages whereas pinocytosis can be carried out by all mammalian cells. Four main 
pinocytotic  pathways  have  been  characterised,  namely  clathrin-mediated  endocytosis, 
caveolae-mediated endocytosis, macropinocytosis and clathrin and caveolae independent 
endocytosis. 
1.3.1.1 Clathrin-mediated endocytosis
Upon receptor binding by ligands such as cholesterol or transferrin (Brodsky et al. 2001; 
Schmid 1997), clathrin is recruited and coated on the inner side of the plasma membrane to 
form a pit (Figure 1.7). The pit is then budded off the membrane to form a vesicle (Belting, 81
Sandgren, & Wittrup 2005; Conner & Schmid 2003; Nichols 2003) with a size from 100 to 
150  nm  in  diameter  (Takei  &  Haucke  2001).  The  clathrin  is  then  depolymerised  and 
recycled, and this results in the formation of an early endosome. The endosome fuses with 
other pre-existing endosomes, which further fuse with lysosomes (Brodsky et al. 2001). 
The pH changes through this endocytic process, from neutral to pH 6 in the lumen of the 
early  endosome.  The  pH  further  decreases  to  5  during  the  progression  from  the  late 
endosome to the lysosome (Maxfield & McGraw 2004). Since the complexes within the 
lysosome  will  be  degraded  (Goldstein  et  al.  1985;  Maxfield  &  McGraw  2004),  it  is 
important for the complexes to escape from the late endosome and release the nucleic acid 
into the cytoplasm.
Most  clathrin-mediated  endocytosis  occurs  through  receptor-mediated  endocytosis. 
However,  other  endocytosis  pathways  such  as  caveolae-mediated  endocytosis are  also 
capable of mediating receptor-dependent uptake events (Khalil et al. 2006; Parton et al. 
1994). 82
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Figure  1.7  Clathrin-mediated  endocytosis.  Following  the  ligand  binding  to  a  specific  cell 
receptor, a clathrin coated pit is formed around the particle. The pit is then pinched off from the 
plasma membrane to form an intracellular clathrin-coated vesicle. Depolymerisation of the clathrin 
leads to the formation of an early endosome. The pH in the early endosome decreases when it 
progresses to a late endosome. Molecules may escape from the late endosome to the cytoplasm, 
otherwise the late endosome fuses with a lysosome where the molecules are degraded. 
1.3.1.2 Caveolae-mediated endocytosis
Caveolae are lipid rafts that are rich in cholesterol and glycosphingolipids (Harris et al.
2002; Matveev et al. 2001).They can be flaskshaped, flat, tubular,  or  detached vesiclar
invaginations (50–80 nm in diameter) on the cell surface (Figure 1.8) (Pelkmans et al. 83
2001; Smart et al. 1999), and contain a high level of caveolin proteins, which are essential 
for caveola formations (Harris et al. 2002).
The  mechanism  of  caveolae-mediated  endocytosis  has  been  elucidated  by  the  cellular 
uptake of the SV40 virus. SV40 binds to the cell membrane and becomes trapped in a 
caveola (~50-60nm). The virus is then taken up into a caveosome and delivered to the
endoplasmic reticulum (Conner & Schmid 2003).  
A major difference between clathrin-mediated and caveolae-mediated endocytosis is that 
caveolae-dependent uptake is non-acidic and non-digestive (Ferrari et al. 2003). Since the 
pH does not decrease in the caveolae, the cargo can be transported directly to the Golgi 
and/or  endoplasmic  reticulum,  avoiding lysosomal  degradation (Khalil  et  al.  2006).
Therefore, caveolae-dependent endocytosis may provide an effective route for nucleic acid 
complex internalisation.84
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Figure  1.8  Caveolae-mediated  endocytosis,  macropinocytosis  and  phagocytosis.  Caveolae-
mediated endocytosis occurs when molecules associate to the cell membrane. The molecules are 
then trapped in a caveola and are taken up by the cell via caveosomes. Caveolar uptake is non-
acidic and non-digestive. 
Macropinocytosis allows internalisation of molecules by actin-mediated cell surface ruffling. The 
molecules  are  then  trapped  in  macropinosomes.  In  some  cells  such  as  macrophage,  the 
macropinosomes are fused to lysosomes and the molecules are degraded. In other cells such as 
A431, the macropinosomes are leaky and the molecules are released into the cytoplasm.  
Phagocytosis  occurs  mainly  in  specialised  cells  such  as  phagocytes.  Cell  surface  extension  is 
formed to engulf the molecules. The molecules are internalised in phagosomes. The phagosomes 
are then acidified and develop into mature phagolysosomes where the molecules are degraded. 85
1.3.1.3 Macropinocytosis
Upon  stimulation by  growth  factors  or  other  signals,  cell membrane  ruffles  (Conner  & 
Schmid  2003; Swanson  &  Watts  1995)  due  to  outward-directed  actin  polymerisation
(Figure  1.8).  The  ruffle  then  fuses  with  the  cell  membrane  to  form  a  macropinosome
(Swanson & Watts 1995). Macropinosomes are relatively large, up to 5 µm in diameter. 
The fate of the macropinosome depends on the cell type (Meier & Greber 2003 Swanson &
Watts 1995).For instance, in macrophages, it migrates toward the center of the cell where it 
becomes acidified and merges with a lysosome (Meier & Greber 2003). In other cell types 
such  as  human  A431  cells,  the  macropinosome  does  not  interact  with  endocytic 
compartments (Swanson & Watts 1995). It is believed that macropinosomes are relatively 
“leaky” vesicles  compared  with  other  types  of  endosomes  (Wadia  et  al. 2004),  so  this 
pathway could be effective for nucleic acid delivery (Khalil et al. 2006). 
1.3.1.4 Phagocytosis
Phagocytosis is carried out to clear large (>0.5 µm) pathogens or debris such as bacteria, 
yeast,  dead  cells  or  arterial fat  deposits.  In  mammals,  phagocytosis  is  performed  by 
specialisedcells such as macrophages, monocytes, and neutrophils (Allen & Aderem 1996). 
Particle internalisation is mediated by interaction of specific receptors on the phagocyte 
with  ligands  on  the  surface  of  the  particle  (Figure  1.8).  This  interaction  leads  to  the 86
formation  of  cell  surface  extensions  which  surround  the  particle.  The  particle  is  then 
internalised and trapped in a phagosome, which matures into a phagolysosome in which the
internalised particle is degraded (Allen& Aderem 1996). 
Since phagocytosis is primarily conducted by specialised cells, it is not expected to play a 
significant  role  in  other  cells  for  gene  delivery. However,  some  studies  showed  that  a 
phagocytosis-like mechanism might take part in the uptake of large cationic lipid-DNA 
complexes (lipoplexes) andPEI polyplexes (Kopatz et al. 2004; Matsui et al. 1997).
1.3.1.5 Other internalisation pathways
Some  molecules  such  as the  interleukin  (IL)  2  receptor  β  subunit  glycosyl 
phosphatidylinositol (GPI)-anchored proteins are internalised through endocytic pathways 
other than clathrin-, caveolae-dependent and macropincytotic endocytosis. The mechanisms 
of these pathways are not clearly understood; however, it is found that these pathways 
involve different components to initiate cellular uptake of molecules (Gong et al. 2008).
It was found that some peptides, such as the TAT, penetratin, and VP22 peptides, may be 
able to enter cells without endocytosis (Brooks et al. 2005; Gupta et al. 2005; Nakase et al. 
2004; Thoren et al. 2003; Vives etal. 1997). It was proposed that the positive charge of the 
peptides plays a role in the direct penetration of the lipid bilayer (Trehin & Merkle 2004). 
However, it was shown that the mechanism of internalisation could change to endocytosis 
when these peptides were linked to other cargo (Khalil et al., 2004; Lundberg et al., 2003; 87
Richard et al., 2003). Further studies need to be done to confirm whether non-endocytic 
uptake can be useful for nucleic acid delivery.
1.3.2 Nucleic acid release within cells 
Following  the  cellular  uptake  of  nucleic  acid  complexes,  the  nucleic  acid  needs  to  be 
dissociated from the complex within the cytoplasm or nucleus, depending on the type of 
nucleic  acid  used,  for  its  respective  biological  function  (Khalil  et  al.  2006).  Since  the 
complexes usually localise to endosomes, escape of the nucleic acid is essential. Strategies 
to mediate endosomal escape include the addition of a helper lipid DOPE to stabilise the 
endosomal membrane or the use of a high buffer capacity peptide such as PEI to enhance 
endosomal escape (Section 1.2.2.2.2).
1.3.3 Nuclear transport
After  the  release  of  nucleic  acids,  plasmid  DNA  must  migrate  to  the  nucleus  for 
transcription whereas siRNA must traffick to the P-body in the cytoplasm. Only molecules 
with size less than 70kDa or ~10 nm diameter can pass through nuclear envelope pores; 
therefore,  plasmid  DNA  is  too  large  to  enter  the  nucleus  through  passive  diffusion 
(Melchior & Gerace 1995). It is generally accepted that plasmid DNA nuclear entry can be 
achieved during mitosis when the integrity of the nuclear envelope is temporarily lost. For 
non-dividing cells, plasmid DNA may need assistance from other factors such as an NLS
for nuclear entry (Jans & Hubner 1996).88
1.4 siRNA versus shRNA encoding plasmid
Compared to delivery of plasmid DNA using a synthetic system, delivering siRNA to cells 
is  theoretically  easier  since  plasmid  DNA  must be  transported  into  the  nucleus  while
siRNA is only required to be released in the cytoplasm. Therefore, siRNA can be delivered 
into both dividing and non-dividing cells for gene silencing without a need of a mechanism 
for nuclear uptake.
The  criteria  for  successful  plasmid  DNA  or  siRNA  delivery  systems  are  similar;  both 
vector systems need to mediate cellular uptake of the complexes and allow release of the 
nucleic  acids  within  the  cells.  However,  differences  in  the  structural  and  chemical 
composition and biological  function between  plasmid  DNA  and siRNA  means that  the 
complex formation properties for plasmid DNA delivery may differ from those of siRNA. 
1.4.1 A comparison of the properties of plasmid DNA and siRNA
1.4.1.1 Similarity 
Plasmid  DNA  and  siRNA  share  two  major  similarities.  Firstly,  they  are  both double 
stranded nucleic acids. Secondly, they both have anionic backbones with the same negative 
charge to nucleotide ratio. Therefore, they are both expected to interact electro-statically 
with cationic polymers. Despite the similarities, siRNA and plasmid DNA are different in 
some aspects which may have implications on the interaction to the cationic polymers. 89
1.4.1.2 Differences
1.4.1.2.1 Differences in size and topology/ geometry attributes
Firstly, plasmid  DNA  and  siRNA  have different  sizes.  While  plasmid  DNA  is  usually 
several kilobase pairs long, siRNA is usually 21-23 base pairs. Secondly, the topology of 
siRNA is different to that of plasmid DNA. siRNA is believed to form an A-form helix 
whereas DNA is expected to be in B-form. A-form has a larger diameter and a smaller rise 
per base pair and displacement of the base pairs from the helix axis; therefore, it is stiffer 
than B-form. As a result, the persistence length, which refers to the tendency of a chain to 
persist in a given direction (Hagerman 1997), of the A-form structure is larger than that of a 
B-form structure (Nelson & Cox 2004).
Geometry attribute A-form RNA B-form DNA
Helix sense Right-handed Right-handed
Rise/ bp along the axis 0.27 nm 0.332 nm
Diameter 2.6 nm 2 nm
Persistence length 72nm ± 7 nm 40-50 nm
Table 1.3 A comparison of the topology and geometry attributes of RNA and DNA (Nelson & 
Cox 2004).90
1.4.1.2.2 Half life and duration of biological function
The second major structural difference between siRNA and DNA is the composition of the 
backbone. The backbone of siRNA consists of ribose which has a hydroxyl group in the 2′ 
position of the pentose ring, while the backbone of DNA consists of deoxyribose which 
contains a hydrogen atom at the 2’ position of the pentose ring.  As a result, RNA is more 
susceptible to hydrolysis by serum nucleases which cleave the phosphodiester backbone of 
nucleic acids (Banan & Puri 2004).
In terms of the duration of the biological function, plasmid DNA lasts longer than siRNA.  
Generally plasmid DNA can be expressed transiently for up to 2-3 weeks (Kay et al. 1997) 
whereas siRNA gene knockdown usually lasts for 3-7 days, dependent on the cell types and 
the half life of the targeted gene (Bartlett & Davis 2006). However, modifying the structure 
of the siRNA could result in longer gene silencing effect (Section 1.1.1.4.2). 
1.5 Project aims and objectives
RNAi holds enormous potential for treating a wide range of diseases; however, delivery of 
siRNA to targeted cells is one of the major hurdles to transfer this technology in therapeutic 
uses. Cationic polymers have been used for gene delivery by condensing plasmid DNA to 
form  a  positive  surface  charged  nanoparticle  for  effective  cellular  binding,  uptake  and 
transfection. Therefore  these  polymers  could  possibly be  used  to  condense  and  deliver 
siRNA into cells. Despite the fact that there are different types of cationic polymer systems 
which could be used for siRNA delivery, the discovery of these systems is through trial and 91
error rather than a systematic development process. Therefore, there is a need to identify 
the important criteria for siRNA delivery.
It  is  hypothesised  that  an  efficient  DNA  or  siRNA  delivery  complex  would  be  a 
nanoparticle  with  positive  surface  charge  which  facilitates  cellular  binding  and uptake. 
These complexes would have similar dissociation properties to allow the nucleic acids to 
detach from the complexes for transcription or gene silencing.  Therefore, the aims of this 
study are:
 to systematically clarify the relationship between the biophysical and transfection 
properties of effective cationic polymer based plasmid DNA delivery systems.
 to  elucidate  the  requirements  of  the  cationic  polymers  for  successful  siRNA 
complex formation and delivery.
 to compare the biophysical properties between efficient DNA and siRNA delivery 
systems  so  as  to  generate  information  for  further  development  of  an  effective 
siRNA delivery system.92
Chapter 2
Materials and methods93
2.1 Materials
Unless  otherwise  stated,  all  tissue  culture  reagents  were  supplied  by  Gibco  BRL 
(Invitrogen), and all general chemicals were supplied by Sigma.
2.1.1 siRNA
Reagents Suppliers
Silencer Cy-3 labelled siRNA Ambion
Anti-Luc siRNA (Appendix I) Dharmacon
Anti-eGFP siRNA (Appendix I) Dharmacon
Anti-GAPDH siRNA (Appendix I) Ambion
Irrelevant siRNA control Ambion
Table 2.1 The siRNA used in this study.94
2.1.2 Transfection reagents
Reagents Suppliers
Linear PEI Polyplus transfection
Branched PEI Sigma
Lipofectin  Invitrogen
Lipofectamine 2000 Invitrogen
siLentfect Biorad
The linear lysine peptides (K8, K16, K24 
and K32) and peptide Y
Synthesised by immunoKontact
The Kbranch peptide Synthesised by UCL chemistry department
Ultrapure water Gibco, Invitrogen
5 × reporter lysis buffer Roche
Luciferase reporter gene assay kits Promega
Protein assay buffer Biorad
Bovine serum albumin Sigma
KDalert GAPDH kits Ambion
CellTiter 96 AQueous One Solution Assay Promega
Table 2.2 The transfection reagents used in this study.95
2.1.3 Reagents for DNA manipulation
Reagents Suppliers
Restriction enzymes and buffers Promega
Ligase and buffers Promega
Ethidium bromide Sigma
Plasmid endofree miniprep and endofree 
maxiprep kits
Qiagen 
QIAquick gel extraction kit Qiagen
DH5 Competent Cells Invitrogen
Agar MERCK
Ampicillin Stratagene
Luria Broth Base (LB) Invitrogen
Magnesium Chloride Fisher Scientific
Table 2.3 The reagents for DNA manipulation used in this study.
2.1.4 Reagents for electrophoresis
Reagents Suppliers
Agarose and low melting point agarose Invitrogen
Loading dye (10 mM Tris pH 7.5, 50 mM 
EDTA, 10% Ficol 400, 0.4% Orange G)
Sigma
1 Kb+ ladder Invitrogen
siRNA ladder Promega
1× TAE (40 mM Tris-acetate, 5 mM 
EDTA)
Sigma 
Table 2.4 The reagents used for electrophoresis. 96
2.1.5 Tissue culture reagents
Reagents/apparatus Suppliers
DMEM, sodium bicarbonate, sodium 
pyruvate, Optimem, Trypsin/EDTA, PBS, 
ULTRApure water 
Gibco, Invitrogen
Black-walled plates for luciferase assay Fisher Scientific
Fetal calf serum (FCS), Minimum 
Essential Medium Eagle
Sigma
DMSO Sigma
Tissue- culture treated flasks, dishes and 
plates
Nunc
Table 2.5 The reagents and apparatus used for tissue culture.
2.1.6 Cell lines
Name Origin
HEK 293T Human  embryonic  kidney  cell  line 
(ATCC: CRL-11268)
HEK 293T eGFP expressing cell Kind gift from Dr. Tassos Georgiadis
(Institute of Child Health, University 
College London)
HT1080   Human fibrosarcoma cell line (ATCC:
CCL-121)
Neuro 2a Mouse neuroblastoma cell line (ATCC: 
CCL-131)
NIH 3T3 Mouse fibroblast (ATCC: CRL-1658)
Table 2.6 The cell line used in this study.97
2.1.7 Reagents, apparatus and machines for PicoGreen related, particle 
sizing and zeta potential assays
Reagents/apparatus/machines Suppliers
TE buffer Sigma
PicoGreen Invitrogen 
Heparin Sigma
Colourless flat bottomed 96 well plate  Greiner bio-one
FLUOstar Optima BMG labtech
Low volume disposable cuvette Sarstedt, Germany
Zetasizer folded capillary cell Malvern
Zetasizer Nano S and the related software 
(Dispersion technology software v.5.03)
Malvern 
Table 2.7 The reagents, apparatus and machines used for the PicoGreen related, particle 
sizing and complex surface charge assays.98
2.1.8 Reagents, apparatus and machines for flow cytometry and 
confocal imaging
Reagents/apparatus/machines Suppliers
Vectashield mounting medium for 
Fluorescence with DAPI
Vector Laboratories
Alexa Fluor 488 phalloidin Molecular Probe, Invitrogen
1 × PBS Gibco, Invitrogen
Polylysine slide and cover slip VWR International Inc.
Formaldehyde Polysciences, Inc
0.5% triton Sigma
Mounting varnish  Maxiflex
Immedge pen Vector Laboratories
Milli-Q water Milli-Q Biocel System
Cy5 DNA labelling kit Mirus
Confocal microscope and the related 
software (LCS Lite version)
Leica
Flow cytometry tube Nunc
Epics XL flow cytometer and the related 
softwares (Summit v.4.3 and FlowJo 
v.8.6.3)
Beckman Coulter
SPECTRAmax plate reader Molecular Devices
Table 2.8 The reagents, apparatus and machines used for flow cytometry and confocal 
imaging.99
2.1.9 Reagents, apparatus and machine for Real Time PCR
Reagents/apparatus/machine Suppliers
RNAeasy kit Qiagen
Taqman primers and probes Applied Biosystems
Platinum qPCR SuperMix-UDG with ROX Invitrogen
DNase I and buffer Invitrogen
Superscript II Invitrogen
Reagents for cDNA formation Invitrogen
ABI Prism and the related software Applied Biosystems
Table 2.9 The reagents, apparatus and machine used for Real Time PCR.
2.1.10 Centrifuges
Centrifuges Suppliers
Microcentrifuge Heraeus Biofuge Fresco
Tabletop centrifuge Sorvall Legend RT
Superspeed centrifuge Sorvall Evolution RC
Table 2.10 The centrifuges used in this study.100
2.2 Methods
2.2.1 Bacterial Manipulation
2.2.1.1 Growth and Maintenance of Escherichia coli 
Escherichia coli (E.coli) were either cultured in liquid LB media at 37 ºC with 250 r.p.m
agitation  or  plated  out  on  solid  LB  plates  containing  1.5 %  bacto  agar.  E.coli 
transformed  with  plasmids  were  maintained  in  the  LB  media  supplemented  with 
ampicillin (100 µg/ml) at the same conditions.
To store the transformed E.coli, the bacterial cultures were mixed with glycerol in 20 % 
volume for volume (v/v) and kept at -80 °C.
2.2.1.2 Transformation of E.coli by heat shock method
100 µl of competent DH5α cells were transformed with 100 ng of plasmid DNA by 
incubating the cells on ice for 40 minutes and then heat-shocking the cells at 42 °C for 
90 seconds, followed by a further 2 minutes incubation on ice. The cells were diluted to 
a final volume of 1 ml in 37 °C pre-warmed LB media and the media/bacterial culture
was agitated at 250 r.p.m at 37 °C for 1 hour. Following incubation, 100 µl of the culture 
was spread on LB agar plates containing 100 µg/ml of ampicillin, and the plates were 
incubated overnight at 37 °C.101
2.2.2  DNA manipulation
2.2.2.1 Restriction Enzyme Digestion
1 µg plasmid DNA (pCEP4 or pCI-Luc) was digested in a final volume of 20 µl with 10 
× buffer, bovine serum albumin (BSA) and restriction enzyme (NotI or HindIII) at 37 °C 
for 3 hours (Table  2.11). Following the digestion, the reaction was stopped by heat 
inactivation of the endonucleases at 65 °C for 10 minutes. The two digestions with NotI
or  HindIII were  performed  sequentially,  and  DNA  digestion  was  verified  by 
visualisation of DNA fragments following 1 % agarose gel electrophoresis. 
Reagents Volume
Milli-Q water 14µl
BSA (10 mg/ml) 2 µl
10× buffer 2 µl
Restriction enzyme (NotI or HindIII) 1 µl
Plasmid DNA (pCEP4 or pCI-Luc)
(1 mg/ml)
1 µl
Total volume 20 µl
Table 2.11 The reagents used for restriction digestion of pCEP4 or pCI-Luc.
2.2.2.2 Agarose Gel Electrophoresis
The  DNA  fragments  were  separated  by  electrophoresis  using  1 %  agarose  gels.  To 
prepare  the  gels,  agarose  powder was  dissolved  in  1 ×  TAE  buffer by boiling in  a 102
microwave oven for 1-2 minutes. After cooling the agarose solution, 0.5 g/ml ethidium 
bromide was added for visualisation of the DNA samples. The agarose solution was then 
poured into a gel rack with a comb inserted on one side of the rack. Once the gel had 
formed, it was put in a gel tank filled with 1 × TAE buffer. DNA samples then were 
mixed with Orange G loading buffer in a 5 to 1 (v/v) and loaded onto the agarose gels. A 
“1 Kb plus DNA ladder” was loaded onto the gels for estimation of the DNA fragment
sizes. Under a voltage of 50-100 V (up to 150 mA), the DNA fragments were resolved 
and  were  visualised  by  exposure  to  a  ultra-violet  lamp  using  an  UVIdoc  gel 
documentation system.
2.2.2.3 Gel Purification of DNA
Following electrophoresis, DNA fragments were excised from 1% agarose gels using a 
clean  scalpel  blade  under  ultra-violet  light.  The  DNA  was  then  extracted  from  the 
agarose gel by a silica membrane in high-salt buffer using a QIAquick gel extraction kit 
following the manufacturer’s instructions.
2.2.2.4 Ligation
The DNA fragments were ligated at vector to insert ratios of 1:3, 1:6 or 1:9 (100 ng 
vector DNA). With a final volume of 10 µl of 10 × T4 DNA ligase buffer (diluted to 1 ×
with distilled water) containing 1 unit of T4 DNA ligase, the ligation reactions were 103
performed overnight at 16 °C. The end products of the reactions were either used to 
transform chemically-competent E.coli (2 µl) or stored at -20 °C for later use.
2.2.2.5 Measurement of nucleic acid concentration and purity
Nucleic acid concentration was measured from light absorbance at a wavelength of 260
nm  (A260)  using  a  NanoDrop  ND-1000  spectrophotometer.    The  DNA  purity  was
determined by dividing the A260 by the absorbance value of protein at 280 nm (A280). 
Any value equal or higher than 1.8-2.0 indicated that the DNA was acceptably pure for 
downstream procedures (Dieffenbach & Dveksler 2003).
2.2.2.6 Plasmid DNA preparation
For small scale plasmid DNA preparation, transformed E.coli were inoculated in 5 ml of 
LB medium containing ampicillin (100 µg/ml) overnight (overnight cultures). Plasmid 
DNA was then prepared from the overnight cultures by alkaline lysis on a resin column 
and  precipitated  with  isopropanol  using  Qiagen  Mini-prep  kits  according  to  the 
manufacturer’s instructions.
For  large  scale  plasmid  DNA  preparation,  100 µl  of  a  6-hour starter  culture  were 
inoculated in 100 ml of LB medium containing ampicillin (100 µg/ml) overnight at 37
oC with constant agitation at 250 r.p.m. Plasmid DNA was then prepared using Qiagen 
Endofree Maxi-Prep kits following the manufacturer’s instructions.104
2.2.3 Cell Culture
2.2.3.1 Propagation of adherent cell lines
All adherent cell lines were maintained in their respective medium as shown in Table 
2.12. Cells were grown in 25 cm
2, 80 cm
2 or 175 cm
2 tissue culture flasks or in 10 cm 
tissue culture dishes in 37 ºC incubators in a 5 % CO2 atmosphere. Cells were passaged 
when 80-90 % confluence was reached. To passage the cells, the cells were washed 
twice with Dulbecco’s phosphate buffered saline (1 × PBS). Following removal of the 
PBS, the cells were incubated with trypsin/EDTA for 5 minutes at 37 °C. The cells were 
then pelleted by centrifugation at 1200 r.p.m (306 × g) for 5 minutes. The supernatant 
was removed and the pellet was resuspended in full growth medium. One tenth of the 
cells were split to a new culture flask. Completed medium was added to fill up the flask 
to its suggested optimum volume.
Cell line Complete growth medium
293T and 293T eGFP expressing cells DMEM supplemented with 10% FCS 
HT 1080 Minimum  Essential  Medium  Eagle 
supplemented with 10% FCS, 1% sodium 
pyruvate and 1% L-Glutamine
Neuro2a  and  Neuro  2a  luciferase 
expressing cells  
DMEM supplemented with 10% FCS, 1% 
sodium  bicarbonate  and  1%  sodium 
pyruvate
NIH 3T3 DMEM supplemented with 10% FCS and 
2% sodium bicarbonate
Table 2.12 The complete growth media to culture the cell lines used in this study. 105
2.2.3.2 Long Term Storage of Cell Lines
For long term storage, 2-5 x 10
6 cells or cells of a 90 % confluent monolayer from a 80 
cm
2 tissue culture flask were pelleted by centrifugation at 1200 r.p.m (306 × g) for 5 
minutes. The cells were then resuspended in 1 ml freezing medium (90 % FCS, 10 % 
dimethylsulfoxide  (DMSO))  and  transferred  to  a  cryovial.  Cells  were  frozen  slowly 
overnight to -70 °C in an isopropanol freezing box, then transferred to liquid nitrogen.
To revive the frozen cells, an aliquot of cells was thawed in a 37 °C waterbath and 
transferred quickly to 9 ml complete growth medium. The cells were pelleted at 1200 
r.p.m (306 × g) to remove the DMSO and then resuspended in 5 ml complete growth 
medium and transferred to a 25 cm
2 tissue culture flask.
2.2.3.3 Mammalian cell transfection
2.2.3.3.1 Plasmid transfection using polyplex
All  the  plasmid  transfections  were  performed  either  with  plasmid  expressing  eGFP 
(pEGFP-N1) (Appendix II) or plasmid expressing luciferase (pCI-Luc) (Appendix II).
Cells were seeded 24 hours before transfection in order to reach 70 % confluence/well in 
either 12 well or 96 well plates. Plasmid transfection complexes were formed by mixing 
50 µl lysine based peptides or PEIs with 50 µl plasmid DNA in different Nitrogen to 
Phosphate  (N/P)  ratios  in  Optimem  for  30  minutes  at  room  temperature (Section 106
2.2.3.3.1.1 for the calculation of the N/P ratio, and Section 4.1.1 and 4.1.2 for the 
lysine based peptides and PEIs). Optimem was then added to dilute the complexes so 
that complexes containing 0.125 to 0.5 µg DNA in 200 µl were used in a well of 96 well 
plates whereas complexes containing 1 to 2 µg DNA in 1ml were used in a well of 12
well plates. After removing complete media from the cells, polyplexes were added to the 
plates.  Following  centrifugation  at  1500  r.p.m (478  ×  g) at  room  temperature  for  5 
minutes to increase the transfection efficiency, the plates were incubated with the cells 
for 4 hours at 37 °C, 5% carbon dioxide. The polyplexes were replaced by normal media 
for 24 hours for luciferase assay or 48 hours to visualise eGFP expression.   
2.2.3.3.1.1 Calculation of Nitrogen/Phosphate (N/P) ratio (charge ratio) 
To calculate the N/P ratios of the lysine based peptides, firstly the nitrogen (N) value of 
each peptide was calculated as follows:
N value= (mass / molecular weight) × net charge
Molecular weight Net charge (N)
K8 1043 +8
K16 2068 +16
K24 3111 +24
K32 4154 +32
Kbranch 3072 +14
Table 2.13 The molecular weight and net charge of the peptides used in this study.107
The calculation of the phosphate (P) value of the DNA and siRNA:
P value= (mass / molecular weight) × net charge
Molecular weight Net charge (P)
Anti-Luciferase  13278 -42
Anti-eGFP  13323.1 -42
pCI-Luc 3753380 -11386
Table 2.14 The molecular weight and net charge of the nucleic acids used in this study.
The calculation of the N/P ratios of B-PEI and L-PEI were performed as follows:
N/P ratio = (Volume of L-PEI in µl × 50) / mass of the nucleic acids
The B-PEI was diluted to 1 mg/ml in MilliQ water. 6.5 µl B-PEI was diluted in 493.5 µl 
MilliQ before use. For calculation of N/P ratio of the B-PEI is as follows:
N/P ratio = (Volume of B-PEI in µl × 10) / mass of the nucleic acids108
2.2.3.3.2 Plasmid transfection using lipoplex or lipopolyplex
The transfection procedures were as stated in Section 2.2.3.3.1, except for transfection 
complex preparation procedures. For plasmid transfection using lipoplexes, 50 µl lipids 
were  mixed  with  50  µl  plasmid  DNA  in  desired  weight  ratios  in  Optimem  for  30 
minutes  at  room  temperature.  For  plasmid  transfection  using  lipopolyplexes,  50  µl 
Lipofectin,  80  µl  epithelial  targeting  peptide  (K16Y)  with  the  sequence  K16-
GACYGLPHKFCG and 50 µl plasmid DNA were prepared in a 2:4:1 ratio (w/w/w) in 
Optimem  for  30  minutes  at  room  temperature. Optimem  was  added  to  dilute  the 
complexes so that complexes containing 0.125 to 0.5 µg DNA in 200 µl were used per 
well of 96 well plates whereas complexes containing 1 to 2 µg DNA in 1 ml were used 
per well of 12 well plates.
2.2.3.3.3 siRNA transfection using polyplex
Cells  were  seeded  24  hours  before  transfection  in  order  to  reach  30-50 % 
confluence/well in either 12 well or 96 well plates. siRNA transfection complexes were 
formed by mixing 50 µl of the cationic polymers or peptides with 50 µl of siRNA in 
different N/P ratios (Section 2.2.3.3.1.1 for calculation of the N/P ratio) in Optimem 
for 30 minutes at room temperature. Optimem was then added to dilute the complexes so 
that complexes containing 1 to 32 nM siRNA in 200 µl were used per well of 96 well 
plates whereas complexes containing 5 to 150 nM siRNA in 1 ml were used per well of 
12 well plates. After removing complete media from the cells, polyplexes were added to 109
the plates. Following centrifugation at 1500 r.p.m (478 × g) at room temperature to 
increase the transfection efficiency, the plates were incubated with the cells for 4 hours 
at 37 °C, 5% carbon dioxide. The polyplexes were then replaced by normal media after 
the transfection.   
2.2.3.3.4 siRNA transfection using Lipofectamine 2000 (L2000) 
The  transfection  procedures  were  as  stated  in  Section  2.2.3.3.3  except  transfection 
complex  preparation  and  exposure  time  of  the  transfection  complexes.  For  24  hour 
transfection in a 96 well plate setting, 0.125-1 µl of L2000 was diluted into 25 µl with 
Optimem  and  was  mixed  with  25 µl  siRNA  in  Optimem  for  20  minutes  at  room 
temperature. The complexes were then overlaid onto the cells containing 150 µl full 
growth  medium  per  well.  Complexes  were  replaced  with  fresh  complete  medium 
following transfection. In a 12 well plate setting, 0.5-1 µl of L2000 was dilute into 25 µl 
with Optimem and was mixed with 25 µl siRNA in Optimem for 20 minutes at room 
temperature.  The  complexes  were  then  overlaid  onto  the  cells containing  950µl  full 
growth medium per well.
For 4 hour transfection in 96 well plates, 0.125-0.5 µl of L2000 was diluted into 25 µl 
with Optimem and was mixed with 25 µl siRNA in Optimem for 20 minutes at room 
temperature. The complexes were then diluted in Optimem so that complexes containing 
1 to 32 nM siRNA in 200 µl were used in 96 well plates. After removing complete 
media from the cells, the complexes were added to the plates. Following centrifugation 110
at 1500 r.p.m (478 × g) at room temperature to increase the transfection efficiency, the 
plates were incubated with the cells for 4 hours at 37 °C. The complexes were then 
replaced by normal media after the transfection. In 12 well plates, 0.5-1 µl of L2000 was
diluted into 25 µl with Optimem and was mixed with 25 µl siRNA in Optimem for 20 
minutes at room temperature.  The complexes  were then  diluted in Optimem so  that 
complexes containing 5 to 150 nM siRNA in 1 ml were used per well. 
2.2.3.3.5 siRNA transfection using siLentfect
The  24  hour  transfection  procedures  were  as  stated  in  Section  2.2.3.3.4  except  the 
transfection complex  preparation procedures.  0.1-0.4 µl/well of siLentfect  was dilute 
into 25 µl with Optimem and was mixed with 25 µl siRNA in Optimem for 20 minutes 
at room temperature. The complexes were then overlaid onto the cells containing 150 µl 
full growth medium per well in a 96 well plates. Complexes were replaced with fresh 
full growth medium following transfection. 111
2.2.4 Construction of stable luciferase expressing Neuro 2a cells 
2.2.4.1 Kill curve
Following seeding of 5 × 10
5 Neuro 2a cells per well of 6 well plates with full growth 
medium for 24 hours, different concentrations of hygromycin B, ranging from 0-1000 
µg/ml, were added to the cells. After washing with PBS, the cells were trypsinised and
counted at day 1, day 2 and day 4 following addition of hygromycin B. During cell 
counting, the cells were treated with trypan blue to distinguish viable cells and were 
counted using a hematocytometer. The numbers of viable cells from the treatments of 
different hygromycin B concentrations over the time course were used to plot a kill 
curve to indicate the optimal hygromycin B concentration for stable cell line generation. 
200 µg/ml hygromycin B was deemed to be suitable for generation of stable Neuro2a
cells.
2.2.4.2 Transfection
The luciferase reporter gene of pCI-Luc was subcloned into pCEP4, which consists of a 
hygromycin  B  resistant  gene, to  yield  pCEP4-Luc  for  transfection  as  described 
previously.  Briefly,  10
6 Neuro  2a  cells  were  seeded  in  a  10  cm tissue  culture  dish 
overnight. The cells were transfected with complex composing 2 µg of pCEP4-Luc and 
8 µg  of  lipofectin  for  4  hours.  Following  removal  of  the  transfection  complex,  full 
growth medium containing 200 µg/ml hygromycin B was added to the cells.112
2.2.4.3 Selection
Fresh full growth medium containing 200 µg/ml hygromycin B was exchanged every 3 
days and dead cells gently washed off with PBS during the selection process, which 
lasted for 4 weeks.  After 10 to 14 days of the transfection procedure, single viable cells 
appeared (Section 3.2.3.4). The single cells were observed until discrete colonies were 
formed. The colonies were harvested into separate wells of a 96 well flat-bottomed plate 
and expanded in antibiotic selection medium until cells were confluent in 6 well plates.
10
5 cells  were  then  seeded  in  96  well  plates  to  test  for  luciferase  expression.  Once 
luciferase  expression  was  confirmed,  the  cells  were  further  expanded  into  a  tissue 
culture flask. Some of the cells were then frozen for long term storage as described 
previously.  
2.2.4.4 In vivo tumour formation
Procedures were performed in line with the animal scientific procedure act 1986 home 
office regulations. 1.5×10
6 Neuro 2a luciferase expressing cells in 100 µl PBS were
injected subcutaneously into the right posterior flank of five 6-8 weeks female AJ 3.1 
mice. After 10 to 15 days, tumours with a minimum 12mm diameter were harvested and 
frozen at -80 °C. Following thawing of the tumours on ice, they were homogenized in 
Reporter Lysis Buffer and the luciferase expression in the lysates were assayed.113
2.2.5 Gene expression and cytotoxicity analyses 
2.2.5.1 Luciferase expression assay
For a 96 well plate setting, cells were washed twice with 1 × PBS and incubated with 20
µl/well  1 × reporter lysis  buffer for 20 minutes  at 4 °C then -80 °C  for at least 30 
minutes. After the cells were defrosted at room temperature, luciferase assay buffer was 
prepared as described according to the manufacturer’s protocol and 100 µl buffer was
added  to  each  well.  Luciferase  activity  in  the  cells  was then  measured  in  terms  of 
Relative Light Unit (RLU) using FLUOstar Optima. Protein content of each cell lysate 
was estimated by transferring 20 µl lysate to 180 µl 1 × Bio-Rad Protein Assay Reagent. 
After 10 minutes incubation of the lysate and the reagent, the OD590 of the mixture was
recorded and the protein content of each lysate was calculated by comparing the OD590 
with a BSA standard curve. RLU per milligram (mg) of protein represented luciferase 
activity per protein unit (RLU/mg). 
For a 12 well plate setting, cells were washed twice with 1 × PBS and incubated with 
100 µl/well 1 × reporter lysis buffer for 20 minutes at 4 °C then -80  °C for at least 30 
minutes. After the cells were defrosted at room temperature, 20 µl/well of cell lysate was
transferred to a 96 well plate. The downstream procedures were then the same as the 96 
well plate luciferase assay as mentioned above.  114
For  gene  knockdown  assays,  the  RLU/mg  of  the  cells  treated  with  siRNA  was
normalised  to  the  untreated  luciferase  expressing  cells  to  yield  percentage  of  gene 
knockdown. 
2.2.5.2 eGFP expression assay
eGFP expression  was detected  by  FLUOstar Optima using  the fluorescent  screening 
detection mode with a 488nm excitation filter and 520 nm emission filter. The eGFP 
signal was expressed as Relative Fluorescent Unit (RFU). To standardise the RFU signal 
with cell number, cell titer assay buffer was prepared according to the manufacturer’s
protocol and 100  µl  of the buffer was added per well of  the cells.  After 2 minutes 
incubation at room temperature with the cell titer assay buffer, the RLU of the lysates, 
which indicated the number of cells, were recorded and the RLU of each lysate was
compared to the standard curve generated from RLU of different cell numbers to yield 
the cell number. The eGFP signal per cell was calculated by dividing RFU by the cell 
number from the same well.
For gene knockdown assays, 293T eGFP expressing cells, a kind gift from Dr. Tassos 
Georgiadis (Institute of Child Health, University College London), were used. Following 
siRNA transfection, the reduced level of RFU from the cells treated with siRNA was
normalised  with  the  untreated  eGFP  expressing  cells  to  yield  percentage  of  gene 
knockdown. 115
2.2.5.3 GAPDH expression assay
The GAPDH knockdown in the cells was studied two days post siRNA transfection in a 
96 well plate setting by measuring the conversion rate of NAD
+ to NADH by GAPDH 
using KDalert GAPDH assay kit following the manufacturer’s instructions. The GAPDH 
activity was measured using real time kinetic measurements by FLUOstar Optima.  
2.2.5.4 Cell toxicity assay
Cell toxicity was assessed using the CellTiter 96 AQueous One Solution Assay which is 
a  colorimetric  method  for  determining  the  number  of  viable  cells.  The  assay  was 
performed essentially as described in the manufacturer’s protocol. 5 × 10
4 Neuro 2a cells 
were transfected with siRNA complexes or B-PEI alone for 4 hours in a 96 well plate as 
described in Section 2.2.3.3.3. Following the transfection, 100μl full growth medium 
was added to the cells and incubated for 24 hours. 20 µl of CellTiter 96 AQueous One 
Solution was added to the untreated cells, treated cells and 3 wells containing medium 
only. The cells were incubated for 3 hours at 37°C, and the absorbance at 490nm was 
recorded using a SPECTRAmax plate reader. Background 490nm absorbance from the 
triplicate set of control wells (medium only-"no cell" control) was calculated and the 
average 490nm absorbance from the “no cell”control wells subtracted from all other 
absorbance values to yield corrected absorbances.116
2.2.6  Methods  related  to  the  biophysical  studies  of  the  nucleic  acid 
complexes
2.2.6.1 Gel retardation assay
Gel  retardation  assay  is  an  application  of  agarose  gel  electrophoresis.  In  this  assay, 
lysine based peptides or PEIs were mixed with nucleic acids and loaded onto the gel. 
Under an electric field, nucleic acids which bind to lysine based peptides or PEIs were 
retarded from migration due to their increased size and the decreased negative charge of 
the complexes. When lysine based peptides or PEIs neutralised all charges of the nucleic 
acids, the complexes did not migrate through the gel, suggesting the formation of stable 
complexes.
To resolve DNA or siRNA complexes, 0.2µg DNA or siRNA was diluted to 10 µl in 
distilled water and used to form a complex with 10µl complex reagents in distilled water 
at  different  N/P  ratios.  Following  30  minutes  incubation  at  room  temperature,  4 µl 
loading dye was added to the complexes. DNA complexes were then loaded onto a 1 % 
agarose gel whereas siRNA complexes were loaded onto a 4 % agarose gel (Section 
2.2.2.2). As a control, 0.2 µg naked DNA or siRNA was diluted to 20 µl in distilled 
water and mixed with 4 µl loading dye prior to addition to the gels. 10 µl DNA or
siRNA ladder was also loaded onto the respective gels. Following electrophoresis, the 
images  of  the  complex  migration  patterns  were  recorded  by  an  UVIdoc  gel 
documentation system.117
2.2.6.2 PicoGreen fluorescence quenching experiment
The PicoGreen fluorescence quenching assay provides another way to investigate the 
effectiveness  of  lysine  based  peptides  or  PEI  nucleic  acid  complex  formation.  The 
PicoGreen  reagent  intercalates  with  double  stranded  nucleic  acids  and  emits 
fluorescence  when  exposed  to  UV  light.  Complex  formation,  however,  shields  the 
nucleic  acids  from  exposure  to  the  excitation  waves  and  therefore  quenches  the 
fluorescent signal.  Thus,  a lower fluorescence value indicates increasing binding of 
nucleic acids to the lysine based peptides or PEIs.
To carry out the assay, PicoGreen was diluted in 1 × TE buffer and added to DNA or 
siRNA diluted in 1 × TE buffer. PicoGreen was added to DNA or siRNA in 1:150 (v/v) 
for 10 minutes at room temperature so that every 100 µl of the solution contained 0.2 µg 
nucleic acid. During the incubation of the DNA or siRNA to the PicoGreen, different 
amount of peptides or PEIs were diluted in 1 × TE buffer. Following incubation, 100 µl 
peptides or PEIs were added per well of flat bottomed 96 well plates and 100 µl (0.2 µg) 
DNA  or  siRNA  containing the  PicoGreen was  added to  the  peptides  or  PEIs.  As  a 
control, 100 µl naked DNA or siRNA labelled with PicoGreen was added to 100 µl 1 ×
TE  buffer  per  well  in  96  well  plates.  Following  30  minutes  incubation  at  room 
temperature, 100 µl 1 × TE buffer was added to each well. The PicoGreen signals were 
then detected with a fluorescent plate reader, FLUOstar Optima. The PicoGreen signals 
from the complexes were normalised with the naked DNA or siRNA control to yield the 
percentage of the PicoGreen signal detected.118
2.2.6.3 Heparin induced complex dissociation assay
Once taken up by the cells, an effective nucleic acid delivery system should allow DNA
or siRNA to dissociate from the vector components so that the DNA can traffick to the 
nucleus for gene expression whereas the siRNA should be retained in the cytoplasm for 
gene silencing. The abilities of the lysine based peptides or PEIs to dissociate from DNA 
were studied using heparin sulfate, a competitive binding agent (Sundaram et al. 2005).
Heparin is highly negative and can compete with nucleic acids in binding with lysine
based  peptides  or  PEIs.  Therefore,  addition  of  different  amount  of  heparin  to  the 
complexes allows an estimation of the dissociation behaviors of complexes.
To carry out this assay, 100 µl (0.2 µg) DNA or siRNA labelled with PicoGreen was 
added to 100 µl peptide or PEI per well in 96 well plates. As a control, 100 µl naked 
DNA or siRNA labelled with PicoGreen was added to 100 µl 1 × TE buffer per well. 
Following 30 minutes incubation at room temperature, 100 µl heparin diluted in 1 × TE 
buffer was added to 200 µl complexes or naked DNA or siRNA for 30 minutes. The 
fluorescent signals from PicoGreen were recorded using the fluorescent plate reader, 
FLUOstar  Optima.  siRNA  or  DNA  alone  labelled  with  PicoGreen  were  used  to 
normalise the PicoGreen signal detected from the complexes.119
2.2.6.4 Particle sizing 
The  sizes  of  the  complexes  were  measured  by  a  technique  called  Dynamic  Light 
Scattering (DLS). In this technique, a laser is applied across the complexes in suspension. 
As a result of the movements of the complexes due to Brownian motion, the intensity of 
the scattered  laser light changes  at a  rate  depending on  the sizes  of the  complexes. 
Analysis of these intensity fluctuations leads to velocities of the complex motions which 
can then use to estimate the sizes of the particles (Malvern Instruments Ltd. 2009).
10 µg DNA or siRNA was diluted to 25 µl in Ultrapure water and mixed with 25 µl 
cationic peptides or PEIs in Ultrapure water at different N/P ratios at room temperature. 
The complexes were then diluted to 500 µl in Ultrapure water and transferred to a low 
volume  transparent  cuvette.  The  cuvette  was  then  placed  into  the  particle  sizing 
machine, Malvern Nano ZS, for particle size measurement using the DLS technique. The 
data were then processed using Dispersion Technology Software (DTS) v.5.03.
Two types of data, the Z-average size and the polydispersity index, were generated. The 
Z-average  size  refers  to  the  mean  hydrodynamic  size  of  the  particle  whereas  the 
polydispersity  index  reflects  the  range  of  the  particle  size  distribution.  The 
polydispersity index can range between 0 and 1. Particle with polydispersity values less 
than 0.2, which were deemed to be monodisperse, were presented in this study.    120
2.2.6.5 Zeta potential 
The  surface  charge  of  the  complex  interacts  with  the  surrounding  ions,  creating  a 
charged layer  around the  complex. This  charged layer is  a spatial  dimension that  is 
associated to the  complex,  and the potential  in the layer is  called the  zeta potential
(Malvern Instruments Ltd. 2009b) (Figure 2.1). 
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Figure 2.1 A schematic diagram showing the zeta potential of a complex.
In order to measure zeta potential of the complexes, an electric field is applied across the 
complex  suspension.  Complexes  with  a  surface  charge  will  migrate  toward  the 
oppositely charged electrode with a velocity proportional to the magnitude of the zeta 
potential (Malvern Instruments Ltd. 2009b). 121
This velocity is measured using the technique of Laser Doppler Anemometry (LDA). 
Upon illumination by laser, the movements of the complexes will cause a frequency 
shift or phase shift of the incident laser. This is measured as the particle mobility which 
can be converted to the zeta potential (Malvern Instruments Ltd. 2009b).
10 µg DNA or siRNA was diluted to 25 µl in Ultrapure water and mixed with 25 µl 
cationic peptides or PEIs in Ultrapure water at different N/P ratios in room temperature. 
The complexes  were then  diluted  to  700 µl in  Ultrapure water  and  transferred  to  a 
capillary cell. The capillary cell was then placed into the Malvern Nano ZS for the zeta 
potential measurement. The data were then processed using DTS v.5.03.122
2.2.7 Methods related to flow cytometry analysis
2.2.7.1 Introduction to flow cytometry analysis
A  flow  cytometry  machine  can  separate,  classify  and  quantify  living  cells in  a 
suspension on the basis of size and the colour of the fluorescence emitted from a labelled 
fluorophore associated with a cellular structure. In principle, cell suspensions are passed 
through a narrow dropping nozzle so that each cell is in a small droplet. One or more 
laser beams are passed through the cell, causing light to scatter and fluorescent dyes to 
emit light at various frequencies. Photomultiplier tubes (PMT) receive the scattered light 
signals and convert them to electrical signals. The electrical signals will then generate 
into data by a computer connected to the machine (Shapiro 2003).
Three  types  of  data  will  be  generated; data  from  forward  scatter,  side  scatter  and 
fluorescence. The forward scatter data estimate the approximate cellular size while the 
side scatter data identify cell complexity and granularity. With these data, the dead cells 
and debris can be identified. Under the illumination of a laser beam, the fluorophores 
associated with the cells will fluoresce and such fluorescence will be collected by the 
PMT (Shapiro 2003).
In this study, the fluorescent dyes propidium iodide (PI) and 7-amino-actinomycin D 
(7aad) were used as dyes for investigating cell death. Both dyes work by binding to 
double stranded nucleic acids and emit fluorescence. As the dyes can only penetrate 123
though the cell membranes of dead or dying cells to intercalate with the genomic DNA, 
they can be used to distinguish viable cells from dead cells (Shapiro 2003).
2.2.7.2 Fluorescence labelling of plasmid DNA
Plasmid  DNA  were  covalently  labelled  with  Cy5  for  flow  cytometry  and  confocal 
studies using Label IT Tracker Cy 5 kit following the manufacturer’s instructions. In 
principle, the labelling reagent covalently attaches to any reactive heteroatom, any atom 
that is not carbon or hydrogen, within the plasmid.
2.2.7.3 PI or 7aad staining of the cells
Cells transfected with either Cy5 labelled DNA or Cy3 labelled siRNA were trypsinised 
from the plates and counted. 2 × 10
5 to 1 × 10
6 cells were then transferred to flow 
cytometry tubes. After pelleting at 1000 r.p.m. (212 × g) at 4
oC for 5 minutes, the cells 
were washed with 500 µl 1 × PBS and were pelleted again at 1000 r.p.m. (212 × g) at 4
oC for 5 minutes. Following three washes with 1 × PBS, the cells were resuspended in 
300 μl  1 × PBS.  3 μl of  100 μg/ml  PI  were  added  to  each  tube  containing  cells 
transfected with Cy5 labelled DNA whilst 3 μl of 100 μg/ml 7aad was added to each 
tube  containing  cells  transfected  with  Cy3  labelled  siRNA.  The  tubes  were  then 
incubated in darkness at 37
oC for 30 minutes. Afterwards, the cells were analysed by the
Epics XL flow cytometer.124
2.2.8 Methods related to confocal microscopy
2.2.8.1 Introduction to confocal microscopy
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Figure 2.2 A schematic diagram showing the components of the microscope and optical 
pathway of the beam.
Confocal microscopy allows production of a final image of a specimen at the same plane 
of focus as the object. A confocal microscope is capable of filtering out the out-of-focus 
light  from  above  and  below  the  point  of  focus  in  the  object.  For  an  image  from  a 
fluorescence microscope, the signal produced is from the full thickness of the specimen 125
which does not allow most of it to be in focus to the observer. On the contrary, the 
confocal microscope is able to eliminate the out-of-focus image by a pinhole located in 
front of the image plane. This pinhole aperture acts as a filter and allows only the in-
focus portion of the light to be imaged. As a result, light from above and below the plane 
of focus of the object is eliminated from the final image (Murphy 2002). 
A major problem of the image from a confocal microscope is that the light from the in-
focus image is greatly reduced by the pinhole. To increase the sensitivity for imaging, 
laser  beams,  which  produce  extremely  bright  light  at  specific  wavelenghts  for 
fluorochrome excitation, are used. Also, photomultiplier-detectors are used to improve 
the sensitivity of the collected signals from the fluorochrome (Murphy 2002).
2.2.8.2 Fixing cells for confocal miscroscopy
2×10
5 cells were seeded per well of 12 well plates so that 50% confluence was reached
overnight. 1 µg of Cy-5 labelled DNA or 100 pmole of Cy-3 labelled siRNA was diluted 
into 25 µl with Optimem and mixed with 25 µl transfection reagents in Optimem to their 
respective formations and incubated for 30 minutes at room temperature. After removing 
the growth medium from the cells, the complexes were added to cells and incubated at
37 °C in humidified atmosphere in 5 % carbon dioxide for 4 hours. Cells were then 
trypsinised, resuspensed in 100 µl of growth medium and seeded on polylysine slides for 
30  minutes  at  37 °C in  humidified  atmosphere  in  5 %  carbon  dioxide.  Following 
washing with 1 × PBS three times, the cells were fixed in 4 % formaldehyde for 20 126
minutes at room temperature. The cells were washed three times with 1 × PBS and then 
permeabilised with 0.5 % Triton X-100 in 1 × PBS for 5 minutes at room temperature. 
In order to distinguish an entire cell, F-actin of the cell was stained using Alexa Fluor 
488 phalloidin for 30 minutes at room temperature. Following washing three times with 
MilliQ water, Vectashield mounting medium for fluorescence with 4'- 6-Diamidino-2-
phenylindole (DAPI) were added on top of the cells and cover slips were overlaid on top 
of the cells. Mounting varnish was used to seal the cover slip.     
2.2.8.3 Slide imaging using confocal microscopy 
The slides were visualised using Lecia confocal microscopy. The images were captured 
using sequential mode in order to avoid crosstalk between different channels. Images 
were taken and analysed using Leica Confocal Software (LCS) Lite version. 127
2.2.9 Methods related to qPCR
2.2.9.1 Isolation of RNA
Following two washes with 1 × PBS, cells were incubated with trypsin/EDTA for 5 
minutes at 37 °C. The cells were then pelleted by centrifugation at 1200 r.p.m (306 × g) 
for 5 minutes. RNA was then purified by selective binding to a silica-based membrane at 
high  salt  concentration  using  the  Qiagen  RNeasy  kit  following  the  manufacturer’s
instructions.
2.2.9.2 RNA yield and quality determination
The  yield  and  quality  of  RNA  can  be  determined  by  spectrophotometry  (Section
2.2.2.5). 
2.2.9.3 DNase I treatment of RNA
Isolation of total RNA invariably contains trace amounts of genomic DNA which may 
affect downstream applications such as real time PCR. To eliminate the contaminating 
genomic DNA, 1 µg of the RNA sample, in a total volume of 16 µl, was incubated with 
2 µl  DNase I and 2 µl DNase  I buffer (10 ×)  at room temperature for 15 minutes. 
Following the reaction, EDTA was added and the sample was incubated at 65 ºC for 5 
minutes for inactivation of the DNase I. 128
2.2.9.4 cDNA synthesis
To prepare cDNA from RNA for subsequent PCR reactions, 1 μg of RNA was incubated 
with 2 μl of random hexamer primers (100 μg/ml) and Ultrapure water to a final volume 
equal to 11 μl. The sample was heated at 70
oC for 10 minutes and then cooled on ice 
immediately. After a brief spin, 8μl of master mix (Table 2.15) was added to the sample. 
Following  incubation at  room temperature  for  2 minutes, 1 μl  of  superscript  II was 
added to the mixture. After gentle mixing and incubation at room temperature for a 
further 10 minutes, the mixture was incubated at 42
oC for 1 hour. To stop the cDNA 
reaction the mixture was incubated at 70
 oC. The mixture was then stored at -20
 oC.
Reagents Volume for one reaction
5 × first strand buffer 4 μl
0.1 DDT 2 μl
10mM dNTP 1 μl
RNasin 1 μl
Table 2.15 The volume of the reagents used to formulate a master mix for a 20μl reaction 
of cDNA synthesis.
It is important to set up a negative control for each sample to see whether there is still 
some  genomic  contamination.  A  negative  control  can  be  set  up  following  the 
aforementioned processes of cDNA synthesis, except 1 μl Ultrapure water was added in 
place of 1 μl of superscript II. If DNA amplification is recorded in the negative control 129
in the subsequent quantitative PCR experiment, this means genomic DNA is present and 
the sample should be reprocessed.
2.2.9.5 Quantitative Real Time PCR
Quantitative Real Time PCR (qPCR) was carried out to quantify the amount of cDNA
synthesised from the mRNA of GAPDH and β-actin in Neuro2a cells from various sets 
of experiments. Generally, the qPCR technology allows the absolute quantity of mRNA 
found in a sample to be ascertained by the incorporation of light emitting dyes into the 
PCR product. 
2.2.9.6 Sequence-specific Taqman probes 
In the study, the Taqman probe assay system was used. This assay system utilises a 
sequence specific dual labelled probe, which has a fluorophore dye incorporated to the 
5’ end of the sequence and a quencher dye at the 3’ end. During the extension phase of 
the PCR, the probe is cleaved and the fluorescent and quenching dyes are separated. 
This  results  in  the  emission  of  a  detectable  fluorescent signal that  is  produced  in  a 
proportional manner to the accumulating PCR product.
As the probe system cannot distinguish the product resulting from a cDNA template or a 
genomic DNA template, it was necessary to ensure that the PCR products were not a 
result of contamination. Therefore as with all the RT-PCR reactions carried out, cDNA 130
samples prepared without inclusion of the reverse transcriptase were included in each 
run to determine if there was any genomic DNA contamination present.
2.2.9.7 qPCR reaction
The reactions were performed in a final volume of 20 μl in thin walled microcentrifuge 
tubes. 10 μl master mix was added per tube, followed by an addition of 1 μl of the 
Taqman probe, 8 μl of Ultrapure water and 1 μl of cDNA (1 μg). 
The tubes were then placed in a controlled heat block in the qPCR machine, ABI Prism, 
and subjected to a thermal cycle as shown in Table 2.16. The results obtained from the 
reactions were analysed using ABI Prism 7000 SDS software version 1.1.
Step Temperature Duration Process
1 95
oC 15 min Activating enzyme
2 95
oC 30 sec Denaturing cDNA 
3 60
oC 30 sec  Annealing cDNA
4 72
oC 30 sec Extending cDNA
5 Plate read
Table 2.16 The thermal cycling profile required for the Taqman probe assay system.
In order to compare the relative mRNA levels from the gene of interest in different 
samples, the mRNA levels of a house keeping gene, β-actin, were also measured from 131
each sample.  The  mRNA  levels  of  β-actin  from  different  samples  could  be  used  to 
normalise the mRNA values of the gene of interest of the respective samples.
2.2.10 Statistical analysis
Data presented in this study was analysed using a two-tailed, unpaired Student t-test
where applicable. Statistical analysis was also performed using Analysis of Variance 
(ANOVA) followed by Tukey's test as a post-hoc test for multiple mean comparisons. 
All statistical analyses were performed with the GraphPad Prism version 4 software.132
Chapter 3
Establishment of models for DNA transfection and 
siRNA knockdown assays133
3.1 Introduction
To  develop  nucleic  acid  delivery  systems,  it  is  important  to  have  suitable  models  to 
evaluate  the  nucleic  acid  delivery  efficiency.  For  plasmid  delivery,  there  are  several 
reporter gene systems such as luciferase and enhanced green fluorescent protein (eGFP)
that  can  be  used  for  vector  formulation  screening.  Likewise,  there  are  different  gene 
silencing models that can be used to evaluate siRNA delivery efficiency. Such systems 
include co-transfection with a reporter gene plasmid and an siRNA targeting the reporter 
gene, endogenous gene silencing and stably transfected reporter gene silencing models. In 
this section, establishment, advantages and disadvantages of different gene expression and 
gene silencing models will be discussed.  
3.1.2 Reporter gene assay models
Reporter genes are useful for the screening of synthetic vector systems for plasmid delivery 
due  to  their  easily  identifiable  characteristics, with  reporter  gene  expression  usually 
detected visually or by other simple assays. The commonly used reporter genes include 
genes that encode green fluorescent protein (GFP) and luciferase. 
3.1.2.1 GFP 
GFP is a fluorescent protein originally observed in the bioluminescent jellyfish Aequorea 
victoria. It is a 238-residue polypeptide with a typical beta barrel structure containing one 134
beta-sheet and alpha helix(s) with the fluorophores located inside the centre of the alpha 
helix (Tsien 1998).
GFP emits green fluorescence with a wavelength of 509 nm when excited by a light wave 
of wavelength 488 nm. An advantage of GFP is that transfected cells can be visualized in 
real  time  under  a  fluorescence  microscope,  and  by  using  a  plasmid  encoding  GFP, 
transfection efficiency  can  be  estimated  by  the  emission  of  fluorescence  (Sambrook  & 
Russell  2001).  To  further  enhance  the  GFP  fluorescence,  a  point  mutation  can  be 
introduced into the GFP DNA sequence to yield a mutant called enhanced GFP (eGFP)
(Stepanenko et al. 2008).
3.1.2.2 Luciferase 
Luciferase is widely used in cell biology to study gene expression. The most commonly 
used form of  luciferase  comes from  the  firefly  Photinus  pyralis. Firefly luciferase  is  a 
monomeric  61kDa  protein,  and  it  catalyses  luciferin  oxidation  using  ATP-Mg
2+  as  a 
cosubstrate. As a result, light is emitted by converting the chemical energy of luciferin 
oxidation through an electron transition, forming the product molecule oxyluciferin (Figure 
3.1) (Wood 1990). By recording the intensity of the light emitted from this reaction, gene 
expression can be estimated. The main advantage of using luciferase as a reporter gene is 
that it allows a sensitive quantitative estimation of gene expression.  135
Figure 3.1 The biochemical process of luciferase-catalysed light emission (Adapted from Wood 
1990).
3.1.3 Gene silencing models
A variety of models for gene silencing include co-transfection of a plasmid encoding a 
reporter gene and its siRNA counterpart, silencing of a stably expressed reporter gene in a
cell line, and silencing of an endogenous gene in a cell. Such models will be described in 
this section.
3.1.3.1 Cotransfection model
In  the  cotransfection  model,  cells  are  transfected  with  plasmid  complexes  and  siRNA 
complexes together (Figure 3.2). The plasmid contains a reporter gene whilst the siRNA 
targets the reporter gene. By analysing the reporter gene expression following the siRNA 
transfection, the siRNA delivery efficacy of the complex system can be evaluated.136
Figure 3.2 A schematic diagram showing the cotransfection model. Cells were seeded 24 hours 
prior to transfection. Plasmid transfection and siRNA transfection complexes were made separately 
according to the transfection protocols. These complexes were mixed and added to the cells. The 
reporter gene silencing was then analysed. 
The advantages of this model are that it is relatively easy to set up and cheap to maintain 
compared  to  other  models.  The  reagents  required  in  this  model  consist  of  a  plasmid 
expressing a reporter gene, siRNA targeting this reporter gene, transfection reagents and a 
cell line. All of these components are used in routine experiments and are therefore easily 
prepared and/or purchased. Since the silencing target in the co-transfection model is usually 
a reporter gene such as GFP, this model is considerably cheaper than an endogenous gene 
knockdown model which involves other assays to estimate the endogenous gene silencing 
such as Real Time Polymerase Chain Reaction (RT-PCR) and Western blotting. However, 
one  of  the  main problems  of  this  model is  the potential  for the  plasmid  complexes  to 137
interfere with  the siRNA  complexes. The plasmid  or  siRNA  complexes  are formed  by 
reversible electrostatic interactions between the complex reagent and the plasmid DNA or 
siRNA.  Mixing  the  plasmid  complexes  with  the  siRNA  complexes  could  lead  to  a 
rearrangement of the complex reagent within the plasmid or siRNA complexes (Figure 
3.3). As a result, some of the complex reagent within the plasmid complexes may dissociate 
from the plasmid complexes and bind to the siRNA complexes or vice versa. Therefore, the 
gene silencing results obtained may not necessarily reflect the siRNA delivery efficiency of 
the siRNA complexes in a particular formulation. Also, since in vivo plasmid delivery using 
complexes is already a hurdle, it could be difficult to use this model to evaluate in vivo
siRNA delivery efficacy.  
Figure  3.3  A  schematic  diagram  depicting  the  “cross-talk”  of  the  DNA  and  siRNA 
transfection  complexes  in  the  cotransfection  model.  Since  both  plasmid  DNA  and  siRNA 
complexes were formed by a reversible electrostatic attraction between the nucleic acids and the 
reagents, there is a possibility that the complex regents on each complex would be attracted and 
bind to the other complexes. Also, the free transfection reagents in the complex medium could bind 
to these complexes.  138
3.1.3.2 Endogenous gene silencing model
Another way to evaluate siRNA delivery efficiency involves delivering siRNA to target 
endogenous genes within the cells. In this system, the gene silencing efficiency can be 
estimated by the remaining expression, relative to unsilenced controls, of target mRNA or 
protein  levels  using  enzyme  assays,  RT-PCR  or  Western  blotting.  Indeed,  there  is  a 
functional assay that could be used to study remaining protein level, the glyceraldehyde-3-
phosphate  dehydrogenase  (GAPDH)  assay,  following  transfection  using  anti-GAPDH 
siRNA.
GAPDH, which is composed of 36 kD protein subunits, is a tetrameric enzyme. As shown 
in Figure 3.4, it catalyses the oxidative phosphorylation of glyceraldehyde-3-phosphate (G-
3-P) to bisphosphoglycerate (BPG).
Figure 3.4 The biochemical process of the GAPDH.
In  the  presence  of  phosphate  and  G-3-P,  the  conversion  rate  of  NAD
+  to  NADH  is 
proportional to the concentration of GAPDH. The higher the GAPDH presence, the faster 
the conversion rate. By measuring the rate of the NAD
+ to NADH conversion, the amount 
of GAPDH present in the cells can be determined. 139
The main advantages of this assay are that it can be used on different cell types and can 
yield gene silencing results within a short period of time compared to methods involving 
RT-PCR and Western blotting. However, this assay is very expensive, so is therefore often 
not ideal for use in formulation screening. This model can rather be used to confirm a 
specific formulation. 
3.1.3.3 Stably transfected reporter gene silencing model
To generate this model, a reporter gene must stably integrate into the host cell genome. By 
transfecting cells with a plasmid encoding both a reporter gene and a selectable marker, the 
cells with the reporter gene integrated into the genome can be identified. The reporter gene 
within  these  stably  transfected  cells  can  then  be  targeted  by  siRNA  delivery  and 
knockdown efficiency can be evaluated.
This model is attractive since the reporter gene silencing can be easily measured by well-
established reporter gene assays. Also, reporter gene assays are usually quick and more 
economical  to  monitor  gene  expression  compared  to  monitoring  endogenous  gene 
expression involving RT-PCR and Western blotting; therefore it can be an ideal model for 
formulation  screening.  However,  generating  such  a  model  can  prove  to  be  very  time 
consuming. 140
3.1.3.4 Control for siRNA experiment
Since an overdose of siRNA can mediate non-specific gene silencing, irrelevant siRNA are 
used as a negative control. Irrelevant siRNA is an siRNA which does not target any gene. 
By  comparing  the  results  of  the  targeted  siRNA  complexes  and  the  irrelevant  siRNA 
complexes, the specificity of the gene silencing of the targeted siRNA complexes can be 
evaluated. 
3.1.4 Aim
 To establish models suitable for high through-put screening of cationic formulations 
for gene expression or gene silencing. 141
3.2 Results
3.2.1 Gene expression model
To  evaluate  the  gene  delivery  efficiency  of  different  cationic  formulations,  plasmids 
containing  eGFP  or  luciferase  reporter  gene  were  used.  A  transfection  protocol  was 
developed to deliver the plasmid to Neuro 2a cells in a 96 well plate setting. The cells were 
seeded 24 hours prior to transfection, and following the removal of full growth medium, the 
transfection complexes were overlaid onto the cells in serum free medium. The cells were 
transfected at 50 to 70% confluence so that the cells would not be overgrown at the time of
analysis. Overgrowth of cells could be a potential problem because many cell types exhibit 
growth  contact  inhibition.  The eGFP  expression  was  analysed  48  hours  following 
transfection  whereas  luciferase  expression  was  evaluated  24  hours  post-transfection
(Figure 3.5). 142
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Figure 3.5 Optimisation of the amounts of plasmid DNA for transfection. 5 × 10
4 Neuro 2a
cells were seeded 24 hours prior to transfection (in a 96 well plate). Plasmid transfection complexes 
were made by mixing a lipid, peptide Y and plasmid DNA together in a 2:4:1 weight ratio for 30 143
minutes in Optimem (Section 2.2.3.3.2). Following removal of full growth medium, complexes 
were overlaid onto the cells for 4 hours. After removing the transfection complexes, full growth 
medium  was  added  to  the  cells.  Luciferase  activity  in  the  cells  was  analysed  24  hours  post-
transfection as a relative luminescence unit (RLU) (Section 2.2.5.1) whereas eGFP expression was
analysed  48  hours  post-transfection  as  a  relative  fluorescence  unit  (RFU)  to  estimate  the 
transfection  efficiencies  of  the  complexes (Section  2.2.5.2).  (A)  Luciferase  activity  (RLU/mg)
following transfection using different amounts of plasmid DNA. It was shown that  0.25 µg of 
plasmid DNA in a well of a 96 well plate yielded a significantly higher transfection efficiency (P < 
0.05) (B) eGFP expression (RFU) following transfection using different amounts of plasmid DNA. 
It was shown that 0.25 µg of plasmid DNA in a well of a 96 well plate yielded a significantly higher 
transfection efficiency (P < 0.05) Statistical analysis was performed using Student t-test. RLU/mg: 
Relative luminescence unit/ protein content of the samples.
Different  amounts  of  plasmid  were  used  to  transfect  Neuro  2a  cells  to  investigate  the 
optimal amount of plasmid for gene delivery screening. As shown in Figure 3.5, Neuro 2a 
cells  were  transfected  with  eGFP  or  luciferase  plasmid.  It  was  observed  that  0.25µg 
plasmid per well was optimal for plasmid transfection. Both 0.125 µg and 0.5µg plasmid
per well yielded a lower gene expression level. 
3.2.2 Gene knockdown model
3.2.2.1 GAPDH knockdown model
The GAPDH knockdown model can be used to investigate endogenous gene knockdown. 
In this model, the cells were seeded 24 hours prior to transfection. Having prepared the 
siRNA complexes with siRNA targeting GAPDH in Optimem, the cells were transfected 144
and the GAPDH levels were analysed 48 hours post-transfection. The cells treated with 
irrelevant siRNA complexes could indicate the non-specific gene silencing although cell 
toxicity could also decrease GAPDH activity. 
Figure 3.6 shows the results of the GAPDH knockdown on Neuro 2a cells. (Please refer to 
appendix III for the GAPDH knockdown on NIH 3T3 and HT1080 cells.) The siRNA 
transfection complexes were formed using a commercial reagent, siLentfect, and siRNA 
targeting GAPDH (siGAPDH) or irrelevant siRNA (irr). The amount of the siLentfect and 
siRNA used per well in the 96 well plate were as indicated.
As shown in Figure 3.6, siRNA alone or siRNA formed complexes with 0.1µl siLentfect 
with  5,  10  or  20  nM  siGAPDH  did  not  mediate  any  gene  silencing.  Increasing  the 
siLentfect to  0.2  µl  allowed  5,  10  or  20  nM  siGAPDH  to induce  30-40%  of  GAPDH 
silencing.  In fact, 0.4 µg siLentfect with 5, 10 or 20 nM siGAPDH was able to mediate 70-
80% of GAPDH knockdown in the cells.  145
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Figure 3.6 The GAPDH knockdown model. 5 × 10
4 Neuro 2a cells were seeded 24 hours prior to 
transfection (in a 96 well plate). siRNA transfection complexes were made by mixing siLentfect 
with siRNA for 30 minutes in Optimem (Section 2.2.3.3.5). The complexes were then overlaid onto 
the cells for 24 hours. After removing the transfection complexes, full growth medium was added to 
the cells. Following 2 days post-transfection, the GAPDH activity of each sample was measured as 
the relative fluorescence unit (RFU) (Section 2.2.5.3). The GAPDH activity of the untransfected 
cells was used to normalise the GAPDH activity of the treated cells to yield the percentage of 
GAPDH activity. It was shown that 0.2 µl siLecfect with siGAPDH (P < 0.05) or 0.4 µl siLecfect 
with siGAPDH (P < 0.05) mediated a significant decrease of GAPDH activity compared to cells 
treated with siLecfect irr complexes containing the same amount of siLentfect and siRNA and the 
untreated cells. Statistical analysis was performed using Student t-test. siGAPDH refers to siRNA 
targeting GAPDH; irr refers to siRNA not targeting any mRNA in the cells.146
3.2.2.2 eGFP knockdown model
A model containing an eGFP stable cell line and siRNA targeting eGFP were used. The 
transfection procedures used to evaluate siRNA delivery efficiency using this model are 
very  similar  to  the  GAPDH  model.  293T  eGFP  expressing  cells (Section  2.1.6) were 
seeded 24 hours prior to transfection. siRNA transfection complexes were made by mixing 
Lipofectamine  2000  (L2000)  and  siRNA  targeting  eGFP  (sieGFP)  for  30  minutes. 
Following 24 hours of transfection, the complexes were removed and full growth medium 
was added to the cells. eGFP silencing was analysed in the subsequent days. 
To  identify  the  optimal  time  point  for  detecting  eGFP  silencing,  the  kinetics  of  eGFP 
expression  in  the cells  was studied at different  time points  using  L2000  with  different 
concentrations of siRNA targeting eGFP (Figure 3.7). As shown in the figure, around 45% 
of eGFP expression was detected immediately after the 24 hour transfection period. The 
eGFP  expression  level  was  around  20%  at 24  hours  post-transfection.  Two  days  after
transfection, the eGFP signal further decreased; however, there is an increase of the eGFP 
expression 3 days after transfection. Therefore, 2 days after transfection is the optimal time 
point to detect eGFP silencing. 147
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Figure 3.7 The kinetics of the eGFP knockdown model. 5 × 10
4 293T eGFP expressing cells 
were seeded 24 hours prior to transfection (in a 96 well plate). siRNA transfection complexes were 
made by mixing L2000 (0.25ug/well) with different concentrations of siRNA targeting eGFP for 30 
minutes.  The  complexes  were  then  overlaid  onto  the  cells  for  24  hours.  After  removing  the 
transfection  complexes,  full  growth  medium  was  added  to  the  cells.  The  remaining  eGFP 
expression was analysed at different time points. Day 0 means the eGFP was measured immediately 
following the 24 hour transfection. Day 1, Day 2 and Day 3 refer to the eGFP measurement made at 
24,  48  and  72  hours  following  transfection  respectively (Section  2.2.3.3.4  and  2.2.5.2). The 
percentage of relative fluorescence unit (RFU) refers to the eGFP signal detected from cells treated 
to  different  sieGFP complexes  normalised with the untreated eGFP expressing cells. Statistical
analysis was performed using ANOVA followed by Tukey’s test and it showed that there was a 
significant decrease of the percentage of RFU of the cells treated with the L2000 sieGFP (from 2 to 
32 nM) complexes on day 1 and day 2 compared to day 0 (P < 0.05).148
Figure  3.8  shows  the  optimisation  of  the  amounts  of  L2000  and  sieGFP  required  to 
mediate eGFP knockdown. The optimal L2000 siRNA complex was used as a positive 
control in the subsequent cationic formations screening. As shown in the figure, naked 
siRNA  does  not  mediate  any  eGFP  silencing.  At  0.125µg  of  L2000  per  well,  siRNA 
concentrations  ranging  from  4nM  to  32nM  in  200  µl  induced  around  75%  of  eGFP 
silencing. When L2000 increased to 0.25µg per well, 80% or more of eGFP knockdown 
was observed using sieGFP ranging from 4nM to 32nM in 200 µl. For 0.5µg L2000 per 
well, although sieGFP ranging from 1nM to 32nM in 200 µl mediated more than 80% 
eGFP silencing, a decrease of eGFP expression of the cells treated with irrelevant siRNA 
indicated  that  there  was  non-specific  gene  silencing  or  cell  toxicity  mediated  by  this 
formulation. Therefore,  the  optimal L2000 siRNA formulation  was 0.25µg L2000 with 
8nM of siRNA because this is the formulation using less siRNA to mediate more than 80% 
gene silencing without any non-specific gene knockdown or cell toxicity.149
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Figure 3.8 eGFP knockdown optimisation. 5 × 10
4 293T eGFP expressing cells were seeded 24 
hours prior to transfection (in a 96 well plate). siRNA transfection complexes were made by mixing 
L2000 with siRNA for 30 minutes. The complexes were then overlaid onto the cells for 24 hours. 
After  removing  the  transfection  complexes,  full  growth  medium  was  added  to  the  cells.  The 
remaining eGFP expression were analysed 2 days post-transfection (Section 2.2.3.3.4 and 2.2.5.2). 
The percentage of relative fluorescence unit (RFU) refers to the eGFP signal detected from cells 
treated to different sieGFP complexes normalised with the untreated eGFP expressing cells. sieGFP 
refers to siRNA targeting eGFP; irr refers to siRNA not targeting any mRNA in the cells. Statistical
analysis was performed using Student t-test and it showed significant difference between the L2000 
sieGFP complexes and the L2000 irr complexes with the same amount of L2000 and siRNA (P < 
0.05). It also showed that the percentage of RFU of the cells treated with the L2000 irr complexes 
with 0.5 µg of L2000 decreased significantly compared to the untreated cells and the cells treated 
with siRNA alone (P < 0.05).150
Indeed, there were some disadvantages of this model for formulation screening. Firstly, the 
293T cells grew quickly and needed to be passaged after 2 days post-transfection, and this 
complicates the procedures for screening. Also, this cell type is easily detached from the 
plastic well which was problematic for other transfection methods described in Section 
2.2.3.3. 
Therefore, a better model would be a cell line containing a gene target with a shorter half 
life which could be used easily for evaluation of siRNA delivery. A mouse neuroblastoma 
cell line (e.g. Neuro 2a) expressing luciferase could be a good model for in vitro and in vivo
formulation  screening.  Neuro  2a  cells  are  easy  to  culture  in  vitro  and  can  be  used  to 
generate subcutaneous tumour  in  a  mouse, which  acts as an  in vivo  model to evaluate 
siRNA delivery. On the other hand, luciferase, which has only a 2 hour half life, is easily 
used  for  in  vitro  and  in  vivo quantification  and  imaging  (Ignowski  &  Schaffer  2004).
Therefore, Neuro 2a luciferase expressing cell line would be a good model for cationic 
formulation screening.
3.2.3 Generation of a luciferase knockdown model
3.2.3.1  Generation  of  luciferase  construct  for  Neuro  2a  luciferase 
expressing cell line 
The  Neuro  2a  cell  line  stably  expressing  luciferase  was  generated  by  integration  of  a 
plasmid  containing  both  the  luciferase  reporter  and  selectable  marker  genes  into  the 151
genome of the cells so that both the luciferase reporter and selectable marker genes were
expressed endogenously. A selectable marker is a gene that confers a specific trait to the 
cells  for  artificial  selection (Goldstein  et  al.  2005).  In  this  study,  the  hygromycin  B 
resistance gene was used as the selectable marker. Hygromycin B is an antibiotic that kills
the cells by inhibiting protein synthesis. The cells expressing a hygromycin B resistance
gene will therefore survive in hygromycin B conditions and the cells lacking this gene will 
not survive (Makridou et al. 2003). Therefore, to make a cell line that expresses luciferase 
stably,  the  first  step  is  to  generate  a  plasmid  construct  containing  both  luciferase  and 
hygromycin B.
3.2.3.2 Plasmid subcloning for stable cell line construction 
Figure 3.9A outlines the plasmids pCEP 4 and pCI-Luc used in the subcloning procedures. 
The pCEP4 consists of a hygromycin B resistance gene and multiple cloning sites (MCS) 
downstream of the CMV prometer. Within the MCS, there are sites for restriction enzymes 
HindIII and NotI. The pCI-Luc contains a firefly luciferase gene flanked by restriction sites
HindIII and NotI, therefore the strategy to generate the plasmid for use in stable cell line
construction is to excise the luciferase gene from pCI-Luc and insert it into the pCEP4
MCS. Figure 3.9B shows the restriction digestion of the pCEP4 and pCI-Luc plasmids. 
Following digestion with HindIII and NotI, the luciferase gene from pCI-Luc (lane 9) was
purified and ligated to the digested pCEP4 (lane 5) to yield pCEP4-Luc (Figure 3.10A). A 
transfection was performed to confirm that the pCEP4-Luc plasmid was able to express the 152
luciferase  reporter  gene  (Figure  3.10B).  This  plasmid  was  used  for  the  subsequent 
transfection for stable cell line generation. 
Figure  3.9 Generation  of  luciferase  plasmid  for  stable  cell  construction. (A)  a  schematic 
diagram of the pCEP4 construct, (B) a schematic diagram of the pCI-Luc, (C) Restriction digestion 
of the pCEP4 and the pCI-Luc plasmids. The pCEP4 and pCI-luc were digested with HindIII and 
NotI for 2 hours at 37°C and resulting fragments separated on a 1% agarose gel (Section 2.2.2).153
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Figure 3.10 Testing of the pCEP4-Luc plasmid for luciferase expression. Neuro 2a cells 
were seeded 24 hours prior to transfection. Plasmid transfection complexes were made by mixing 
lipid:peptide:DNA  in  a  2:4:1  weight ratio  for  30  minutes  in  Optimem (Section  2.2.3.3.2  and 
2.2.5.1).  The  complexes  were  then  overlaid  onto  the  cells  for  24  hours.  After  removing  the 
transfection  complexes,  full  growth  medium  was  added  to  the  cells.  Luciferase  activity  was
analysed  24  hours  post-transfection.  (A)  a  schematic  diagram  of  the  pCEP4-Luc  plasmid.  (B)154
Luciferase activity in Neuro 2a cells transfected with the pCEP4-Luc plasmid compared to the 
untreated cells. Statistical analysis was performed using Student t-test and it showed a significant 
difference between the luciferase activity in transfected cells and the untransfected cells (P < 0.01).
3.2.3.3 Optimisation for hygromycin B selection
In order to establish the hygromycin B concentration suitable for selection, Neuro 2a cells 
were incubated with different amounts of hygromycin B for 4 days. As shown in Figure 
3.11, when no hygromycin B was added, the cells proliferated after 2 days but the cell 
number decreased after 4 days. The decrease of cell number was due to cell death as a 
result of overgrowth. Conversely, cell growth was observed from cells treated with 100 and 
200µg/ml of hygromycin B after 2 days, suggesting that these amounts of hygromycin B 
were not enough to kill the cells not expressing the resistance gene. When the hygromycin 
B concentration increased to 400µg/ml, the cell number decreased after 2 days of treatment, 
indicating that 400µg/ml of hygromycin B is lethal for the Neuro 2a cells. Further increase 
of  hygromycin  B  concentration  caused  a  higher  cell  death  rate  of  the  Neuro  2a  cells. 
400µg/ml of hygromycin B was therefore chosen as the concentration  for the selection 
process as it was the minimum hygromycin B concentration needed to mediate cell death. 
Therefore, cells expressing a low amount of the hygromycin B resistance gene will survive.  155
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Figure 3.11 Generation of a kill curve for stable cell selection. Neuro 2a cells were treated with 
different concentrations of hygromycin B for 4 days. The viable cells were counted on day 1, day 2 
and day 4 using a trypan blue exclusion assay (Section 2.2.4.1) in order to generate the kill curve.
3.2.3.4  Transfection  of  pCEP4-Luc  and  selection  of  hygromycin  B 
resistant cell line
To generate the stable luciferase expressing cell line, Neuro 2a cells were transfected with 
the pCEP4-luc plasmid and cultured in 400µg/ml of hygromycin B for 2 months. Briefly, 
the  cells  were  cultured  with  full  growth  medium  in  a  6  cm  plate  24  hours  prior  to 
transfection.  Lipofectin  was  used  to  form  complexes  with  a  plasmid  for  30  minutes. 
Following removal of the growth medium from the cells, the transfection complexes were 156
added to the cells for 4 hours. The transfection complexes were then removed and full 
growth medium with 400µg/ml of hygromycin B was added to the cells for the selection 
process. This full growth medium with 400µg/ml of hygromycin B was replaced every two 
days. 
Within the first 10 days of this selection process, the majority of cells did not survive. The 
living cells were scattered in the plate and some wells contained a single surviving cell
(Figure 3.12). These single cells were located and observed for the subsequent selection
process. For the further 10 to 20 days, some of the single cells grew into colonies. The 
colonies were then selected, expanded and tested for luciferase expression.157
Figure  3.12  A  schematic  diagram  showing  the  process  to  identify  a  single  hygromycin  B 
resistance cell. Following transfection using the pCEP-4-Luc plasmid, the cells were treated with 
hygromycin B. The hygromycin B resistant cells would either survive as a single cell (yellow cell) 
or in a cluster of cells (pink cells). The single cells were identified and observed to follow colony 
formation. These single cell colonies were then isolated and expanded.
After expansion of the cells from the colonies, the cells were assayed for level of luciferase 
expression. As shown in Figure 3.13A, some of the cells were luciferase negative while 
some of the cells were luciferase positive. It is an assumption that the luciferase expressing 
cells must contain the luciferase and hygromycin B resistance genes integrated within their 
genome, or else survival within the hygromycin selective conditions would not be possible 
over the two month period.  158
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Figure 3.13 Neuro 2a stably expressing luciferase cells for in vitro and in vivo use. (A) The 
luciferase activity within the hygromycin B resistant single cell colonies. The luciferase activity of 
Neuro 2a clone 2 is significantly higher than Neuro 2a clone 1 (P < 0.01). (B) Luciferase activity
from  a  tumor  generated  from  the  Neuro  2a  luciferase  expressing  cells  from  clone  2  was 
significantly higher than that of the normal tumour, which refers to a tumour generated from the 
parental Neuro 2a cells (P < 0.01). Statistical analysis was performed using Student t-test.159
To test if the Neuro 2a luciferase expressing cells can be used in vivo to establish tumours 
in  the  same  way  as  the  parental  Neuro2a  cells,  the  cells  were  injected  into  a  mouse 
subcutaneously (Section  2.2.4.4).  A  tumour  was  observed  15  days  after  injection.  As 
shown in Figure 3.13B, luciferase expression was observed. Therefore, this Neuro 2a-Luc 
cell line can be used as a model to evaluate gene silencing in vitro and in vivo.  
3.2.3.5 Optimisation of the Neuro 2a-Luc model
To identify the optimal time point for detecting luciferase silencing in the stably transfected 
cells, the kinetics of luciferase expression in the Neuro-2a-Luc cells was studied. The cells 
were transfected with siRNA as described in Section 3.2.2.2 and the luciferase expression 
was analysed at different time points. Figure 3.14 shows the results of the kinetic study. 
The percentage of relative luminescence units (RLU) is the luciferase signal detected from 
cells  treated  with  different  siLuc  complexes  normalised  to  the  untreated  luciferase 
expressing cells. As shown in the figure, around 20% of luciferase expression was detected 
from day 0 to day 2 post-transfection. The luciferase expression level began to increase 3 
days following transfection. Therefore, any time less than 2 days post-transfection would be 
optimal  to  detect  luciferase  silencing.  Taking  consideration  of  the  Neuro  2a  cell 
proliferation rate, the optimal time to detect luciferase silencing would be 24 hours post-
transfection.  160
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Figure  3.14  The  kinetics  of  the  luciferase  knockdown  model. 5  ×  10
4 Neuro  2a  luciferase 
expressing cells were seeded 24 hours prior to transfection (in a 96 well plate). siRNA transfection 
complexes  were  made  by  mixing  L2000  (0.25ug/well)  with  siRNA  targeting  luciferase  for  30 
minutes in Optimem. The complexes were then overlaid onto the cells for 24 hours. After removing 
the transfection complexes, full growth medium was added to the cells. The remaining luciferase 
activity were analysed at different time points (Section 2.2.3.3.4 and 2.2.5.1). The percentage of 
luciferase activity refers to the luciferase activity detected from cells treated with different siLuc 
complexes  normalised to  the  untreated  luciferase  expressing  cells. Day  0  means  the  luciferase 
activity  was  measured  immediately  following  the  24  hour  transfection.  Day  1,2  and  3  denote 
luciferase  activity  measurement  at  24,  48  and  72  hours  respectively. Statistical  analysis  using 
ANOVA followed by Tukey’s test showing the percentage of luciferase activity in the cells treated 
with the L2000 siRNA (1 to 32 nM) complexes (from day 0 to day 3) were significantly different to 
the untreated luciferase expressing cells (P < 0.01).161
Figure 3.15 shows the optimisation of L2000 siLuc complexes needed to induce luciferase 
knockdown. The optimal  L2000  siRNA complex  was used as  a positive control in  the 
subsequent cationic formation screening. Similar to the eGFP silencing experiment, naked 
siRNA did not mediate any luciferase silencing. At 0.125µg of L2000 per well, siRNA 
concentrations ranging from 1nM to 32nM in 200µl could induce around 80% of luciferase 
silencing.  Further increase  of  L2000 to  0.5µg per well  with  the same  range of  siRNA 
slightly  increased  the  gene  silencing  efficacy.  Importantly,  the  increase  of  the  L2000
amount did not cause cell toxicity. To conclude, 0.125µg of L2000 with 1nM in 200µl of 
siRNA was enough to mediate 80% luciferase knockdown in this model. 162
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Figure 3.15 Luciferase knockdown optimisation. 5 × 10
4 Neuro 2a luciferase expressing cells 
were seeded 24 hours prior to transfection (in a 96 well plate). siRNA transfection complexes were 
made by mixing L2000 with siRNA for 30 minutes. The complexes were then overlaid onto the 
cells for 24 hours. After removing the transfection complexes, full growth medium was added to the 
cells. The remaining luciferase activity was analysed 24 hours post-transfection (Section 2.2.3.3.4 
and 2.2.5.1). The percentage of luciferase activity refers to the luciferase activity detected from 
cells treated with different siLuc complexes normalised to the untreated luciferase expressing cells. 
Statistical  analysis  was  performed  using  Student  t-test and  it  showed  a  significant  difference 
between the L2000 siLuc complexes and the L2000 sieGFP complexes with the same amount of 
L2000 and siRNA (P < 0.05). siLuc refers to siRNA targeting luciferase; sieGFP refers to siRNA 
targeting eGPF which is a negative control in the experiment.163
3.3 Discussion
3.3.1 Gene expression models for high throughput cationic formulation 
screening
In this study, a model using Neuro 2a cells and eGFP or luciferase expressing plasmid was 
established for the evaluation of plasmid delivery efficiency. This model was optimised to 
transfect cells in 96 well plate conditions which allowed high throughput screening of the 
cationic  formulations,  and  was used  to  compare  the  transfection  efficiency  of  different 
plasmid DNA complexes formed with different cationic polymers in chapter 4.
3.3.2 GAPDH and 293T eGFP expressing cell line models were not ideal 
for this study
To  study  gene  silencing  mediated  by  different  synthetic  siRNA  delivery  systems,  a 
GAPDH silencing model, eGFP and luciferase stable cell line models were established. 
These models have their own advantages and disadvantages and therefore would be useful 
in different experimental circumstances. For instance, the GAPDH gene knockdown model 
can be used on different cell types; however, it is the most expensive model to use in this 
study. Therefore, this model would be useful for verifying a specific cationic formulation 
on different cell types rather than high throughput screening. On the other hand, the 293T 
eGFP model is a better alternative to the GAPDH gene knockdown model for screening 
purposes because it is very economical. However, due to the long half life of eGFP (48 164
hours) (Ignowski & Schaffer 2004) and the fast growth rate of the 293T cells (24 hours 
doubling time), this model requires high maintenance to culture the treated cells which may 
not be ideal for high throughput screening purposes. Also, since the 293T cells can often be 
found not very adherent to the plate, washing steps in transfection procedures could easily 
detach  the  cells.  Therefore,  this  model  is  not  ideal  to  be  used  in  evaluating  different 
transfection methods which include several washing steps.   
3.3.3  Neuro  2a  luciferase  expressing  cells  were  more  suitable  for  this 
study
The Neuro 2a luciferase  expressing cell gene knockdown model is more ideal than the 
GAPDH and eGFP models for formulation screening. Even though Neuro 2a cells grow 
quickly, the 2 hour half life of the luciferase allows the transfected cells to be analysed 24 
hours post-transfection. Another advantage of the Neuro 2a luciferase cells is that they can 
generate a tumour containing cells which are expressing luciferase in vivo. Since luciferase
can be easily imaged in vivo in a real time fashion (Ignowski & Schaffer 2004), this model 
allows researchers to use fewer animals to evaluate the kinetics and the efficacy of certain 
siRNA complexes in vivo.  
3.3.4 Stable cell line construction
In this study, the Neuro 2a cells stably expressing luciferase were expanded from single cell 
colonies identified in a 6 cm plate. Other strategies to expand the stable cells could be 165
seeding the cells in a 96 well plate with one cell per well. This can be done using cell 
sorting techniques (Shapiro 2003). However, this technique may not be practical because 
some cells, such as Neuro 2a, do not respond well to such isolation and consequently do not 
proliferate well in single cell conditions. 
3.3.5 L2000 as an siRNA delivery reagent
In this study, L2000 was used as a positive control to deliver siRNA because it is well-
known as an effective commercial siRNA delivery reagent. However, it is also known to be 
toxic to the cells. Fedorov and co-workers showed that treatment of L2000 on cells can 
alter global gene expression patterns in the cells (Fedorov et al. 2005). Therefore, despite 
its effectiveness for siRNA delivery, there is still a need to develop better siRNA delivery
formulations for clinical use. Also, L2000 does not target to a specific cell type; therefore, 
it may not be ideal for siRNA delivery in a clinical setting. 
3.4 Conclusion
In  this  section,  gene  expression  and  gene  silencing  models  were  established  for  the 
development of DNA and siRNA delivery systems. The gene expression efficiency was 
assessed by luciferase or eGFP expression following transfection, whilst gene silencing 
efficiency was estimated by the remaining luciferase expression level from the luciferase 
expressing  cell  model.  The  gene  silencing  efficiency  can  be  further  confirmed  by 
endogenous knockdown of the GAPDH level within the cells.166
Chapter 4
A study on the biophysical and transfection properties of 
different cationic formulations of DNA complexes167
4.1 Introduction
Gene therapy is a powerful tool to treat diseases by delivering nucleic acids to induce 
expression of missing genes, elevate expression of existing genes and/or silence disease 
related genes in targeted cells. However, one of the main hurdles in gene therapy is to 
develop an efficient and safe vector system. Although viral vectors are highly efficient for 
gene  delivery,  high  toxicity  and  immunogenicity  of  these  vectors  remains  a  concern. 
Synthetic or nonviral vectors are attractive alternatives to viral vectors due to their low 
immunogenicity  and  low  acute  toxicity.  However,  the  main  disadvantage  of  nonviral 
vectors is the low transfection efficiency compared with viral vectors. Therefore, improving 
the  delivery  efficiency  of  the  non-viral  system  could  be  a  way  to  produce  a  safe  and 
efficient vector system for DNA delivery. 
Two biophysical properties that limit the cellular delivery of DNA are their polyanionic 
nature and large size. The polyanionic characteristic hinders the interaction between DNA
and the cell membrane while the size restricts it from passive diffusion through the cell 
membrane.  To overcome these barriers, cationic molecules have been used to neutralise
the negative charge of the DNA and form nano-sized complexes to facilitate cellular uptake
(Grayson et al. 2006). The complex must then be able to dissociate from the DNA within 
cells to allow them to be transcribed (Kichler et al. 2001).  Therefore, the abilities of the 
cationic  molecule  to  bind,  dissociate  and  form  nano-sized  particles  with  the  DNA  are 
important criteria for a successful DNA delivery system.168
To understand the characteristics of efficient DNA delivery systems, lysine based peptides 
and polyethylenimine (PEI), which are widely used for plasmid DNA delivery, were used 
to  form  complexes  with  plasmid  DNA.  The  subsequent  biophysical  and  transfection 
properties of those complexes were analysed. 
4.1.1 Lysine based peptides
Lysine based peptides have been used to package DNA for gene delivery (Zenke et al. 1990; 
Erbacher et al. 1996). Lysine, which is the basic unit of these peptides, can be protonated 
through a nitrogen atom and condense DNA to form complexes, which can subsequently 
enter cells by endocytosis (Mislick et al. 1995). 
In  this  study,  two  types  of  lysine  based  peptides  were  used,  the  linear  lysine  and  the 
Kbranch peptides.
4.1.1.1 The linear lysine peptides
Four different linear lysine peptides were used in this study. The molecular weight and net 
charge of the peptides K8, K16, K24 and K32 (Figure 4.1) are summarised in Table 4.1. 
Since the linear lysine peptides differ only in their sizes, this may help to elucidate the 
relationship between peptide size and nucleic acid packaging and delivery efficacy.169
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Figure 4.1 The structures of the linear lysine peptides.
Molecular weight Net charge per peptide
K8 1043 +8
K16 2068 +16
K24 3111 +24
K32 4154 +32
Table 4.1 The molecular weight and the net charge of the K8, K16, K24 and K32 peptides.
4.1.1.2 The Kbranch peptide
The KBranch peptide (3 kDa), which has a charge of +14 per peptide, contains a branched 
lysine domain to condense DNA (Figure 4.2). It also contains an integrin targeting domain 
to facilitate cellular binding and uptake (Hart et al. 1998; Mustapa et al. 2007).170
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Figure 4.2 The structure of the Kbranch peptide.
The Kbranch peptide is similar in size to the linear lysine peptides; therefore, the nucleic 
acid packaging properties of the Kbranch peptide can be compared with those of the linear 
lysines to better understand the effect of molecular structure on nucleic acid packaging.
4.1.2 PEI
PEIs have been used to deliver DNA or other kinds of nucleic acid in various cell types in 
vitro and in vivo (Boussif et al. 1996; Goula et al. 1998; Kichler et al. 2001; Grayson et al. 
2006; Sundaram et al. 2007; Shim & Kwon 2008). They are made either as a branched or 
linear  form.  The  branched  form  is  produced  by  cationic  polymerisation  from  aziridine 
monomers whereas the linear form is generated from cationic polymerisation from a 2-
substituted 2-oxazoline monomer, or at low temperature using aziridine monomers (Figure 
4.3) (Godbey et al. 1999).171
Figure 4.3 The structures of the linear and branched PEI (Adapted from Godbey et al. 1999).
The basic unit of PEI consists of a backbone of two carbons and one nitrogen atom. The 
nitrogen atom can be protonated and can bind to and condense DNA to form complexes 
(Godbey et al. 1999). The complexes can be taken up by the cells through endocytosis 
(Ogris et al. 1998). 
In this study, branched and linear PEIs were used. The branched PEI (B-PEI) was 25 kDa 
whereas the linear PEI (L-PEI) was 22 kDa. Since L-PEI and B-PEI have a similar size, the 172
relationship  between  the  structure  of  the  complex  reagent  and  nucleic  acid  complex 
formation and transfer can be studied. PEIs are larger in size than the lysine based peptides; 
therefore, comparing the results from the PEI complexes with the lysine based complexes 
may  allow  the  clarification  of  the  effect  of  the  complex  reagent  size  and  chemical 
composition on the nucleic acid complex formation and transfer.
4.1.3 Aims
 To  identify  the  biophysical  properties  of  different  DNA  complexes  formed  by 
different cationic polymers and DNA.
 To elucidate and evaluate the relationship between the biophysical properties and 
transfection efficiency. 
 To clarify the criteria of a successful DNA delivery system which can be used to 
develop siRNA delivery systems.173
4.2 Results
4.2.1 Binding properties of the lysine based peptides or PEIs to DNA 
In order to deliver DNA to the cell, the vector system should firstly bind to the DNA to 
form a complex and later dissociate within the cell. Therefore, the binding capacity of the 
vector system to the DNA represents an important criterion for successful DNA delivery. 
PEIs and the lysine based peptides are both cationic and can therefore bind to anionic DNA. 
To  examine and compare  the  binding capacity  of  the lysine based peptides  or  PEIs to 
DNAs, gel retardation and PicoGreen quenching assays were performed. 
4.2.1.1 Gel retardation assay of the lysine based peptides or PEIs
To perform the gel retardation assay, the lysine based peptides or PEIs were mixed with 
DNA in distilled water at different nitrogen to phosphate (N/P) ratios for 30 minutes at
room temperature. The complexes were then resolved using 1% agarose gel electrophoresis.
The gel was visualised under UV.
Generally, increasing charge ratios (Section 2.2.3.3.1.1 for calculation of an N/P ratio) of 
the complexes retarded the complex migrations (Figure 4.4). As shown in Figure 4.4A
and  B,  all  the  linear  lysine  peptides  (K8,  K16,  K24  and  K32)  bound  to  DNA  and 
completely retarded the DNA migration at an N/P ratio of 3:1.  The complete retardation 
indicated packaging of DNA within the complex reagents. The Kbranch peptide bound to 174
and formed a stable complex with DNA starting from an N/P ratio of 4:1 (Figure 4.4C). 
Stable DNA complex formation was also observed using B-PEI at an N/P ratio of 5:1 and 
L-PEI at an N/P ratio of 2.5:1 (Figure  4.4D).175
Figure 4.4 The binding properties of peptides or PEIs with plasmid DNA. The lysine based 
peptides or PEIs were mixed with 5 kb plamsid DNA (pCI-Luc) in distilled water at different N/P 
ratios for 30 minutes. The complexes were then run on a 1% agarose gel. The gel was visualised 
using UV (Section 2.2.6.1). (A) the K8 DNA and K16 DNA complexes, (B) the K24 DNA and K32 
DNA  complexes,  (C) the  Kbranch  DNA  complexes,  (D) the  Branched  PEI  (B-PEI)  DNA  and 
Linear PEI (L-PEI) DNA complexes. The formulations of the complexes are expressed as an N/P 
ratio.  K8, K16,  K24  and  K32  completely  retarded  the DNA  migration at  an  N/P  ratio  of  3:1. 176
Kbranch, B-PEI and L-PEI completely retarded the DNA migration at N/P ratios of 4:1, 2:1, 5:1 
and 2.5:1 respectively.
4.2.1.2  PicoGreen fluorescence  quenching  assay  of the  lysine  based 
peptides or PEIs
To  perform the PicoGreen  fluorescence quenching  assay, the  plasmid  DNA was firstly 
mixed  with  the  PicoGreen  reagent  in  TE  buffer  for  10  minutes  at  room  temperature, 
followed by mixing with the lysine based peptides or PEIs in TE buffer at different N/P 
ratios for 30 minutes at room temperature. The fluorescence emission from each complex 
was measured using FLUOstar Optima. 
The PicoGreen signals from the complexes were normalised with the naked DNA control to 
yield the percentage of the PicoGreen signal detected. As the PicoGreen signals are directly 
proportional to the amount of free DNA, lower PicoGreen signals detected suggest better 
packaging of the DNA within the complexes. 
Increasing the lysine based peptides or PEIs to DNA charge ratios, to a certain N/P ratio,
led  to  decreased DNA  fluorescence  levels  (Figure  4.5  and  4.6).  All  the  linear  lysine 
peptides (K8, K16, K24 and K32) bound to DNA and minimised the fluorescence detected 
at an N/P ratio of 1.5:1 (Figure 4.5). A further increase of the N/P ratio beyond the 1.5:1 
N/P ratio of these complexes did not further reduce the fluorescence signal detected. On the 
other hand, the N/P ratios of the Kbranch peptide, B-PEI and L-PEI necessary to minimise 177
the  fluorescence  signals from  the  PicoGreen  labelled  DNA  were  2:1,  5:1  and  2.5:1 
respectively (Figure  4.6).  Having  reached  the  N/P  ratios  that  minimise  the  PicoGreen 
signals, a further increase of the N/P ratios of these complexes did not further decrease the 
fluorescence signals  detected. The minimum fluorescence signals  detected  at these  N/P 
ratios suggested that DNA were encapsulated within the complexes. 178
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Figure 4.5 The relative binding affinity of linear lysine peptides with plasmid DNA. Linear 
lysine peptides were mixed with PicoGreen labelled pCI-Luc in TE buffer at different N/P ratios for 
30  minutes.  The  fluorescence  intensity  of  the  complexes  was  then  measured  using  FLUOstar 
Optima. The PicoGreen signals from the complexes were normalised with the naked DNA control 
to yield the percentage of relative fluorescence unit (RFU) (Section 2.2.6.2). Statistical analysis was 
performed using ANOVA followed by Tukey’s test and it showed a significant decrease of the 
percentage of RFU starting from a 1.5:1 N/P ratio for all the complexes (P < 0.05). The percentage 
of RFU of the K8 DNA complexes from an N/P ratio 1.5:1 onwards is significantly different to the 
K16 DNA, K24 DNA and K32 DNA complexes with the same N/P ratio (P < 0.05).179
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Figure 4.6 The relative binding affinity of Kbranch or PEIs with plasmid DNA. The Kbranch 
peptide or PEIs were mixed with PicoGreen labelled pCI-Luc in TE buffer at different N/P ratios 
for 30 minutes. The fluorescence intensity of the complexes was then measured using FLUOstar 
Optima. The PicoGreen signals from the complexes were normalised with the naked DNA control 
to yield the percentage of relative fluorescence unit (RFU) (Section 2.2.6.2). (A) Kbranch DNA 180
complexes.  Statistical  analysis  was  performed  using  ANOVA  followed  by  Tukey’s  test  and  it 
showed a significant decrease of the percentage of RFU starting from a 2:1 N/P ratio for all the 
Kbranch DNA  complexes  (P  < 0.05). (B)  B-PEI  DNA  and  L-PEI  DNA  complexes. Statistical
analysis  was  performed  using  ANOVA followed  by  Tukey’s  test  and  it  showed  a  significant 
decrease of the percentage of RFU starting from a 2.5:1 N/P ratio of the PEI DNA complexes (P < 
0.05).181
The DNA condensation abilities of the polymers, estimated from the gel retardation and 
PicoGreen fluorescence quenching assays, are summarised in Table  4.2. Overall, DNA 
were packaged by the linear lysine peptides starting from an N/P ratio of 1.5:1 to 3:1. The 
Kbranch peptide packaged DNA starting from an N/P ratio of 2:1 to 4:1. L-PEI and B-PEI 
packaged DNA at a 2.5:1 and 5:1 N/P ratio respectively. 
The N/P ratio of the polymer necessary to mediate 
DNA condensation
Gel retardation assay PicoGreen fluorescence 
quenching assay
K8 3:1 1.5:1
K16 3:1 1.5:1
K24 3:1 1.5:1
K32 3:1 1.5:1
Kbranch 4:1 2:1
B-PEI 5:1 5:1
L-PEI 2.5:1 2.5:1
Table  4.2 The DNA  condensation  abilities  of  the  complex reagents  estimated  by  different 
assays.182
4.2.2 Dissociation properties of the lysine based peptides or PEIs to DNA 
To mediate effective DNA delivery, complex reagents are expected to package DNA into 
stable  complexes  for  cellular  uptake.  However,  the  complex  reagents  must  be  able  to 
dissociate from DNA within cells for transcription. To study the stability and dissociation 
properties of the DNA complexes, a range of different concentrations of heparin sulphate 
were added to the complexes.  Heparin has a highly negative charge and can compete with 
DNA to bind to the lysine based peptides or PEIs (Sundaram et al. 2005). Therefore, the 
addition  of  different  amounts  of  heparin  to  each  complex  allows  an  estimation  of  the 
dissociation behaviours of the complexes.
4.2.2.1 Heparin induced complex dissociation assay
To carry out the heparin  induced complex  dissociation assay, the  complexes  were first 
prepared as described in Section  2.2.6.3. Different concentrations of heparin were then 
added and incubated with those complexes in a range of charge ratios for 30 minutes in TE 
buffer at room temperature. The emissions of the fluorescence from those complexes were 
then measured using FLUOstar Optima. 
A range of five N/P ratios for each complex were chosen according to the binding studies. 
N/P ratios where the plasmid DNA appeared to be fully condensed were chosen in order to 
assess  the  effect  on  complex  stability.  Under  heparin  conditions,  when  the  complexes 
started to dissociate, the PicoGreen signal would increase due to the release of the labelled 183
DNA. Since the PicoGreen signals from the complexes were normalised with the naked 
DNA control to yield the percentage of the PicoGreen signal detected, a complete complex 
dissociation would lead to a value close to 100% of PicoGreen signal.
4.2.2.2 Dissociation of the linear lysine peptide DNA complexes
In general, increased N/P ratios enhanced the binding between the linear lysine peptides
(K8, K16, K24 and K32) and DNA (Figure 4.7 and 4.8). The K8 DNA complexes with 
N/P  ratios  of  0.75:1,  1.5:  and  3:1  dissociated  readily  under  trace  amounts  of  heparin
(Figure 4.7A). The 0.75:1 N/P ratio K8 DNA complexes became fully dissociated at a 
heparin concentration of 0.04 U/ml whereas the 1.5:1 N/P ratio K8 DNA complexes were 
completely dissociated at 0.08 U/ml of heparin. The K8 DNA complexes with an N/P ratio 
of 3:1 were fully dissociated at 0.167 U/ml of heparin. On the other hand, the 6:1 and 12:1 
N/P  ratio  K8  DNA  complexes  began  to  dissociate  at  0.08  and  0.33  U/ml  of  heparin 
respectively. The  6:1 charge ratio  complexes  became fully  dissociated at 0.67  U/ml of 
heparin whereas the 12:1 N/P ratio complexes were completely dissociated at 1.33 U/ml of 
heparin. 184
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Figure 4.7 The dissociation properties of K8 or K16 with plasmid DNA. K8 or K16 were mixed 
with PicoGreen labelled pCI-Luc in TE buffer at different N/P ratios for 30 minutes. Different 
concentrations  of  heparin  were  added  to  the  complexes  and  the  fluorescence  intensity  of  the 
complexes was measured using FLUOstar Optima. The PicoGreen signals from the complexes were 185
normalised with the naked DNA control to yield the percentage of relative fluorescence unit (RFU)
(Section  2.2.6.3).  (A)  K8 DNA  complexes.  (B)  K16 DNA  complexes. Statistical  analysis  was 
performed using ANOVA followed by Tukey’s test and it showed a significant increase of the 
percentage of RFU of the complexes treated with the concentration of heparin marked with * (each 
* has the same colour as the curve of the N/P ratio of the complexes it corresponds to). In addition, 
complexes  treated  with  higher  heparin  concentrations  displayed  a  significant  increase  of  the 
percentage of RFU compared to that of the untreated complexes (P < 0.05).
The 0.75:1 and 1.5:1 charge ratio K16 DNA complexes dissociated readily under trace 
amounts  of  heparin  and  became  fully  dissociated  at  0.08  and  0.167  U/ml  of  heparin 
respectively (Figure 4.7B). The K16 DNA complexes with N/P ratios of 3:1 and 6:1 began 
to dissociate at 0.08 and 0.33 U/ml of heparin respectively, and both of these complexes 
were completely dissociated at 0.67 U/ml of heparin. With an N/P ratio of 12:1, the K16 
DNA complexes remained stable at 0.67 U/ml of heparin and were fully dissociated at 1.33 
U/ml of heparin.
As shown in Figure 4.8A, the dissociation of the K24 DNA complexes with charge ratios 
of 0.75:1 and 1.5:1 were initiated under trace amounts of heparin, and these complexes 
were completely dissociated at 0.167 and 1.3 U/ml of heparin respectively. For the K24 
DNA complexes with charge ratios of 3:1 and 6:1, the concentration of heparin required to 
initiate dissociation were 0.08 and 0.33 U/ml respectively, with both of these complexes 
becoming fully dissociated at 1.33 U/ml of heparin. With an N/P ratio of 12:1, the K24 
DNA complexes remained stable at 0.67 U/ml of heparin and were fully dissociated at 1.33 
U/ml of heparin.186
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Figure 4.8 The dissociation properties of K24 or K32 with plasmid DNA. K24 or K32 were 
mixed  with  PicoGreen  labelled  pCI-Luc  in  TE  buffer  at  different  N/P  ratios  for  30  minutes. 
Different concentrations of heparin were added to the complexes and the fluorescence intensity of 187
the complexes was measured using FLUOstar Optima. The PicoGreen signals from the complexes 
were normalised with the naked DNA control to yield the percentage of relative fluorescence unit 
(RFU) (Section 2.2.6.3). (A) K24 DNA complexes, (B) K32 DNA complexes. Statistical analysis 
was performed using ANOVA followed by Tukey’s test and it showed a significant increase of the 
percentage of RFU of the complexes treated with the concentration of heparin marked with * (each 
* has the same colour as the curve of the N/P ratio of the complexes it corresponds to). In addition, 
complexes  treated  with  higher  heparin  concentrations  displayed  a  significant  increase  of  the 
percentage of RFU compared to that of the untreated complexes (P < 0.05).
Figure 4.8B showed that the K32 DNA complexes with N/P ratios of 0.75:1 and 1.5:1 
started to dissociate under trace amounts of heparin. These complexes became completely 
dissociated at 0.33 and 1.33 U/ml of heparin respectively. The K32 DNA complexes with 
charge  ratios  of  3:1  and  6:1  began  to  dissociate  at  0.167  and  0.33  U/ml  of  heparin 
respectively, and both of these complexes were fully dissociated at 1.33 U/ml of heparin. 
The K32 DNA complexes with an N/P ratio of 12:1 were not dissociated under 1.33 U/ml 
of heparin. 
The results  of  the heparin  induced  nucleic acid  dissociation  assays of  the linear lysine 
peptide DNA complexes are summarised in Table 4.3. Overall, increasing the size of the 
linear  lysine  peptides  enhanced  the  binding  of  the  peptides  to  DNA,  which  in  turns 
improves the complex stability. 188
DNA complexes N/P ratio Heparin 
concentration 
necessary to initiate 
dissociation (U/ml)
Heparin 
concentration 
necessary to allow 
complete 
dissociation (U/ml)
0.75:1 0-0.02 0.08
1.5:1 0.02 0.167
3:1 0.04 0.167
6:1 0.08 0.67
K8
12:1 0.33 1.33
0.75:1 0-0.02 0.08
1.5:1 0-0.02 0.67
3:1 0.08 0.67
6:1 0.33 0.67
K16
12:1 0.67-1.33 1.33
0.75:1 0-0.02 0.167
1.5:1 0-0.02 1.33
3:1 0.08 1.33
6:1 0.33 1.33
K24
12:1 0.67-1.33 1.33
0.75:1 0-0.02 0.33
1.5:1 0-0.02 1.33
3:1 0.167 1.33
6:1 0.33 1.33
K32
12:1 N/A N/A
Table 4.3 A summary of the heparin induced dissociation of different linear lysine peptide 
DNA complexes.189
4.2.2.3 Dissociation of the Kbranch peptide DNA complexes
The Kbranch DNA complexes, with charge ratios of 1:1 and 2:1, began to dissociate under 
trace amounts of heparin and were completely dissociated at 0.08 and 0.33 U/ml of heparin 
(Figure 4.9). With an N/P ratio of 4:1, the Kbranch DNA complexes started to dissociate at 
a heparin concentration of 0.08 U/ml and became fully dissociated at 0.33 U/ml of heparin. 
The dissociation of the 8:1 charge ratio Kbranch DNA complexes were initiated at 0.33 
U/ml of heparin, and these complexes were completely dissociated at 0.67 U/ml of heparin.
With an N/P ratio of 16:1, the Kbranch DNA complexes remained stable at 0.67 U/ml of 
heparin and were fully dissociated at 1.33 U/ml of heparin.190
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Figure 4.9 The dissociation properties of Kbranch with plasmid DNA. Kbranch were mixed 
with PicoGreen labelled pCI-Luc in TE buffer at different N/P ratios for 30 minutes. Different 
concentrations  of  heparin  were  added  to  the  complexes  and  the  fluorescence  intensity  of  the 
complexes was measured using FLUOstar Optima. The PicoGreen signals from the complexes were 
normalised with the naked DNA control to yield the percentage of relative fluorescence unit (RFU)
(Section 2.2.6.3). Statistical analysis was performed using ANOVA followed by Tukey’s test and it 
showed  a  significant  increase  of  the  percentage  of  RFU  of  the  complexes  treated  with  the 
concentration of heparin marked with * (each * has the same colour as the curve of the N/P ratio of 
the complexes it corresponds to). In addition, complexes treated with higher heparin concentrations 
displayed  a  significant  increase  of  the  percentage  of  RFU  compared  to  that  of  the  untreated 
complexes (P < 0.05).191
4.2.2.4 Dissociation of the PEI DNA complexes
As shown in Figure 4.10A and B, the B-PEI DNA complexes with N/P ratios of 2.5:1 and 
5:1 began to dissociate under trace amounts of heparin, with these complexes being fully 
dissociated at 5.3 and 21.3 U/ml of heparin respectively. With charge ratios of 10:1, 20:1 
and 40:1, the B-PEI DNA complexes started to dissociate at 0.167, 0.33 and 0.67 U/ml of 
heparin respectively, and the complexes became fully dissociated at 21.3 U/ml of heparin. 192
0
20
40
60
80
100
0 0.2 0.4 0.6 0.8 1 1.2 1.4
Heparin concentration (U/ml)
P
e
r
c
e
n
t
a
g
e
 
o
f
 
R
F
U
2.5
5
10
20
40
(B)
(A)
0
20
40
60
80
100
120
0 5 10 15 20 25
Heparin concentration (U/ml)
P
e
r
c
e
n
t
a
g
e
 
o
f
 
R
F
U
2.5
5
10
20
40
*
*
*
*
*
*
* *
*
*
Figure 4.10 The dissociation properties of B-PEI with plasmid DNA. B-PEI were mixed with 
PicoGreen  labelled  pCI-Luc  in  TE  buffer  at  different  N/P  ratios  for  30  minutes.  Different 193
concentrations  of  heparin  were  added  to  the  complexes  and  the  fluorescence  intensity  of  the 
complexes was measured using FLUOstar Optima. The PicoGreen signals from the complexes were 
normalised with the naked DNA control to yield the percentage of relative fluorescence unit (RFU)
(Section 2.2.6.3). (A) B-PEI DNA complexes exposed to 0 to 1.33 U/ml of heparin, (B) B-PEI
DNA complexes  exposed to  0 to 21 U/ml of heparin. Statistical analysis  was performed  using 
ANOVA followed by Tukey’s test and it showed a significant increase of the percentage of RFU of 
the complexes treated with the concentration of heparin marked with * (each * has the same colour 
as the curve of the N/P ratio of the complexes it corresponds to). In addition, complexes treated 
with  higher  heparin  concentrations  displayed  a  significant  increase  of  the  percentage  of  RFU 
compared to that of the untreated complexes (P < 0.05).
The 2.5:1 and 5:1 N/P ratio L-PEI DNA complexes dissociated readily under trace amounts 
of heparin and were completely dissociated at 2.6 and 5.3 U/ml of heparin respectively 
(Figure 4.11A and B). The dissociation of the L-PEI DNA complexes with charge ratios of 
10:1, 20:1 and 40:1 were initiated at 0.167, 0.67 and 1.33 U/ml of heparin, and all of these 
complexes were fully dissociated at 5.3 U/ml of heparin.
The results of the heparin induced nucleic acid dissociation assays of the Kbranch DNA, B-
PEI DNA and L-PEI DNA complexes are summarised in Table 4.4. Overall, B-PEI DNA 
complexes are more stable than the L-PEI DNA complexes. The L-PEI DNA complexes 
are more stable than the Kbranch DNA complexes. 194
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Figure 4.11 The dissociation properties of L-PEI with plasmid DNA. L-PEI were mixed with 
PicoGreen  labelled  pCI-Luc  in  TE  buffer  at  different  N/P  ratios  for  30  minutes.  Different 
concentrations  of  heparin  were  added  to  the  complexes  and  the  fluorescence  intensity  of  the 195
complexes was measured using FLUOstar Optima. The PicoGreen signals from the complexes were 
normalised with the naked DNA control to yield the percentage of relative fluorescence unit (RFU)
(Section 2.2.6.3). (A) L-PEI DNA complexes exposed to 0 to 1.33 U/ml of heparin, (B) L-PEI
DNA complexes  exposed to  0 to 21 U/ml of heparin. Statistical analysis  was performed  using 
ANOVA followed by Tukey’s test and it showed a significant increase of the percentage of RFU of 
the complexes treated with the concentration of heparin marked with * (each * has the same colour 
as the curve of the N/P ratio of the complexes it corresponds to). In addition, complexes treated 
with  higher  heparin  concentrations  displayed  a  significant  increase  of  the  percentage  of  RFU 
compared to that of the untreated complexes (P < 0.05).196
DNA complexes N/P ratio Heparin 
concentration 
required to initiate 
dissociation (U/ml)
Heparin 
concentration 
required to allow 
complete 
dissociation (U/ml)
1:1 0-0.02 0.08
2:1 0-0.02 0.33
4:1 0.08 0.33
8:1 0.33 0.67
Kbranch
16:1 0.67-1.33 1.33
2.5:1 0-0.02 5.3
5:1 0-0.02 21.3
10:1 0.167 21.3
20:1 0.33 21.3
B-PEI
40:1 0.67 21.3
2.5:1 0-0.02 2.6
5:1 0-0.02 5.3
10:1 0.167 5.3
20:1 0.167 5.3
L-PEI
40:1 1.33 5.3
Table  4.4  A  summary  of  the  heparin  induced dissociation  of  the Kbranch  and  PEI  DNA 
complexes.197
4.2.3 Size and zeta potential of the complexes
The particle size and surface charge are important characteristics of a DNA delivery system
for cellular binding and uptake. Positive charged particles with sizes larger than 50 nm are 
expected to be efficiently taken up by cells (Gao et al. 2005). The particle size can be 
measured as a mean hydrodynamic size (Section 2.2.6.4) using Zetasizer Nano ZS, and the 
surface charge can be measured as zeta potential (Section 2.2.6.5) using Zetasizer Nano ZS. 
4.2.3.1 Particle size
To measure the particle size, the lysine based peptides or PEIs were mixed with DNA in 
distilled water at different N/P ratios for 30 minutes at room temperature. The sizes of the 
complexes were then measured using Dynamic Light Scattering (DLS).
The measured average hydrodynamic diameters of the complexes formed from DNA and 
peptides  are  shown  in  Figure  4.12  and  4.13. With  the  exception  of  the  K32  DNA 
complexes at an N/P ratio of 0.75:1, all the linear lysine peptides formed complexes with 
DNA with mean hydrodynamic sizes ranging from 45 nm to 100 nm. For the Kbranch 
peptide DNA  complexes,  the  mean  complex  sizes  were  between  70 nm  and  130 nm. 
Generally, increasing the N/P ratio of the lysine based peptide DNA complex decreased the 
complex size. 198
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Figure 4.12 The effective diameter of peptide DNA complexes. The peptides were mixed with 
pCI-Luc in distilled water at different N/P ratios for 30 minutes. The size of each complex was then 
measured using Zetasizer Nano ZS (Section 2.2.6.4). (A) Linear lysine peptide DNA complexes.199
Statistical analysis was performed using Student’s t-test and it showed a significant decrease of the 
effective diameters of the complexes from an N/P ratio of 0.75:1 to 6:1 (P < 0.05). (B) KBranch
DNA complexes. Statistical analysis was performed using Student t-test and it showed a significant 
decrease of the effective diameters of the Kbranch DNA complexes from an N/P ratio of 1:1 to 2:1, 
4:1 or 8:1 (P < 0.05). The formulations of the complexes are expressed as an N/P ratio.
The mean hydrodynamic sizes of L-PEI DNA complexes ranged from 80 nm to 110 nm 
(Figure  4.13).  However,  the  mean  complex  sizes  of  the  B-PEI  DNA  complexes  were
distributed across a wider range, from 95 nm to 1000 nm. With N/P ratios of 10:1 and 20:1, 
the complex sizes of the B-PEI DNA complexes were 150 nm and 95 nm respectively,
which  are  similar  to  the  observation  from  Tang  and  Szoka  (Tang  &  Szoka  1997).
Decreasing the N/P ratio increased the hydrodynamic sizes of the complexes. For example, 
at an N/P ratio of 2.5:1, the mean size of the B-PEI DNA complex was 1000 nm. Overall, it 
was found that  an increase  of  the  N/P  ratios  of  the  lysine based  peptide  or  PEI DNA 
complexes decreased the mean complex size. 200
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Figure 4.13 The effective diameter of PEI DNA complexes. PEIs were mixed with pCI-Luc in 
distilled water at different N/P ratios for 30 minutes. The size of each complex was then measured
using Zetasizer Nano ZS (Section 2.2.6.4). The formulations of the complexes are expressed as an 
N/P  ratio. Statistical  analysis  was  performed  using  Student  t-test and  it  showed  a  significant 
decrease of the effective diameters of the B-PEI DNA complexes (P < 0.05). A significant decrease 
of the effective diameter of the L-PEI DNA complexes from an N/P ratio of 2.5:1 to 5:1, 10:1 or 
20:1 was also observed (P < 0.05).201
4.2.3.2 Zeta potential
To measure the zeta potential, the lysine based peptides or PEIs were mixed with DNA in 
distilled water at different N/P ratios for 30 minutes at room temperature. The average zeta 
potential of the complexes was then measured using Laser Doppler Anemometry.
Generally, the average zeta potential of the linear lysine peptide DNA complexes increased
with the N/P ratio (Figure 4.14). With an N/P ratio of 0.75:1, the average zeta potential of
the K8 DNA complexes was -17 mV (Figure 4.14A). Increasing the N/P ratio to 1.5:1 
increased the mean zeta potential of the K8 DNA complexes to +27 mV. Further increasing 
the N/P ratio to 3:1 and 6:1 increased the zeta potential of these complexes to +34 and +32 
mV respectively.202
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Figure 4.14 The zeta potential of peptide DNA complexes. The peptides were mixed with pCI-
Luc in distilled water at different N/P ratios for 30 minutes. The zeta potential of the complexes was
then  measured using  Zetasizer  Nano  ZS (Section  2.2.6.5).  (A)  Linear  lysine  peptide DNA 
complexes.  Statistical  analysis  was  performed  using  Student  t-test  and  it  showed  a  significant 203
increase of the zeta potential of the linear lysine DNA complexes (For K8 DNA, K16 DNA or K24 
DNA complexes, an increase was observed from an N/P ratio of 1.5:1 to 3:1 or 6:1; for K32 DNA 
complexes, an increase was observed from an N/P ratio of 0.75:1 to 6:1; P < 0.05). (B) Kbranch
DNA complexes. A significant increase of the zeta potential of the Kbranch DNA complexes (from 
an N/P ratio od 2:1 to 8:1) was also observed (P < 0.05). The formulations of the complexes are 
expressed as an N/P ratio.
The average zeta potential of the K16 DNA complexes with an N/P ratio of 0.75:1 were -13 
mV (Figure 4.14A). Increasing the N/P ratio to 1.5:1 increased the zeta potential of the 
K16 DNA complexes to +34 mV. At N/P ratios of 3:1 and 6:1, the zeta potential of these 
complexes were +39 and +42 mV respectively.
Similar to the K8 or K16 DNA complexes, the zeta potential of the K24 DNA complexes 
with an N/P ratio of 0.75:1 were –10 mV(Figure 4.14A). Increasing the N/P ratios to 1.5:1, 
3:1 and 6:1 increased the average zeta potential of the K24 DNA complexes to +19, +39 
and +49 mV respectively.
As shown in Figure 4.14A, the zeta potential of the K32 DNA complexes with N/P ratios 
of 0.75:1, 1.5:1, 3:1 and 6:1 were +23, +35, +42 and +53 mV respectively. 
The average zeta potential of the Kbranch DNA complexes with an N/P ratio of 1:1 was -9 
mV (Figure 4.14B). Increasing the N/P ratios to 2:1, 4:1 and 8:1 increased the average 
potential of the Kbranch complexes to +38, +42 and +52 mV respectively. 204
For the PEI DNA complexes, generally an increase of the N/P ratio increased the average 
zeta potential (Figure 4.15). The mean zeta potential of the B-PEI DNA complexes with 
N/P ratios of 2.5:1, 5:1, 10:1 and 20:1 were +38, +51, +50 and +52 mV whereas that of the 
L-PEI DNA complexes with the N/P ratios of 2.5:1, 5:1, 10:1 and 20:1 were +36, +40, +38 
and +48 mV.
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Figure 4.15 The zeta potential of PEI DNA complexes. PEIs were mixed with pCI-Luc 
in distilled water at different N/P ratios for 30 minutes. The zeta potential of the complexes 
were then measured Zetasizer Nano ZS (Section 2.2.6.5). Statistical analysis was performed 
using Student t-test and it showed a significant increase of the zeta potential of the B-PEI DNA 
complexes from an N/P ratio of 2.5:1 to 5:1, 10:1 or 20:1 (P < 0.05). A significant increase of the 
zeta potential of the L-PEI DNA complexes from an N/P ratio of 10:1 to 20:1 was also observed (P 
< 0.05).205
4.2.4  Transfection  studies  on  the  lysine  based  peptides  or  PEI DNA 
complexes
To  investigate  the  gene  delivery  efficiency  of  different  DNA  complex  formulations,  a 
plasmid  containing  a  luciferase  gene  was  used  for  complex  formation  with  the  lysine 
peptides or PEIs. The complexes were then added to Neuro 2a cells for 4 hours in serum 
free Optimem medium. The cells were harvested 24 hours post-transfection for analysis of 
luciferase expression.
As shown in Figure 4.16A, the K8 DNA complexes were not able to deliver DNA to the 
cells effectively when the N/P ratio was below 12:1; modest gene expression was detected 
at an  N/P  ratio  of  12:1.  The  K16  DNA  complexes  mediated  relatively  sufficient  gene 
delivery starting from an N/P ratio of 3:1. Increasing the N/P ratio to 6:1 improved the
transfection efficiency. However, the transfection efficiency decreased when the N/P ratios
were further increased to 24:1.206
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Figure 4.16 Plasmid transfection efficiency mediated by peptides/plasmid (pCI-Luc). 5 × 10
4
Neuro 2a cells were seeded 24 hours before transfection (in a 96 well plate). The complexes were 
made  by  mixing  peptides  with  pCI-Luc  in  Optimem at  different  N/P  ratios  for  30  minutes. 
Following removal of full growth medium, complexes were overlaid onto the cells for 4 hours. 
After removing the transfection complexes, full growth medium was added to the cells. Luciferase 207
activity in the cells was analysed 24 hours post-transfection to estimate the transfection efficiencies 
of the complexes (Section 2.2.3.3.1 and 2.2.5.1). (A) Plasmid transfection using K8, K16, K24 or 
K32/DNA complexes. Statistical analysis was performed using ANOVA followed by Tukey’s test. 
A significant increase of the luciferase activity in the cells treated with the K8 DNA complexes at 
an N/P ratio of 12:1 compared to the untreated cells or cells treated with the K8 DNA complexes at 
all other N/P ratios was observed (P <0.05). A significant increase of luciferase activity in the cells 
treated with the K16 DNA complexes at N/P ratios of 3:1 to 12:1 compared to the untreated cells or 
cells treated with the K16 DNA complexes at N/P ratios of 0.75:1, 1.5:1 and 24:1 was observed (P 
<0.05).  A  significant  increase  of  luciferase  activity  in  the  cells  treated  with  the  K24  DNA 
complexes at N/P ratios of 1.5:1 to 6:1 compared to the untreated cells or cells treated with the K24 
DNA complexes at N/P ratios of 0.75:1, 12:1 and 24:1 was observed (P <0.05). It was observed that 
a significant increase of the luciferase activity in the cells treated with the K32 DNA complexes at
N/P ratios of 1.5:1 and 3:1 compared to the untreated cells or cells treated with the K32 DNA 
complexes  at  N/P  ratios  of  0.75:1,  12:1  and  24:1 (P  <0.05).  (B)  Plasmid  transfection  using 
Kbranch/DNA complexes. Statistical analysis was performed using ANOVA followed by Tukey’s 
test and it showed that there was a significant increase of the luciferase activity in the cells treated 
with the Kbranch DNA complexes at N/P ratios of 2:1 and 4:1 compared to the untreated cells or 
cells treated with the Kbranch DNA complexes at N/P ratios of 0.5:1, 1:1, 8:1 and 16:1 (P <0.05). 
The formulations of the complexes are expressed as N/P ratios.
The K24 DNA complexes transfected the cells adequately starting from a 1.5:1 N/P ratio. 
The transfection efficiency of these K24 DNA complexes remained similarly effective at 
N/P ratios of 3:1 and 6:1. Further increasing the N/P ratio of these complexes decreased the 
transfection efficiency. 208
Similar to the K24 DNA complexes, the K32 DNA complexes delivered DNA to the cells
sufficiently starting from a 1.5:1 N/P ratio. The tranfection efficiency peaked at an N/P
ratio of 3:1. Increasing the N/P ratio of this complex from 12:1 onwards decreased the 
transfection efficiency.
The Kbranch peptide DNA complexes mediated gene delivery starting from an N/P ratio of 
2:1 (Figure 4.16B). The best transfection performances of the complexes were at N/P ratios 
of 2:1 and 4:1. However, further increase of the Kbranch peptide to DNA decreased the 
transfection efficiency. It is noted that the transfection efficiency of these complexes is 28 
fold higher than the most effective transfection complex of the linear lysine peptide DNA 
complexes  (i.e  the  K16  DNA  complexes  at  an  N/P  ratio  of  6:1  and  the  K32  DNA 
complexes at an N/P ratio of 3:1).
Both B-PEI and L-PEI have a similar transfection pattern (Figure 4.17). An increase of the
N/P ratio from 2.5:1 gradually increased the transfection efficiency. Similar to Boussif and 
co-workers’ finding, the transfection performance peaked at 10:1 (Boussif et al. 1995), but 
a further increase of the N/P ratio decreased the transfection performance. Compared to the
B-PEI DNA complex  at an N/P ratio of 10:1, the L-PEI DNA complex  could mediate 
higher transfection efficiency by 5 fold at the same N/P ratio. Indeed, L-PEI is the most 
effective transfection reagent in this study; it could mediate transfection 5 fold higher than 
B-PEI and 130 fold higher than the Kbranch peptide.209
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Figure  4.17  Plasmid  transfection  efficiency  mediated  by  PEIs/plasmid (pCI-Luc). 5 ×  10
4
Neuro 2a cells were seeded 24 hours before transfection (in a 96 plate). The complexes were made 
by mixing PEIs with pCI-Luc in Optimem at different N/P ratios for 30 minutes. Following removal 
of full growth medium, complexes were overlaid onto the cells for 4 hours. After removing the 
transfection complexes, full growth medium was added to the cells. Luciferase activity in the cells 
was analysed 24 hours post-transfection to estimate the transfection efficiencies of the complexes
(Section  2.2.3.3.1  and  2.2.5.1). Statistical  analysis  was  performed  using ANOVA  followed by 
Tukey’s test and it showed that there was a significant increase of the luciferase activity in the cells 
treated with the B-PEI DNA complexes at N/P ratios of 5:1 to 40:1 compared to the untreated cells 
or cells treated with the B-PEI DNA complexes at N/P ratios of 2.5:1 and 80:1 (P <0.05). The cells 
treated with the B-PEI DNA complexes at N/P ratios of 10:1 and 20:1 were observed to have the 
highest luciferase activity compared to the cells treated with other B-PEI DNA complexes (P <0.05). 
Similarly, a significant increase of the luciferase activity in the cells treated with the L-PEI DNA 
complexes at N/P ratios of 5:1 up to 40:1 compared to the untreated cells or cells treated with the L-
PEI DNA complexes at N/P ratios of 2.5:1 and 80:1 was observed (P <0.05). The cells treated with 
the L-PEI DNA complexes at an N/P ratio of 10:1 was observed to have the highest luciferase 210
activity compared to the cells treated with other L-PEI DNA complexes (P <0.01). The formulations 
of the complexes are expressed as N/P ratios.
4.2.5 DNA complexes mediated cellular binding, uptake and cell death 
To better understand the relationship between cellular uptake of the DNA complexes and 
transfection  efficiency,  Cy5  labelled  DNA  was  used  to  form  complexes  with  different 
reagents in Optimem and incubated with the Neuro 2a cells. Following the transfection, 
flow cytometry was performed to detect the Cy5 signal on the cells. Cy5 signal positive 
cells indicated cellular binding and uptake of the complexes. To also study the effect of the 
complexes on cell viability, propidium iodide (PI) was used to stain for dead cells. 
As shown in Figure 4.18, exposure to naked DNA mediated poor transfection efficiency; 
only 3% of the cells bound to or took up the plasmid. The K8 DNA complexes were also 
ineffective; only 5% of the cells were Cy5 positive. Compared to the K8 DNA complexes, 
it seems that an increase of the lysine length improved cellular binding and/or uptake of the 
complexes; cellular binding and/or uptake of the K16, K24 or K32 DNA complexes were 
35%, 62% and 55% respectively. On the other hand, the L-PEI, B-PEI or the Kbranch 
peptide DNA complexes were better in cellular binding and/or uptake; the L-PEI DNA 
complexes induced 64% whereas the Kbranch peptide or B-PEI DNA complexes mediated 
72% of complex binding or uptake by the cells.211
Figure 4.18 Cellular binding and/or uptake efficiencies of peptide or PEI plasmid (pCI-Luc)
complexes. Briefly, Neuro 2a cells were seeded 24 hours before transfection. The complexes were 
made by mixing peptides or PEIs with Cy 5 labelled pCI-Luc in Optimem for 30 minutes (Section 
2.2.3.3.1 and 2.2.7.2). Following removal of full growth medium, complexes were overlaid onto the 
cells for 4 hours. The cells were harvested for analysis after transfection. Propidium iodide (PI) was
used to estimate the cell viability following transfection (Section 2.2.7.3). (A) Cells exposed to 
DNA only, (B) cells exposed to the K8/DNA complex at a 3:1 N/P ratio, (C) cells exposed to the 
K16/DNA complex at a 3:1 N/P ratio, (D) cells exposed to the K24/DNA complex at a 3:1 N/P ratio,
(E)  cells  exposed  to  the  K32/DNA  complex  at  a  3:1  N/P  ratio,  (F)  cells  exposed  to  the 
Kbranch/DNA complex at a 4:1 N/P ratio, (G) cells exposed to the B-PEI/DNA complex at a 10:1 
N/P ratio, (G) cells exposed to the L-PEI/DNA complex at a 10:1 N/P ratio.212
In terms of cell viability, it is clear that naked plasmid DNA or the DNA complexes were 
toxic to the cells; around 10% to 18% cell death was observed following the exposure of 
the naked DNA or complexes. 
4.2.6 Internalisation of the DNA complexes
From flow cytometry analysis, it is clear that some of the DNA complexes can mediate 
cellular  binding  and/or  uptake.  To  confirm  whether  the  complexes  can  be  taken  up 
following transfection, Neuro 2a cells were transfected with Cy5 labelled DNA for 4 hours 
in serum free medium. The cells were then harvested and stained with phalloidin for the 
cell membrane and DAPI for the nucleus. 
The results showed that plasmids were inside the cells, mainly clustered in the cytoplasm
(Figure 4.19). This indicated that the complexes were taken up by the cells within 4 hours. 213
Figure 4.19 Localisation of plasmid following transfection. Briefly, Neuro 2a cells were seeded 
24 hours before transfection. The complexes were made by mixing peptides or PEIs with Cy 5 
labelled pCI-Luc (Purple) for 30 minutes. Following removal of full growth medium, complexes 
were overlaid onto the cells for 4 hours (Section 2.2.3.3.1 and 2.2.7.2). The cells were then washed 
and stained with phalloidin for the F-actin on the cell membrane (Green) and DAPI for the nucleus 
(Blue) (Section 2.2.8.2 and 2.2.8.3). (A) Untreated cells (the untreated cells showed the same result 
as the cells exposed to naked DNA only or the K8 DNA complexes), (B) cells exposed to the 
Kbranch DNA complexes (the cells incubated with the K16 DNA, K24 DNA, K32 DNA, B-PEI 
DNA and L-PEI DNA complexes showed a similar results as the cells exposed to the Kbranch DNA 
complexes). 
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4.3 Discussion
4.3.1 The hypothesis of a successful cationic polymer based DNA delivery 
system and the aims of the study
To be successful in gene delivery, a vector system should be able to form a stable DNA 
complex to (1) encapsulate and protect the DNA from degradation in the extracellular space, 
(2) mediate cellular binding and uptake, (3) allow DNA dissociating from the carrier for 
gene expression. Therefore, an ideal DNA delivery system should contain reagent that can 
bind and condense DNA stably, form a complex with a positive surface charge to facilitate 
complex-cell membrane interaction and form a nano-sized complex to facilitate endocytosis 
for effective cellular uptake. Then, the reagent should dissociate from DNA within the cells 
so that the DNA can traffick to the nucleus for gene expression (Chesnoy et al. 2000; 
Zhdanov et al. 2002; Niculescu-Duvaz et al. 2003). 
In this study, the biophysical and transfection properties of the DNA complexes formed by 
plasmid  DNA  and  cationic  polymers  with  different  sizes  and  physical  structures  and 
chemical  composition  were  investigated.  These  polymers  included  the  linear  lysine 
peptides (K8, K16, K24 and K32), a branched lysine peptide (the Kbranch peptide), linear 
and branched PEI. Understanding the relationship between the biophysical and transfection 
characteristics  of  the  DNA  complexes  would  be  useful  for  the  development  of  other 
successful nucleic acid delivery systems such as siRNA delivery systems.215
4.3.2 The N/P ratio of the complexes, and the size, physical structure and 
chemical composition of the polymers play a role in complex stability
From both the gel retardation and PicoGreen fluorescence quenching assays, it was found 
that all the lysine peptides and PEIs can condense and package DNA stably at certain N/P 
ratios. In general, an increase of the N/P ratios, to a certain point, enhances binding and 
encapsulation of DNA which could be important for DNA delivery. Having reached the 
N/P ratios that can completely encapsulate DNA, a further increase of the N/P ratios of the 
complexes did not improve the DNA packaging. This suggests that a further addition of the 
polymers to DNA upon the N/P ratios which led to complete DNA condensation would 
result in free polymers present alongside with the complexes.
In the heparin dissociation assay, it was interesting to find that the molecular sizes of the 
complex reagents could play a part in term of DNA packaging. Complex reagents with a 
larger molecular size had a higher affinity to DNA when the N/P ratio of the complexes 
was the same. For example, K32 (4 kDa) binds more strongly to DNA than K8 (1 kDa) 
does at the same N/P ratio (Table 4.5). The reason for this observation could be that the 
larger peptide can improve encapsulation of DNA and therefore it is harder to dissociate the 
DNA from the complex. 216
DNA complexes N/P ratio Heparin 
concentration 
necessary to initiate 
dissociation (U/ml)
Heparin 
concentration 
necessary to allow 
complete 
dissociation (U/ml)
K8 3:1 Trace amount 0.167
K32 3:1 0.167 1.33
Table  4.5  A  summary  of  heparin  induced  dissociation  of  the  K8  DNA  and  K32  DNA 
complexes at an N/P ratio of 3:1.
Apart from the size of the reagents, the physical structure and/or chemical composition of 
the reagents also plays a role in DNA binding. Similar to the finding by Dunlap and co-
workers (1997), showing that B-PEI condensed DNA more effectively than L-PEI, it is 
found that B-PEI (25 kDa) binds 4 times more effectivey to DNA than L-PEI (22 kDa) does 
at the same N/P ratio (Table 4.6). Intriguingly, the size of B-PEI (25 kDa) is only slightly
larger than the size of L-PEI (22kDa). Therefore, the 4-fold difference in binding force 
between the complexes is probably due to the structural difference (i.e linear and branched)
and/or the chemical composition between the PEIs. The branched characteristic of B-PEI 
may enhance better DNA encapsulation compared to the linear characteristic of the L-PEI.
Also, B-PEI consists of the primary, secondary and tertiary amines whereas L-PEI only 
contains secondary amines for DNA binding. Since the primary amine group has a stronger 
affinity to DNA than the secondary amine group, this may further enhance the binding 
between B-PEI and DNA (Brissault et al. 2006).   217
DNA complexes N/P ratio Heparin concentration required to allow 
complete dissociation (U/ml)
10:1 21.3
20:1 21.3
B-PEI
40:1 21.3
10:1 5.3
20:1 5.3
L-PEI
40:1 5.3
Table 4.6 A summary of heparin induced dissociation of the B-PEI DNA and L-PEI DNA 
complexes.
4.3.3 The N/P ratio is inversely related to the size and the zeta potential of 
the complexes
The average hydrodynamic sizes of the complexes generally were inversely related to the 
N/P ratios. For example, increasing the N/P ratio of the K24 DNA complexes from 0.75:1 
to 6:1 decreased the  size from 79 nm to 53 nm. By  contrast, the zeta  potential of  the 
complexes was directly related to the N/P ratios. For instance, increasing the N/P ratio of 
the K24 DNA complexes increased the zeta potential from -10 mV to 47 mV. All the 
reagents used in this study formed positively charged DNA complexes with sizes between 
50 nm and 150 nm, therefore it was highly likely that all these complexes could internalise
in the cells through either clathrin- or caveolae-mediated  endocytosis and possibly mediate 
gene  delivery  (Bishop  1997).  Among  all  the  complexes,  the  Kbranch  peptide  DNA 
complex was more likely to bind to the cell because this polymer consists of an integrin 
receptor targeting region while other polymers used in this study do not contain a receptor 
targeting region (Hart et al. 1998; Mustapa et al. 2007).218
4.3.4 The transfection efficiency of the complexes
From the transfection studies, it was found that the transfection efficiency increased with 
the charge ratio up to an optimal point. A further increase of the charge ratio beyond this 
actually decreased the transfection efficiency. This observation could be explained by the 
fact that an initial increase of the charge ratios of the DNA complexes improved the DNA 
condensation which would be beneficial for gene transfer. However, having reached the 
optimal charge ratios of the complexes for the DNA condensation, a further increase of the 
polymers to the complexes would not enhance the DNA packaging. As a result, the excess 
amounts of polymers  would  appear as  free polymers  in  the buffer.  These free  cationic 
polymers may then bind to the proteoglycans on the cell membrane, and this may decrease
the  amounts  of  the  available  proteoglycans  for  the  binding  of  the  positive  charged 
complexes. As a result, transfection efficiency decreases. 
Among  the  linear  lysine  based  peptides,  the  K16  DNA,  K24  DNA  and  K32  DNA 
complexes mediated similar transfection efficiency, which was higher than the K8 DNA 
complexes. One of the possible reasons for this could be that the K8 peptides were not able 
to  package  DNA  as  well  as  the  K16,  K24  and  K32  peptides.  From  the  PicoGreen 
fluorescence quenching assay (Figure 4.5), the K8 peptides could only minimise the DNA 
signal down to 30% whereas the K16, K24 and K32 peptides could minimise the DNA 
signal down to 20%. Being less effective in DNA packaging may result in poor cellular 
uptake of the K8 DNA complexes due to poor complex stability.219
Compared  to  B-PEI,  L-PEI  was  a  better  transfection  reagent,  found  to  mediate  5-fold 
higher transfection than B-PEI. Since B-PEI binds 4-fold stronger to DNA than L-PEI does 
(Table 4.6), it could be harder for the B-PEI DNA complexes to dissociate from DNA 
within the cells for transcription than the L-PEI DNA complexes. 
Overall, the transfection efficiency of the reagents is as follows:
L-PEI > B-PEI >> Kbranch > K16, K24, K32 > K8
The finding that the PEI DNA complexes transfected better than the lysine based peptide 
DNA complexes could be due to the fact that PEIs perform better in endosomal escape. 
During transfection, PEI DNA complexes are taken up by the cells through endocytosis 
(Ogris  et  al.  1998).  Inside  the  cell,  H
+ are  pumped  into  the  endosome  by  proton 
translocating ATPase followed by passively diffused Cl
-. The high buffer capacity of the 
PEI causes accumulation of large amount of H
+, and this in turn leads to accumulation of 
Cl
-. Thus the osmotic potential inside the endosome decreases and results in the influx of a 
large  amount  of  water.  This  causes  the  endosome  osmotic  swelling  and  subsequent 
disruption. The PEI DNA complexes then escape from the endosome and traffick to the 
nucleus for gene expression (Kichler et al. 2001). However, the lysine based peptide DNA 
complexes are not able to mediate effective endosomal escape, and most of the complexes 
end up degraded by lysosome (Erbacher et al. 1996). 
The Kbranch peptide was more effective in delivering DNA into the cells than the lysine 
tails as measured by the luciferase reporter gene assay. It was around 28-fold higher than 220
the most effective transfection complexes of the linear lysine peptide DNA complexes such 
as the K16 or K32 DNA complexes. This result is expected as the Kbranch peptide contains 
an integrin targeting peptide which facilitates receptor-mediated endocytosis, therefore this 
improves cellular uptake of the complexes. However, when compared to the B-PEI, the 
transfection efficiency  of  the  Kbranch  peptide  was 130-fold  lower.  This  observation  is 
likely due to the fact that the Kbranch DNA complexes were less efficient in mediating 
endosomal escape than the B-PEI DNA complexes.
4.3.5  The  relationship  between  the  transfection  efficiency  and  cellular 
binding and uptake of the complexes
From  results  of  the  cellular  uptake  of  DNA  complexes  formed  from  the  linear  lysine 
peptides, it was found that all of the complexes could mediate cellular binding and uptake 
(35%-60%) except  the  K8 DNA  complexes,  which mediated a  very low  percentage of 
cellular binding and uptake of the complex (5%). This finding was consistent with the low 
transfection efficiency of the K8 DNA complexes among the linear lysine based peptide 
DNA complexes.
It is expected that the Kbranch DNA complexes mediated a relatively effective cellular 
uptake and binding (72%) since the Kbranch peptide contains an integrin receptor targeting 
region which can enhance the complex taking up process by the cells through receptor-
mediated endocytosis (Hart et al. 1995).221
Despite the B-PEI DNA complexes being more effectively bound and taken up by the cells 
than the L-PEI DNA complexes, the L-PEI DNA complexes were indeed 5 times more 
efficient in transfecting cells than the B-PEI DNA complexes. This indicates that the L-PEI 
DNA complexes could be more effective in endosomal escape and/or allowing DNA to 
traffick to the nucleus for gene expression.
Overall, the cellular binding and uptake efficiencies of the complexes are as follows:
Kbranch, B-PEI > L-PEI > K24 > K32 > K16 >> K8
Although the Kbranch DNA complexes were not as effective as the B-PEI DNA complexes 
in transfection, their abilities to mediate cellular binding and uptake were similar; 74% of 
the transfected cells bound to and took up these complexes. It is not surprising to note that 
the Kbranch DNA complexes were able to mediate cellular binding and uptake effectively 
because of the targeting domain on the KBranch peptide. However, it is interesting that the 
B-PEI DNA complexes, which do not have a targeting ligand, can mediate cellular binding 
and uptake as effective as the Kbranch DNA complexes.
The  explanation  could  be  that  the  B-PEI  DNA  complexes  were  more  resistant  to 
dissociation  than  the  Kbranch  DNA  complexes (Table  4.7),  therefore  the  B-PEI  DNA 
complexes were more stable and less susceptible to degradation inside the cells. On the 
other  hand,  the  Kbranch  DNA  complexes  could  have  a  higher  percentage  of  cellular 
binding and uptake than the B-PEI DNA complexes initially, but once the Kbranch DNA 
complexes were taken up, some of them were degraded because these complexes were less 222
stable. This observation is similar to Ramsay and Gumbleton’s (2002) observation that 
cationic polymer DNA complexes which were more resistant to dissociation could yield 
higher cellular uptake.      
DNA complexes N/P ratio Heparin 
concentration 
required to initiate 
dissociation (U/ml)
Heparin 
concentration 
required to allow 
complete 
dissociation (U/ml)
Kbranch 4:1 0.08 0.33
B-PEI 10:1 0.167 21.3
Table 4.7 A summary of heparin induced dissociation of the Kbranch DNA and B-PEI DNA 
complexes.
The percentage of cells binding to and taking up the L-PEI DNA complexes (64.6%) was 
similar to that of the K24 DNA complexes (61.3%); however, the L-PEI DNA complexes 
were 130-fold better in transfection than the K24 DNA complexes. This observation was 
probably due to the fact that the K24 DNA complexes were less effective in endosomal 
escape and/or allowing DNA to traffick to the nucleus for gene expression compared to the 
L-PEI DNA complexes (Read et al. 2006).223
The results of the confocal microscopy confirmed that the complexes that were shown to 
mediate  cellular  binding  and uptake  from  the  flow  cytometry  experiment  were  able  to 
internalise within the cells following transfection.
As expected, no DNA was detected in the nucleus. This is because the nuclear membrane 
blocks the DNA from transporting to the nucleus. The DNA could enter the nucleus during 
cell division when the nuclear envelope breaks down (Brunner et al. 2000).
4.3.6  The  relationship  between  the  biophysical  properties  and  the 
transfection efficiency of the complexes
The  transfection  efficiency  and  the  biophysical  properties  of  the  complexes  were 
summarised as Table 4.8. The table showed the N/P ratios of the each complex which 
yielded comparative high transfection efficiency in the respective complex.224
Table 4.8 A summary of the biophysical properties of the effective transfection complexes.
In general, these complexes had a positive zeta potential and average hydrodynamic size 50 
nm  –  150 nm. Also,  DNA  was  completely  condensed  inside  the  complexes. These 
complexes began to dissociate from DNA under heparin concentrations of 0 to 0.33U/ml, 
Best 
transfection 
reagents
N/P 
ratio
Condensation 
of DNA
Amount of 
heparin to 
initiate 
complex 
dissociation 
(U/ml)
Heparin 
concentration 
to allow 
complete 
dissociation 
(U/ml)
Average 
hydrodynamic 
size (nm)
Zeta 
potential 
(mV)
3:1 Complete 0.083 0.67 54 +39
6:1 Complete 0.33 0.67 47 +42
K16
12:1 Complete 0.67 1.33 N/A N/A
1.5:1 Complete Very closed 
to 0
1.33 68 +29
3:1 Complete 0.083 1.33 64 +39
K24
6:1 Complete 0.33 1.33 54 +47
1.5:1 Complete Very closed 
to 0
1.33 87 +35
3:1 Complete 0.167 1.33 72 +42
K32
6:1 Complete 0.33 1.33 65 +53
2:1 Complete Very closed 
to 0
0.33 87 +37 Kbranch
4:1 Complete 0.083 0.33 104 +42
10:1 Complete 0.167 21.3 83 +49 B-PEI
20:1 Complete 0.33 21.3 92 +52
10:1 Complete 0.167 5.3 142 +37 L-PEI
20:1 Complete 0.33 5.3 79 +48225
and became fully dissociated under heparin concentrations of 0.33U/ml onwards. Therefore, 
these  biophysical  characteristics  could  be  important  parameters  to  investigate  when 
designing other kinds of DNA delivery system.  
4.4 Conclusion
In conclusion, the biophysical properties such as the binding and dissociation properties of 
the  complex  reagents  and  DNA,  the  size and  the  surface  charge of  the  complexes  are 
important  parameters,  which  are  influenced  by  the  size  and  structure  of  the  cationic 
polymer  used,  governing  the  transfection  efficiency.  Therefore,  these  parameters  are 
important to consider for the development of siRNA delivery systems.226
Chapter 5
A study on the biophysical and transfection properties 
of different cationic formulations of siRNA complexes227
5.1 Introduction
The criteria for delivering DNA to cells are similar to those of delivering siRNA. Both
DNA and siRNA are negatively charged and therefore need a vector system to transport 
them through the hydrophobic cell membrane into a cell (Grayson et al. 2006). As with 
DNA delivery, a vector system for siRNA delivery is expected to allow the formation of
stable positively charged particles with a size larger than 50 nm for endocytosis (Gao et 
al. 2005). Once within the cells, the siRNA needs to dissociate from the vector and 
traffick to the P-body in the cytoplasm for gene silencing (Jagannath & Wood 2009). In 
Chapter Four, the important criteria of a DNA complex for effective gene delivery were 
identified and discussed. These criteria require consideration for the establishment of an 
siRNA delivery system.
Despite plasmid DNA and siRNA being negatively charged double stranded nucleic 
acids, the structural and compositional differences between plasmid DNA and siRNA 
could result in different complex formation properties. siRNA is considerably smaller 
than plasmid DNA; siRNA is usually 21 base pairs whereas plasmid DNA can range 
from 1 kb to greater than 10 kb. As a ribonucleic acid, the strand pitch and diameter and 
the geometrical form of siRNA are different to plasmid DNA (Nelson & Cox 2004).
Also, siRNA is more susceptible to hydrolysis by nucleases than plasmid DNA (Banan 
& Puri 2004). Therefore, these size and compositional differences between siRNA and 
DNA could lead to differences in nucleic acid packaging and thus complex formation.
In this chapter, the lysine based peptides and PEIs were used to form complexes with 
the siRNA. The biophysical and transfection properties were then studied. The results228
from this study can be compared to the results in Chapter Four, the DNA complex study, 
in order to  generate useful information for the establishment of an effective siRNA 
delivery system.
5.1.2 Aims
 To measure the biophysical properties of different siRNA complex formulations.
 To elucidate and evaluate the relationship between the biophysical properties 
and transfection efficiency. 
 To clarify the criteria of a successful siRNA delivery system.229
5.2 Results
5.2.1 Binding properties of lysine based peptides or PEIs to siRNA 
The  binding  capacity  of  the  vector  system  to  the  siRNA  represents  an  important 
criterion for successful siRNA delivery. PEIs and the lysine based peptides are both 
cationic and can therefore bind to anionic siRNA. To examine and compare the binding 
capacity of the lysine based peptides or PEIs to siRNA, gel retardation and PicoGreen 
quenching assays were performed. 
5.2.1.1 Gel retardation assay on lysine based peptides or PEIs
To study the binding characteristics of the cationic polymers and siRNA, the polymers 
were mixed in distilled water with siRNA at different N/P ratios and incubated for 30 
minutes at room temperature. The complexes were then resolved using 4% agarose gel
electrophoresis. The gel was visualised under UV.
As shown in Figure  5.1A, the smear pattern in  the gel of the K8 and K16 siRNA 
complexes indicate that these lysine peptides could bind to and form complexes with 
siRNA; however, most of the complexes were found to be negatively charged and so 
migrated towards the positive electrode. The K8 and K16 peptides could not completely 
retard siRNA migration even up to an N/P ratio of 128:1, suggesting that siRNA cannot 
be packaged by these peptides. From Figure 5.1B, the smear pattern shows that the K24 
and K32 peptides bound to siRNA. With the N/P ratio below 16:1, these complexes 
migrated towards the positive electrode. Intriguingly, with N/P ratios higher than 16:1, 230
the  complexes  migrated  in  the  opposite  direction,  towards  the  negative  electrode. 
Overall, these results showed that the interactions between siRNA and the K24 and K32 
peptides were similar, which were different to the interaction between siRNA and the 
K8 and K16 peptides.  
The Kbranch peptide was able to bind to siRNA and completely retard the siRNA from 
migration,  starting  from  a  N/P  ratio  of  60:1  (Figure  5.1C).  siRNA  packaging  was
achieved using B-PEI at an N/P ratio of 5:1 and L-PEI at an N/P ratio of 10:1 (Figure 
5.1D).231
Figure 5.1 The binding properties of peptides or PEIs with siRNA. Peptides or PEIs were 
mixed with siRNA in distilled water at different N/P ratios for 30 minutes. The complexes were 
then run on a 4% agarose gel. The gel was visualised using UV (Section 2.2.6.1). (A) the K8 
siRNA and K16 siRNA complexes, (B) the K24 siRNA and K32 siRNA complexes, (C) the 
Kbranch  siRNA  complexes,  (D)  the  B-PEI  siRNA  and  L-PEI  siRNA  complexes.  The 
formulations of the complexes are expressed as an N/P ratio. K8 and K16 were not able to retard 
siRNA from migrating through the gel. K24 and K32 were able to retard the siRNA migration. 
With the N/P ratio above 16:1, these K24 siRNA and K32 siRNA complexes migrated towards 
the positive electrode. Kbranch, B-PEI and L-PEI completely retarded the siRNA migration at 
N/P ratios of 60:1, 5:1 and 10:1 respectively.232
5.2.1.2  PicoGreen  fluorescence  quenching  assay  on  lysine  based 
peptides or PEIs
To perform the PicoGreen fluorescence quenching assay, complexes were prepared by 
mixing the complex reagents with PicoGreen labelled siRNA in TE buffer at different 
N/P ratios. Following incubation at room temperature for 30 minutes, the complexes 
were  assayed  for  remaining  PicoGreen  signals  using  FLUOstar  Optima.  As  the 
PicoGreen signals are directly proportional to the free siRNA, lower PicoGreen signals 
detected suggest better packaging of siRNA within the complexes.
  
In general, increasing the lysine based peptide to siRNA charge ratios decreased the 
fluorescence level to a minimum beyond which a further increase in peptide had no 
effect (Figure 5.2). Indeed, all the linear lysine peptides bound to siRNA and minimised 
the fluorescence signal starting from an N/P ratio of 2:1.  The Kbranch peptide bound to 
siRNA and the minimal fluorescence signal was detected at a 3:1 N/P ratio and above
(Figure 5.3A). PEIs bound to siRNA and minimised the fluorescence signal starting 
from an N/P ratio of 5:1 (Figure 5.3B).233
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9
N/P ratio
P
e
r
c
e
n
t
a
g
e
 
o
f
 
R
F
U
K8
K16
K24
K32
* *
*
Figure 5.2 The binding of the linear lysine peptides to siRNA. The linear lysine peptides 
were mixed with PicoGreen labelled siRNA TE buffer at different N/P ratios for 30 minutes. 
The fluorescence intensity of the complexes was then measured using FLUOstar Optima. The 
formulations of the complexes are expressed as an N/P ratio. The PicoGreen signals from the 
complexes were normalised with the naked DNA control to yield the percentage of relative 
fluorescence unit (RFU) (Section 2.2.6.2). Statistical analysis was performed using ANOVA 
followed by Tukey’s test and it showed a significant decrease of the percentage of RFU starting 
from a 2:1 N/P ratio of all the complexes (P < 0.05). The percentage of RFU of the K8 siRNA 
complexes from an N/P ratio 2:1 and onwards is significantly different to the other siRNA 
complexes with the same N/P ratio in the figure (P < 0.05).234
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Figure 5.3 The binding of the Kbranch peptide or PEIs to siRNA. The Kbranch peptide or 
PEIs  were  mixed  with  PicoGreen  labelled  siRNA  TE  buffer  at  different  N/P  ratios  for  30 
minutes.  The  fluorescence  intensity  of  the  complexes  was  then  measured using  FLUOstar 
Optima. The  PicoGreen signals  from the  complexes  were  normalised  with the  naked DNA 
control to yield the percentage of relative fluorescence unit (RFU) (Section 2.2.6.2). (A) the 
Kbranch  siRNA  complexes. Statistical  analysis  was  performed  using  ANOVA  followed  by
Tukey’s test and it showed a significant decrease of the RFU starting from a 3:1 N/P ratio of all 
the Kbranch siRNA complexes (P < 0.05). (B) the B-PEI or L-PEI siRNA complexes. Statistical
analysis was performed using ANOVA followed by Tukey’s test and it showed a significant 235
decrease of the percentage of RFU starting from a 5:1 N/P ratio of the PEI DNA complexes (P < 
0.05). The formulations of the complexes are expressed as an N/P ratio.
The siRNA packaging abilities of the polymers, estimated from the gel retardation and 
PicoGreen fluorescence quenching assays, are summarised in Table 5.1. Overall, these 
results suggested that all the complex reagents can bind to siRNA, but only the Kbranch 
peptide, L-PEI and B-PEI can package siRNA into a complex.
The N/P ratio of the polymer necessary to mediate siRNA packaging
Gel retardation assay PicoGreen fluorescence quenching assay
K8 Not applicable 2:1
K16 Not applicable 2:1
K24 Not applicable 2:1
K32 Not applicable 2:1
KBranch 60:1 3:1
B-PEI 5:1 5:1
L-PEI 5:1 5:1
Table 5.1 The siRNA packaging abilities of the complex reagents estimated by different 
assays.236
5.2.2 Dissociation properties of the lysine based peptides or PEIs to 
siRNA 
To study the stability of the siRNA complexes, a range of different concentrations of 
heparin sulphate were added to the complexes. The addition of different amounts of 
heparin to  each complex  allows an estimation of the dissociation  behaviours  of the 
complexes.
5.2.2.1 Heparin induced complex dissociation assay
To carry out the heparin induced complex dissociation assay, complexes were made 
using  the  complex  reagents  and  PicoGreen  labelled  siRNA  as  described  in  the 
PicoGreen fluorescence quenching assay (Section 2.2.6.3). Following the incubation of 
the complexes, different concentrations of heparin were added to the complexes. The
PicoGreen signals from the complexes were then measured using FLUOstar Optima. An 
increase of the PicoGreen signals indicates siRNA dissociation from the complexes. 
5.2.2.1.1 Dissociation of the linear lysine peptide siRNA complexes
Increased N/P ratios enhanced the binding between the linear lysine based peptides and 
siRNA (Figure 5.4-5.5). Compared to other linear lysine peptide siRNA complexes, the 
K8 siRNA complexes dissociated readily when exposed to heparin. As shown in Figure 
5.4A, all four K8 siRNA complexes formulated at N/P ratios of 1:1, 2:1, 4:1 and 8:1 
dissociated after exposure to trace amounts of heparin. The K8 siRNA complexes with 237
N/P ratios of 1:1 and 2:1 became fully dissociated at a heparin concentration of 0.67 
U/ml whereas the K8 siRNA complexes with an N/P ratio of 4:1 fully dissociated at a 
heparin concentration of 1.33 U/ml. Only around 60% of the K8 siRNA complexes with 
an N/P ratio of 8:1 dissociated at a heparin concentration of 1.33 U/ml.238
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Figure 5.4 The dissociation properties of K8 or K16 siRNA complexes. K8 or K16 were 
mixed with  PicoGreen labelled siRNA in TE  buffer at  different N/P ratios for 30 minutes. 
Different concentrations of heparin were added to the complexes and the fluorescence intensity 
of  the  complexes  was  measured  using  FLUOstar  Optima.  The  PicoGreen  signals  from  the 
complexes were normalised with the naked DNA control to yield the percentage of relative 239
fluorescence unit (RFU) (Section 2.2.6.3). (A) the K8 siRNA complexes, (B) the K16 siRNA 
complexes. Statistical analysis was performed using ANOVA followed by Tukey’s test and it 
showed  a  significant increase  of the  percentage of RFU of  the  complexes treated  with  the 
concentration of heparin marked with * (each * has the same colour as the curve of the N/P ratio 
of  the  complexes  it  corresponds  to).  In  addition,  complexes  treated  with  higher  heparin 
concentrations displayed a significant increase of the percentage of RFU compared to that of the 
untreated complexes (P < 0.05). The formulations of the complexes are expressed as an N/P 
ratio.
The K16 siRNA complexes with N/P ratios of 1:1 and 2:1 dissociated readily in trace 
amounts of heparin and became fully dissociated at 0.167 and 0.67 U/ml of heparin 
respectively (Figure  5.4B).  With  an  N/P  ratio  of  4:1,  the  K16  siRNA  complexes 
dissociated starting from 0.08 and 0.167 U/ml of heparin and became fully dissociated
at 0.67 U/ml of heparin. The K16 siRNA complexes with an N/P ratio of 8:1 started to 
dissociate at 0.33 U/ml of heparin and were fully dissociated at 1.33 U/ml of heparin. 
As shown in Figure 5.5C, the K24 siRNA complexes with N/P ratios of 1:1 and 2:1 
dissociated readily and became fully dissociated at 0.33 and 0.67 U/ml respectively. The 
4:1 N/P ratio K24 siRNA complexes started to dissociate at 0.167 U/ml of heparin and 
became fully dissociated at 0.67 U/ml of heparin. With an N/P ratio of 8:1, the K24 
siRNA  complexes  dissociated  starting  from  0.67  U/ml  of  heparin  and  were  fully 
dissociated at 1.33 U/ml of heparin. 240
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Figure 5.5 The dissociation properties of K24 or K32 siRNA complexes. K24 or K32 were 
mixed with  PicoGreen labelled siRNA in TE  buffer at  different N/P ratios for 30 minutes. 
Different concentrations of heparin were added to the complexes and the fluorescence intensity 
of  the  complexes  was  measured using  FLUOstar  Optima.  The  PicoGreen  signals  from  the 
complexes were normalised with the naked DNA control to yield the percentage of relative 
fluorescence unit (RFU) (Section 2.2.6.3). (A) the K24 siRNA complexes, (B) the K32 siRNA 
complexes. Statistical analysis was performed using ANOVA followed by Tukey’s test and it 241
showed  a  significant increase  of the  percentage of RFU of  the  complexes treated  with  the 
concentration of heparin marked with * (each * has the same colour as the curve of the N/P ratio 
of  the  complexes  it  corresponds  to).  In  addition,  complexes  treated  with  higher  heparin 
concentrations displayed a significant increase of the percentage of RFU compared to that of the 
untreated complexes (P < 0.05). The formulations of the complexes are expressed as N/P an 
ratio.
Similar to other linear lysine peptide siRNA complexes, the K32 siRNA complexes 
with an N/P ratio of 1:1 dissociated readily when exposed to trace amounts of heparin
(Figure 5.5D). These complexes became fully dissociated at a heparin concentration of 
0.67 U/ml. For the K32 siRNA complexes with N/P ratios of 2:1 and 4:1, they started to 
dissociate at 0.08 and 0.167 U/ml of heparin respectively, and these complexes became 
fully dissociated at 0.67 U/ml of heparin. The 8:1 N/P ratio K32 siRNA complexes 
began to dissociate at 0.67 U/ml of heparin and became fully dissociated at 1.33 U/ml of 
heparin. 
The  results  of  the  heparin  induced  complex  dissociation  assay  of  the  linear  lysine 
peptide siRNA complexes are summarised in Table 5.2. Overall, increasing the N/P 
ratio enhanced the binding between the linear lysine peptides and siRNA.242
siRNA complexes N/P ratio Heparin 
concentration 
required to initiate 
dissociation (U/ml)
Heparin 
concentration 
required to allow 
complete 
dissociation (U/ml)
K8 1:1 0-0.02 0.67
2:1 0-0.02 0.67
4:1 0-0.02 1.33
8:1 0-0.02 More than 1.33
K16 1:1 0-0.02 0.167
2:1 0-0.02 0.67
4:1 0.08-0.167 0.67
8:1 0.33 1.33
K24 1:1 0-0.02 0.33
2:1 0-0.02 0.67
4:1 0.167 0.67
8:1 0.67 1.33
K32 1:1 0-0.02 0.67
2:1 0.08 0.67
4:1 0.167 0.67
8:1 0.67 1.33
Table 5.2 A summary of the heparin induced dissociation of different linear lysine peptide 
siRNA complexes.243
5.2.2.1.2 Dissociation of the KBranch siRNA complexes
Increased N/P ratios enhanced the binding between the KBranch peptides and siRNA. 
Figure  5.6 demonstrates  that  increasing  the  Kbranch  peptide enhanced  the  binding 
between the Kbranch peptides and siRNA. At N/P ratios of 1.5:1 and 3:1, the Kbranch 
siRNA complexes dissociated under trace amounts of heparin and were fully dissociated 
at 0.167 and 0.33 U/ml of heparin respectively. The Kbranch siRNA complexes at an
N/P ratio of 6:1 started to dissociate around 0.08 and 0.167 U/ml of heparin. These 
complexes were fully dissociated at 0.67 U/ml of heparin. When the N/P ratio increased 
to 12:1, the Kbranch siRNA complexes began to dissociate at 0.33 U/ml of heparin and 
became fully dissociated at 1.33 U/ml of heparin.244
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Figure  5.6  The  dissociation  properties of  the  Kbranch siRNA complexes. The Kbranch 
peptide was mixed with PicoGreen labelled siRNA in TE buffer at different N/P ratios for 30 
minutes. Different concentrations of heparin were added to the complexes and the fluorescence 
intensity of the complexes was measured using FLUOstar Optima. The formulations of the 
complexes are expressed as an N/P ratio. The PicoGreen  signals from the  complexes  were 
normalised with the naked DNA control to yield the percentage of relative fluorescence unit 
(RFU) (Section 2.2.6.3). Statistical analysis was performed using ANOVA followed by Tukey’s 
test and it showed a significant increase of the percentage of RFU of the complexes treated with 
the concentration of heparin marked with * (each * has the same colour as the curve of the N/P 
ratio of the complexes it corresponds to). In addition, complexes treated with higher heparin 
concentrations displayed a significant increase of the percentage of RFU compared to that of the 
untreated complexes (P < 0.05).245
5.2.2.1.3 Dissociation of the PEI siRNA complexes
Increasing PEIs increased the binding to siRNA (Figure 5.7 and 5.8). As shown in
Figure 5.7A, the B-PEI siRNA complexes at N/P ratios of 1.25:1 and 2.5:1 dissociated 
readily under trace  amounts  of heparin. The 1.25:1  N/P  ratio complexes were fully 
dissociated at 1.33 U/ml of heparin while the 2.5:1 N/P ratio complexes became fully 
dissociated at 5.3 U/ml of heparin (Figure 5.7B). With N/P ratios of 5:1, the B-PEI 
siRNA complexes started to dissociate around 0.02 and 0.04 U/ml of heparin (Figure 
5.7A) and became fully dissociated at 5.3 U/ml of heparin (Figure 5.7B). The B-PEI 
siRNA complexes with N/P ratios of 10:1 and 20:1 began to dissociate at 0.167 and 
0.33 U/ml of heparin respectively, (Figure 5.7A) and became fully dissociated at 5.3 
U/ml of heparin (Figure 5.7B). 246
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Figure 5.7 The dissociation properties of the B-PEI siRNA complexes. B-PEI was mixed 
with PicoGreen labelled siRNA in TE buffer at different N/P ratios for 30 minutes. Different 
concentrations of heparin were added to the complexes and the fluorescence intensity of the 
complexes was measured using FLUOstar Optima. The PicoGreen signals from the complexes 
were normalised with the naked DNA control to yield the percentage of relative fluorescence 
unit (RFU) (Section 2.2.6.3). (A) the B-PEI siRNA complexes exposed to 0 to 1.33 U/ml of 
heparin , (B) the B-PEI siRNA complexes exposed to 0 to 21.3 U/ml of heparin. Statistical 
analysis was performed using ANOVA followed by Tukey’s test and it showed a significant 247
increase of the percentage of RFU of the complexes treated with the concentration of heparin 
marked with * (each * has the same colour as the curve of the N/P ratio of the complexes it 
corresponds to). In addition, complexes treated with higher heparin concentrations displayed a 
significant increase of the percentage of RFU compared to that of the untreated complexes (P < 
0.05). The formulations of the complexes are expressed as an N/P ratio.
Figure 5.8 shows that the L-PEI siRNA complexes with N/P ratios of 1.25:1 and 2.5:1 
dissociated  readily  under  trace  amounts  of  heparin.  Both  of  these  complexes  were 
completely dissociated at 0.33 U/ml of heparin. With 5:1 and 10:1 N/P ratios, the L-PEI 
siRNA complexes started to dissociate at 0.08 and 0.167 U/ml of heparin respectively, 
and these complexes were fully dissociated at 0.67 U/ml of heparin. The 20:1 N/P ratio 
L-PEI siRNA complexes began to dissociate at a heparin concentration of 0.67 U/ml 
and became completely dissociated at 1.33 U/ml of heparin.248
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Figure 5.8 The dissociation properties of the L-PEI siRNA complexes. Briefly, L-PEI were 
mixed with  PicoGreen labelled siRNA in TE  buffer at  different N/P ratios for 30 minutes. 
Different concentrations of heparin were added to the complexes and the fluorescence intensity 
of the complexes was measured using FLUOstar Optima. The formulations of the complexes are 
expressed as an N/P ratio. The PicoGreen signals from the complexes were normalised with the 
naked DNA control to yield the percentage of relative fluorescence unit (RFU) (Section 2.2.6.3).
Statistical analysis was performed using ANOVA followed by Tukey’s test and it showed a 
significant increase of the percentage of RFU of the complexes treated with the concentration of 
heparin  marked  with  *  (each  *  has  the  same  colour  as  the  curve  of  the  N/P  ratio  of  the 
complexes it corresponds to). In addition, complexes treated with higher heparin concentrations 
displayed a significant increase of the percentage of RFU compared to that of the untreated 
complexes (P < 0.05).249
The results of the heparin induced complex dissociation assay of the Kbranch siRNA, 
B-PEI  siRNA  and  L-PEI  siRNA  complexes  are  summarised  in  Table  5.3. Overall, 
increasing the N/P ratio enhanced the binding between the Kbranch peptide, B-PEI or 
L-PEI and siRNA. It appears that B-PEI binds more strongly to siRNA than L-PEI does. 
In other words, the B-PEI siRNA complexes are more stable than the L-PEI siRNA 
complexes.  
siRNA complexes N/P ratio Heparin 
concentration
necessary to initiate 
dissociation (U/ml)
Heparin 
concentration 
necessary to allow 
complete 
dissociation (U/ml)
KBranch 1.5:1 0-0.02 0.167
3:1 0-0.02 0.33
6:1 0.08-0.167 0.67
12:1 0.33 1.33
B-PEI 1.25:1 0-0.02 1.33
2.5:1 0-0.02 5.3
5:1 0.02-0.04 5.3
10:1 0.167 5.3
20:1 0.33 5.3
L-PEI 1.25:1 0-0.02 0.33
2.5:1 0-0.02 0.33
5:1 0.08 0.67
10:1 0.167 0.67
20:1 0.67 1.33
Table 5.3 A summary of the heparin induced dissociation of the Kbranch and PEI DNA 
complexes.250
5.2.3 Size and zeta potential of the complexes
The particle size and surface charge are important characteristics of an siRNA delivery 
system for cellular binding and uptake. Positive charged particles with sizes larger than 
50 nm are expected to be efficiently taken up by cells (Gao et al. 2005). The particle 
size can be measured as a mean hydrodynamic size (Section 2.2.6.4) using Zetasizer
Nano ZS, and the surface charge can be measured as zeta potential (Section 2.2.6.5) 
using Zetasizer Nano ZS. 
5.2.3.1 Size of the complexes
To  study  the  hydrodynamic  sizes  of  the  siRNA  complexes,  complex  reagents  were 
mixed with siRNA in distilled water and incubated at room temperature for 30 minutes. 
The complex sizes were then estimated by the DLS technique.
The mean hydrodynamic sizes of complexes formed from all the linear lysine peptides 
and  siRNA  could  not  be  determined  due  to  the  highly  polydisperse  nature  of  the 
complexes. This  suggests  that  the  linear  lysine  peptides  formed  highly  irregular 
complexes or a wide range of different sized complexes with siRNA. Therefore, these 
complexes are expected to be ineffective for siRNA delivery.
The Kbranch peptide formed complexes with siRNA at an N/P ratio of 1:1 with a size of 
144 nm (Figure 5.9A). Gradually increasing the N/P ratio decreased the complex size, 
and  the  size  of  the  Kbranch  siRNA  complexes  at  an N/P  ratio  of  6:1  was  92  nm. 
However, increasing the N/P ratio from 6:1 to 12:1 increased the heterogeneity of these251
complexes. At an N/P ratio of 12:1, the average hydrodynamic size of the Kbranch 
siRNA complexes was 464 nm with a large standard deviation. This indicates that a 
further increase of the N/P ratio of the Kbranch peptide siRNA complex may cause 
aggregation  or  instability  of  the  complex  which  will  result  in  heterogeneous  sized 
complexes.252
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Figure 5.9 The effective diameter of the KBranch or PEIs siRNA complexes. The Kbranch 
peptide or PEIs were mixed with siRNA in distilled water at different N/P ratios for 30 minutes. 
The size of the complexes was then measured using Zetasizer Nano ZS (Section 2.2.6.4). (A)
the  mean  hydrodynamic  size  of  the  Kbranch  siRNA  complexes.  Statistical  analysis  was 
performed using Student t-test and it showed a significant decrease of the effective diameters of 
the Kbranch siRNA complexes from an N/P ratio of 1:1 to 3:1 or 6:1 (P < 0.05). (B) the mean253
hydrodynamic size of the B-PEI or L-PEI siRNA complexes. Statistical analysis was performed 
using Student t-test and it showed a significant decrease of the effective diameters of the B-PEI 
siRNA complexes from an N/P ratio of 2.5:1 to 10:1 (P < 0.05). A significant increase of the 
effective diameter of the L-PEI siRNA complexes from an N/P ratio of 2.5:1, 5:1 or 10:1 to 20:1 
was also observed (P < 0.05). The formulations of the complexes are expressed as an N/P ratio.
Increasing the N/P ratios decreased the size of the B-PEI siRNA complexes (Figure 
5.9B). Aside from the B-PEI siRNA complexes at an N/P ratio of 2.5:1, the B-PEI 
siRNA complexes with N/P ratios of 5:1, 10:1 and 20:1 ranged from 60 nm to 100 nm.
On the other hand, all the L-PEI siRNA complexes, which had N/P ratios between 2.5:1 
and 20:1, ranged from 70 nm to 110 nm. Conversely, an increase of the N/P ratios of the 
L-PEI siRNA complexes did not increase the complexes size.
5.2.3.2 Zeta potential of the complexes
To  measure  the  zeta  potential,  the  lysine  based  peptides  or  PEIs  were  mixed  with 
siRNA in distilled water at different N/P ratios for 30 minutes at room temperature. The 
average zeta potential of the complexes was then measured using LDA.
The zeta potential of the linear lysine peptide siRNA complexes could not be measured 
due to their high polydispersity. On the other hand, the average zeta potential of the 
Kbranch peptide siRNA complex at an N/P ratio of 1.5:1 was -27.2 mV (Figure 5.10A). 
Increasing the N/P ratio to 3:1 increased the average zeta potential to +31 mV. However, 
a further increase of the N/P ratio did not increase the zeta potential.254
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Figure 5.10 The zeta potential  of the Kbranch or PEIs siRNA complexes. The cationic 
polymers were mixed with siRNA in distilled water at different N/P ratios for 30 minutes. The 
zeta potential of the complexes was then measured using Zetasizer Nano ZS (Section 2.2.6.5). 
(A)  the  average  zeta  potential  of  the  Kbranch  siRNA  complexes.  Statistical  analysis  was 
performed using Student t-test. There are no significant different between the Kbranch siRNA255
complexes with N/P ratios of 3:1, 6:1 or 12:1. (B) the average zeta potential of the B-PEI or L-
PEI siRNA complexes. Statistical analysis was performed using Student t-test and it showed a 
significant decrease of the zeta potential of the B-PEI siRNA complexes from an N/P ratio of 
2.5:1, 5:1 or 10:1 to 20:1 (P < 0.05). A significant increase of the zeta potential of the L-PEI 
siRNA complexes from an N/P ratio of 2.5:1 to 5:1, 10:1 or 20:1 was also observed (P < 0.05).
The formulations of the complexes are expressed as an N/P ratio.
Both the B-PEI and L-PEI siRNA complexes with N/P ratios between 2.5:1 and 20:1 
have a positive average zeta potential (Figure 5.10B). The average zeta potential of the 
B-PEI siRNA complex was between +45 mV and +55mV whereas that of the L-PEI 
siRNA complex was between +30 mV and +45 mV. An increase of the N/P ratio of the 
L-PEI  siRNA  complex  gradually  increased  the  average  zeta  potential;  however, 
increasing the N/P ratio of the B-PEI siRNA complex did not increase the average zeta 
potential.
5.2.4 Transfection studies on the lysine based peptide or PEI siRNA 
complexes
To investigate the siRNA delivery efficiency of the complexes, siRNA transfection was 
carried out using Neuro 2a cells stably expressing luciferase as described in Section 
2.2.3.3.3  and  2.2.3.3.4.  By  using  siRNA  targeting  luciferase  (siLuc),  the  gene 
knockdown efficacy was determined by the remaining luciferase activity. To ensure the 
luciferase knockdown was due to specificity of the anti-luciferase siRNA, an siRNA 
targeting eGFP (sieGFP) was used as a control. As a positive control, complexes formed 
with  commercially  available  Lipofectamine  2000  (L2000)  and  siRNA  were  used  to 
transfect the cells.  256
As shown in Figure 5.11, no significant luciferase knockdown was observed from the 
siRNA complexes composed of the linear lysine or Kbranch peptides whereas L2000 
siRNA complexes induced 80% gene knockdown. It was perhaps not surprising to note 
that no gene knockdown was observed for the linear lysine peptides since these peptides 
cannot form homogenously sized and charged complexes for cellular uptake. However, 
it  was  unexpected  that  the  Kbranch  peptide  siRNA  complexes,  which  can  form 
positively charged stable siRNA nanoparticles, cannot mediate gene silencing.257
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Figure 5.11 siRNA transfection efficiency mediated by the lysine based peptide siRNA 
complexes. 5  ×  10
4 Neuro  2a  luciferase  expressing  cells  were  seeded  24  hours  before 
transfection (in a 96 well plate). The complexes were made by mixing the linear lysine or 
Kbranch peptides with siRNA targeting luciferase (siLuc) at different N/P ratios for 30 minutes. 
Complexes with siRNA targeting eGFP (sieGFP) were used as a control to assess non-specific 
gene  silencing  mediated  by  the  complexes.  Following  removal  of  full  growth  medium, 
complexes were overlaid onto the cells for 4 hours. After removing the transfection complexes, 
full growth medium was added to the cells (Section 2.2.3.3.3 and 2.2.3.3.4). Luciferase activity 
in the cells was analysed 24 hours post-transfection to estimate the transfection efficiencies of 
the  complexes (Section  2.2.5.1).  The  luciferase  activity  of  the  untreated  cells  was  used  to 
normalise the luciferase activity of the treated cells to yield the percentage of luciferase activity. 
(A) siRNA transfection using the K8, K16, K24 or K32 siRNA complexes. Statistical analysis 
was performed using Student t-test and it showed that there was a significant decrease of the 258
luciferase activity in the cells treated with the L2000 siLuc complexes compared to the cells 
treated with the L2000 sieGFP complexes (P <0.05) while there was no significant luciferase 
activity decrease of the cells treated with the linear peptide (K8, K16, K24 and K32) siLuc 
complexes compared to the cells treated with the linear peptide sieGFP complexes. (B) siRNA 
transfection  using  the  Kbranch  siRNA  complexes.  Statistical  analysis  was  performed  using 
Student t-test and it showed that there was a significant decrease of the luciferase activity in the 
cells treated with the L2000 siLuc complexes compared to the cells treated with the L2000 
sieGFP complexes (P <0.05) while there was no significant luciferase activity decrease of the 
cells treated with the Kbranch siLuc complexes compared to the cells treated with the Kbranch 
sieGFP complexes. The formulations of the complexes are expressed as an N/P ratio.
The L-PEI siRNA complexes, which were formulated from an N/P ratio of 2.5:1 to an
N/P ratio of 20:1, did not mediate gene silencing (Figure 5.12A).  On the other hand, 
the  B-PEI  siRNA  complexes  at  an N/P  ratio  of  20:1  mediated  60%  luciferase 
knockdown (Figure 5.12B). A further increase of the N/P ratio of the B-PEI siRNA 
complex to 40:1 resulted in a decreased luciferase signal when both siLuc and sieGFP 
complexes were used. This suggested that complexes at this N/P ratio were either toxic 
to the cells or delivering excessive amount of siRNA to cells which results in non-
specific gene silencing.
To determine whether the decreased luciferase signal caused by the N/P ratio 40:1 B-
PEI  siRNA  complex  was  due  to  toxicity,  the  viability  of  the  cells  from  the  same 
experiment setting presented in Figure 5.12B was analysed. As shown in Figure 5.13, 
the percentage of viable cells treated with the N/P ratio 40:1 B-PEI siRNA complex was 
around 60% compared to cells treated with siRNA alone, suggesting that it was the cell 
toxicity rather than non-specific gene silencing caused the decrease of luciferase signal 
in Figure 5.12B. By contrast, both the L2000 siRNA and N/P ratio 20:1 B-PEI siRNA 
complexes were less toxic to the cells, causing around 20% loss of viable cells.259
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Figure 5.12 siRNA transfection efficiency mediated by the B-PEI siRNA and L-PEI siRNA 
complexes. 5  ×  10
4 Neuro  2a  luciferase  expressing  cells  were  seeded  24  hours  before 
transfection (in a 96 well plate). The complexes were made by mixing B-PEI or L-PEI with 
siLuc at different N/P ratios for 30 minutes. Complexes with sieGFP were used as a control to 
assess  non-specific  gene  silencing  mediated  by  the  complexes.  Following  removal  of  full 
growth  medium,  complexes  were  overlaid  onto  the  cells  for  4  hours.  After  removing  the 
transfection complexes, the full growth medium was added to the cells (Section 2.2.3.3.3 and 
2.2.3.3.4).  Luciferase  activity  within  the  cells  was  analysed  24  hours  post-transfection  to 
estimate the transfection efficiencies of the complexes (Section 2.2.5.1). The luciferase activity 
of the untreated control was used to normalise against the luciferase activity of cells treated with 260
siRNA or the complexes to yield the percentage of luciferase activity. (A) siRNA transfection 
using the L-PEI siRNA complexes. Statistical analysis was performed using Student t-test and it
showed that there was a significant decrease of the luciferase activity in the cells treated with 
the L2000 siLuc complexes compared to the cells treated with the L2000 sieGFP complexes (P 
<0.05) while there was no significant luciferase activity decrease of the cells treated with the L-
PEI siLuc complexes compared to the cells treated with the L-PEI sieGFP complexes.  (B)
siRNA transfection using the B-PEI siRNA complexes. Statistical analysis was performed using 
Student t-test and it showed that there was a significant decrease of the luciferase activity in the 
cells treated with the L2000 siLuc complexes compared to the cells treated with the L2000 
sieGFP complexes (P <0.05). A significant luciferase activity decrease of the cells treated with 
the B-PEI siLuc complexes compared to the cells treated with the B-PEI sieGFP complexes (P < 
0.05). The cells treated with the B-PEI siLuc complexes or the B-PEI sieGFP complexes at an 
N/P ratio of 40:1 showed a significant decrease of the luciferase activity compared to the cells 
treated  with  the  siRNA  alone  or  the  untreated  cells  (P  <  0.05).  The  formulations  of  the
complexes are expressed as an N/P ratio.261
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Figure  5.13  Cellular  toxicity  mediated  by  B-PEI  siRNA  complexes. 5  ×  10
4 Neuro  2a 
luciferase expressing cells were seeded 24 hours before transfection (in a 96 well plate). The 
complexes were made by mixing B-PEI with siLuc or sieGFP at different N/P ratios for 30 
minutes. Following removal of full growth medium, complexes were overlaid onto the cells for 
4 hours. After removing the transfection complexes, the full growth medium was added to the 
cells  (Section  2.2.3.3.3  and  2.2.3.3.4).  The  cell  viability was  analysed  24  hours  post-
transfection by a CellTiter 96 AQueous One Solution Assay to estimate the cytotoxicity effect
of the complexes on the cells (Section 2.2.5.4). The absorbance of the untreated cells was used 
to  normalise  against  the  absorbance  of  the  cells  treated  with  siRNA  alone  or  the  siRNA 
complexes to yield the percentage of cell viability. Statistical analysis was performed using
Student t-test and it showed that there was a significant decrease of viability of the cells treated 
with  the  B-PEI  siRNA  complexes  at  N/P  ratios  of  20:1  and  40:1  and  the  L2000  siRNA 
complexes compared to the cells treated with siRNA or B-PEI or L2000 only (P <0.05). The 
formulations of the complexes are expressed as an N/P ratio. The cell viability of the treated
cells was normalised with the untreated control to yield percentage of cell viability.262
In order to further confirm that the luciferase knockdown mediated by the B-PEI siRNA 
complexes at a 20:1 N/P ratio was due to a specific siRNA effect, B-PEI was used to 
form  a  complex  with  an  siRNA  targeting  an  endogenous  gene  glyceraldehyde-3-
phosphate dehydrogenase (siGAPDH) at the same N/P ratio. The complex was then 
used to transfect the Neuro 2a cells and the GAPDH knockdown was recorded (Figure 
5.14). As a control for gene knockdown specificity, an sieGFP was used to form a 
complex with B-PEI and the complex was used for cell transfection.    263
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Figure 5.14 GAPDH gene knockdown mediated by the B-PEI siRNA complexes. 5 × 10
4
Neuro 2a cells were seeded 24 hours before transfection (in a 96 well plate). The complexes 
were made by mixing B-PEI with different concentration of siGAPDH at an N/P ratio of 20:1 
for 30 minutes. Complexes with sieGFP were used as a control to assess non-specific gene 
silencing mediated by the complexes. Following removal of full growth medium, complexes 
were overlaid onto the cells for 4 hours. After removing the transfection complexes, full growth 
medium  was  added  to  the  cells (Section  2.2.3.3.3  and  2.2.3.3.4).  GAPDH  mRNA  levels 
(Section  2.2.9)  and  activities  (Section  2.2.5.3)  in  the  cells  were  analysed  48  hours  post-
transfection to estimate the transfection efficiencies of the complexes. (A) GAPDH activities.
The GAPDH activity of the untreated cells was used to normalise the GAPDH activity of the 
treated cells to  yield the percentage of GAPDH activity. Statistical analysis was performed 264
using Student t-test and it showed that there was a significant decrease of GAPDH activity in 
the cells treated with the B-PEI siLuc complexes with 5 to 20 nM compared to the cells treated 
with  the  B-PEI  sieGFP  complexes at  the  same  siRNA  concentrations  (P  <0.05).  When 
compared to the cells treated with siRNA only, a significant decrease of the GAPDH activity of 
the cells treated with the B-PEI sieGFP (5 to 20 nM) complexes was observed (P <0.05). The 
L2000 siLuc complexes mediated a significant GAPDH activity decrease in the cells compared 
to the cells treated with the L2000 sieGFP complexes (P < 0.05). (B) GAPDH mRNA levels
assayed by real time PCR. The mRNA level of the untreated cells was used to normalise against 
the treated cells to yield the percentage of mRNA level. Statistical analysis was performed using 
Student t-test and it showed that there was a significant decrease of GAPDH activity in the cells 
treated with the B-PEI siLuc complexes with 20 and 40 nM or the L2000 siLuc complexes 
compared to the cells treated with the B-PEI sieGFP complexes or the L2000 sieGFP complexes 
at the same siRNA concentrations respectively (P <0.05).
As shown in Figure 5.14A, the B-PEI siGAPDH complex, with an N/P ratio of 20:1 
and  5  nM  of  the  siRNA,  mediated  50%  GAPDH  knockdown.  However,  the  B-PEI 
sieGFP complex also induced a decrease of the GAPDH expression by 20%. Increasing 
the amount of the siGAPDH from 10 nM to 40 nM enhanced the GAPDH knockdown, 
although at the same time the B-PEI sieGFP complex resulted in a further decrease of 
the GAPDH expression. The decrease of the GAPDH in the cells treated by the B-PEI 
sieGFP  complexes  suggested  that  these  complexes  either  induced  non-specific  gene 
silencing or cellular toxicity. 
Compared to the B-PEI siGAPDH complexes with 10 and 20 nM of siRNA, the L2000 
siGAPDH complex could mediate more than 60% of GAPDH knockdown whereas the 
L2000  sieGFP  complex  did  not  lead  to  a  decrease  of  GAPDH  expression (Figure 
5.14A). Also, it was shown that siRNA alone could not mediate gene silencing. 265
To find out if the decrease of the GAPDH levels in the cells treated with the B-PEI 
sieGFP complexes was due to toxicity or non-specific gene silencing, the mRNA levels 
of the GAPDH in the cells exposed to the B-PEI siRNA complexes were analysed. As 
shown in Figure 5.14B, the B-PEI siGAPDH complexes with 20 and 40 nM siRNA 
induced GAPDH knockdown whereas the B-PEI sieGFP complexes with 20 and 40 nM 
of siRNA did not. This indicated that increasing the siRNA amounts within the B-PEI 
siRNA complexes causes cellular toxicity.
5.2.5  siRNA  complexes  mediated  cellular  binding,  uptake  and  cell 
death 
From the siRNA transfection study, it is noted that no specific gene knockdown was 
mediated  by  the  linear  lysine  peptide siRNA  complexes.  This  was  perhaps  not 
surprising since the linear lysine peptides could not form monodisperse nanoparticles 
with siRNA. Unexpectedly, the Kbranch peptide or L-PEI siRNA complexes did not 
mediate gene silencing even though they can form positively charged nanoparticles. 
These results could be due to no cellular uptake of the complexes or the complexes 
being destroyed following entry into the cells by the endosome (Khalil 2006).
In order to examine the relationship between cellular uptake of the siRNA complexes 
and transfection efficiencies, Cy 3 labelled siRNA was used to form complexes with the 
different cationic polymers used in this study. Following 4 hours of transfection, the 
Neuro  2a  cells  were harvested.  Cellular  binding  and  uptake  of  the  complexes  were 
assayed using flow cytometry (Figure 5.15). Cy3 signal positive cells indicated cellular 266
binding and uptake of the complexes. To also estimate the cellular toxicity induced by 
the complexes, 7-amino-actinomycin D (7aad) was used to stain for dead cells. 267
Figure  5.15  Cellular  binding  and  uptake  efficiencies  of  the  cationic  polymer  siRNA 
complexes. Briefly, Neuro 2a cells were seeded 24 hours before transfection. The complexes 
were  made  by  mixing  the  cationic  polymers  with  Cy  3  labelled  siRNA  for  30  minutes. 
Following removal of full growth medium, complexes were overlaid onto the cells for 4 hours. 
The cells were harvested for analysis after transfection (Section 2.2.3.3.3 and 2.2.3.3.4). Cells 
stained with 7aad were to estimate the cell viability following transfection (Section 2.2.7.3). (A)
untreated cells, (B) cells exposed to naked siRNA only, (C) cells exposed to the B-PEI/siRNA 
complex at 20:1 N/P ratio, (D) cells exposed to the L-PEI/siRNA complex at 20:1 N/P ratio, (E)
cells  exposed  to  the  Kbranch/siRNA  complex  at  6:1  N/P  ratio,  (F)  cells  exposed  to  the 
L2000/siRNA complex.268
As shown in Figure 5.15, the Cy3 signals were detected from the cells transfected with 
the  B-PEI  (Figure 5.15C)  or  L2000  (Figure 5.15F)  siRNA  complexes.  The  Cy  3 
signals were detected from ~70% of the cells transfected with L2000 siRNA complexes 
and ~60% of the cells treated with B-PEI siRNA complexes. On the other hand, only a 
very low Cy3 signal could be detected from the cells exposed to the L-PEI (Figure
5.15D) or the Kbranch peptide (Figure 5.15E) siRNA complexes. 
As  shown  in  Figure  5.15,  55%  of  cells  exposed  to  naked  siRNA  were dead.  The 
percentage of cell death of cells exposed to the B-PEI or L-PEI siRNA complexes were 
26% and 28% respectively. The Kbranch siRNA complexes mediated 36% cell toxicity 
while the L2000 siRNA complexes induced 11% cell toxicity. These findings suggested
that  cell  death  and  siRNA  delivery  efficiency  could  form  a  reversely correlated 
relationship.
5.2.6 Internalisation of the siRNA complexes
To confirm the findings from the flow cytometry (i.e. siRNA uptake), Neuro 2a cells 
were transfected with Cy 3 labelled siRNA complexes in different formulations for 4 
hours in serum free medium. The cells were then harvested and stained with phalloidin 
for  the  cell  membrane  and  DAPI  for  the  nucleus.  The  cells  were  then  assessed  by 
confocal microscopy.
The results showed that no siRNA signal was detected from the cells transfected with 
either the Kbranch peptide or L-PEI siRNA complexes which were consistent to the 
findings  from  the  flow  cytometry (Figure  5.16).  siRNA  was  detected  in the  cells 269
exposed to the L2000 or B-PEI siRNA complexes. In particular, siRNA predominantly 
clustered in the cytoplasm for the cells transfected with the L2000 siRNA complexes. 
On the other hand, for the cells treated with B-PEI siRNA complexes, siRNA localised 
predominantly in the nucleus and comparatively less in the cytoplasm. 270
Figure  5.16  Localisation  of  siRNA  following  transfection.  Briefly,  Neuro  2a  cells  were 
seeded 24 hours before transfection. The complexes were made by mixing the cationic polymers 
with Cy 3 labelled siRNA (Red) for 30 minutes. Following removal of full growth medium, 
complexes were overlaid onto the cells for 4 hours (Section 2.2.3.3.3 and 2.2.3.3.4). The cells 
were then washed and stained with phalloidin for the F-actin on the cell membrane (Green) and 
DAPI  for  the  nucleus  (Blue) (Section  2.2.8.2  and  2.2.8.3).  (A) cells  exposed  to  the 
Kbranch/siRNA  complexes  (untreated  cells,  cells  exposed  to  the  naked  siRNA  or  the  L-
PEI/siRNA  complexes  showed  the  same  result  as  the  cells  exposed  to  the  Kbranch/siRNA
complexes)  (B)  cells  exposed  to  the  B-PEI/siRNA  complex,  (C)  cells  exposed  to  the 
L2000/siRNA complex. 271
5.3 Discussion
The criteria to deliver DNA and siRNA to the cells are believed to be similar. For 
instance, both the nucleic acids need to be packaged inside the vectors to form stable 
nanoparticles with a positive surface charge for cellular entry (Grayson et al. 2006). 
Once inside the cells, both nucleic acids must be dissociated from the vector systems to 
their respective compartments for gene expression or silencing. Therefore, it is expected 
that  a  successful  siRNA  delivery  system  would  demonstrate  similar  biophysical 
properties to a successful DNA delivery system. However, the differences in the size 
and the chemical composition of siRNA and DNA could lead to different biophysical 
characteristics  of  siRNA  complexes  compared  to  that  of  DNA  complexes.  These 
differences in biophysical properties could result in a different nucleic acid delivery
behaviour of the siRNA complexes compared to the DNA complexes.
In this chapter, the biophysical and transfection properties of the siRNA  complexes 
were investigated. This information can be compared to the biophysical and transfection 
properties of the DNA  complexes  using the same vector reagents. The  comparative 
study could allow the generation of ideas for the development of an effective siRNA 
delivery system.  
5.3.1 The importance of the physical and chemical structure and the 
size of the complex reagents for siRNA packaging
From the results of the gel retardation assay, it was observed that a linear complex 
reagent structure may not be as effective as a branched structure to package siRNA. For 272
instance, the linear lysine peptides were not able to completely retard and encapsulate
siRNA whereas the branched lysine peptide, the Kbranch peptide, was able to do so. 
Also, B-PEI, which completely retarded the siRNA migration at a 5:1 N/P ratio, was 
more effective  in  packaging  siRNA  than  L-PEI, which  completely encapsulated  the 
siRNA at an N/P ratio of 10:1. 
The chemical composition of the complex reagents plays a role in the siRNA packaging. 
For  example,  PEIs, which  are  denser  in  charge  than  the  lysine  peptides, packaged
siRNA  more  effectively  than  the  lysine  peptides.  The  L-PEI  and  B-PEI completely 
retarded the siRNA migration at an N/P ratio of 10:1 and 5:1 respectively, whereas the 
Kbranch peptides completely ceased the siRNA  migration at a 60:1 N/P  ratio. This 
suggests that complex reagent with a higher charge density would be more effective for 
siRNA encapsulation. 
Another important parameter for effective siRNA packaging could be the size of the 
complex reagent. The effective B-PEI and L-PEI siRNA packaging reagents were 25 
and 22 kDa respectively; these polymers were 5-6 times larger than the lysine based 
peptides, which were 1-4 kDa in size. This indicated that larger complex reagent could 
be more efficient for siRNA packaging.
B-PEI can package siRNA more efficiently than L-PEI. Similarly, the Kbranch peptide 
is  more  effective in  encapsulating  siRNA  than  the  linear  lysine  peptides.  This  may 
suggest that the branched structure of the complex reagents could be more beneficial for 
siRNA packaging than the linear structure. 273
5.3.2  A  different  observation  between  the  PicoGreen  fluorescence 
quenching assay and the gel retardation assay 
From  the  gel  retardation  assay,  it  is  clear  that  the  linear  lysine  peptides  were  not 
effective in packaging siRNA; only the Kbranch peptide, B-PEI and L-PEI were able to 
package siRNA. However, the results of the PicoGreen fluorescence quenching assay 
showed that all the complex reagents used in this study were able to bind to siRNA
effectively. There were discrepancies between the results from the gel retardation and 
PicoGreen fluorescence quenching assays and these are summarised in Table 5.1. The 
difference in the results could be due to the fact that in the gel retardation assay, an 
electric field is applied across the complexes and therefore the migration patterns of the 
complexes  are  influenced  by  the  overall  charge  of  the  complexes  and  the  binding 
strength between cationic peptides and siRNA. There is not this kind of force in the 
PicoGreen fluorescence quenching assay, therefore, the results in this assay may differ. 
In  fact,  the  results  of  the  B-PEI  or  L-PEI  siRNA  complexes  were  similar  in  both 
experiments, suggesting that the PEI siRNA complexes were very stable. Conversely, 
the lysine peptide siRNA complexes were not very stable. 
5.3.3 Dissociation patterns of the siRNA complexes
From the heparin induced complex dissociation assay, it was found that an increased 
N/P  ratio  enhanced  the  binding  between  the  complex  reagents  and  siRNA.  For  the 
lysine  based  peptides,  it  was  observed  that  peptides  with  a  larger  size  bound  more 274
strongly  to  siRNA.  The  affinity  of  siRNA  to  the  lysine  peptides  is  summarised  as 
follows:
K32, K24 > K16 > Kbranch (consists of 13 lysines)
The K8 peptide was not included in this comparison because the overall dissociation 
pattern of the K8 siRNA complexes in different N/P ratios were different to that of the 
other  linear  lysine  siRNA  complexes.  The  K8  siRNA  complexes  dissociated  more 
gradually than the other linear lysine siRNA  complexes.  The K8 siRNA complexes 
started to dissociate more readily in low heparin concentration compared to other lysine 
peptide  siRNA  complexes;  however,  different  to  the  other  lysine  peptide  siRNA 
complexes,  the  dissociation  rate  of  the  K8  siRNA  complexes  decreased  when  the 
heparin increased. The reason for this could be that the K8 peptides were not strongly 
bound  to  either  the  siRNA  or  the  heparin,  therefore  the  K8  peptides  which  were 
dissociated from siRNA by heparin could be reversibly bound back to siRNA.
   
Nevertheless, the results showed that the different molecular sizes of the peptides gave 
rise  to  different  binding  properties  to  siRNA,  with  larger  peptides  interacting  more 
strongly with siRNA. 
Compared to L-PEI, B-PEI had a higher affinity to siRNA. This could be due to the fact 
that B-PEI (25kDa) is larger than L-PEI (22kDa). On the other hand, B-PEI contains 
primary,  secondary  and  tertiary  amine  groups whereas  L-PEI  mainly  consists  of 
secondary amine group (von Harpe et al. 2000). It was shown that the primary amine 
group had more affinity than the secondary amine group to nucleic acids such as DNA. 275
Therefore, this may explain the reason why the B-PEI siRNA complexes were more 
difficult to dissociate than the L-PEI siRNA complexes. 
5.3.4 The size and zeta potential of the complexes
The mean hydrodynamic  size  and zeta  potential of the linear lysine peptide  siRNA 
complexes  could  not  be  determined  due  to  high  polydispersity.  In other  words,  the 
complexes  formed  from  the  linear  lysine  peptides  and  siRNA  were  either  too 
heterogeneous in size or shape. By contrast, the Kbranch peptides could form uniquely 
sized complexes (monodisperse) with siRNA, showing that the branched lysine peptide 
was more effective in packaging siRNA than the linear lysine peptides.
Both B-PEI and L-PEI could form monodisperse complexes with siRNA. An increase in
the N/P ratio of the B-PEI siRNA complexes was generally found to decrease the mean 
hydrodynamic size and zeta potential. By contrast, increasing the N/P ratio of the L-PEI 
siRNA complexes was found to generally increase the mean hydrodynamic size and 
zeta potential. This observation clearly suggested that B-PEI packaging siRNA in  a 
different way to L-PEI. This difference could be due to the physical branched structure 
of the B-PEI or higher affinity of the B-PEI to siRNA.
5.3.5 The siRNA delivery efficiency of the complexes
From the siRNA transfection study using the Neuro 2a luciferase expressing model, it 
was found that only the B-PEI siRNA complexes could transfect the cells at a N/P ratio 
of 20:1. Other complex reagents used in the study such as the linear lysine, Kbranch 276
peptides and L-PEI were not able to do so. Indeed, it was not surprising that the linear 
lysine peptide siRNA complexes were not able to deliver siRNA to the cells since these 
complexes were not monodisperse nanoparticles. Therefore, it was predicted that those 
complexes would not be effective in delivering siRNA to the cells. 
Unexpectedly,  the  Kbranch  siRNA  and  L-PEI  siRNA  complexes,  which  formed
positively charged monodisperse complexes with sizes around 100 nm, were not able to 
transfect the cells. The reason for this could be due to either no cellular uptake of the 
complexes, the siRNA failing to be released in the cytoplasm or the complexes being
destroyed in the cells following endocytosis.
B-PEI was found to form positively charged monodisperse complexes with siRNA and
mediated  siRNA  delivery.  However,  only the  20:1  N/P  ratio  of  the  complexes  was
effective  in  luciferase  gene  silencing.  Further  increasing  the  N/P  ratio  of  these 
complexes to 40:1 resulted in a decrease of luciferase activity in the cells treated with 
both the B-PEI siLuc and B-PEI sieGFP complexes due to cell toxicity.
Compared to complexes formed by other polymers and siRNA with similar N/P ratios, 
the 20:1 N/P ratio B-PEI siRNA complexes required the highest amount of heparin to 
mediate complex dissociation. In order words, the B-PEI siRNA complexes with an N/P 
ratio of 20:1 were the most stable complexes in this study. Therefore, stability of the 
complex  could  be  an  important  criterion  for  successful  siRNA  delivery.  However, 
further increasing the N/P ratio of the B-PEI siRNA complexes to 40:1, which would 
improve the stability of the complexes, led to non-specific gene silencing and/or toxicity277
(Grayson  et  al.  2006),  showing  that  the  balance  between  complex  stability  and  the 
resulting cellular toxicity and/or non-specificity is important.
The  results  of  the  GAPDH  gene  silencing  assay  showed  that  the  B-PEI  siRNA 
complexes with a 20:1 N/P ratio could mediate specific gene silencing on other targeted 
genes.  However,  it  was  found  that  increasing  the  amount  of  siRNA  within  the 
complexes could induce cellular toxicity and/or non-specific gene silencing. The real 
time PCR results indicated that an increase of the amount of the siRNA within the 
complexes  did  not  induce  a  non-specific  gene  silencing  effect.  This  suggests  that 
transfection with a large amount of the B-PEI siRNA complexes is toxic to the cells.
5.3.6 The relationship between the transfection efficiency and cellular 
binding and uptake of the complexes
Flow  cytometry to  measure  the  complex  uptake  showed  that  only  B-PEI  siRNA 
complexes  and the positive control  L2000 siRNA  complexes  could mediate cellular 
binding and uptake of the complexes.  In particular, the L2000 siRNA complexes were 
more effective in mediating gene silencing. 
The results of the confocal microscopy appeared to show that a large percentage of the 
siRNA delivered by the B-PEI siRNA complexes was localised in the nucleus whereas 
the  siRNA  delivered  by  L2000  siRNA  complexes  was  mainly  accumulated  in  the 
cytoplasm  30  minutes  after  transfection.  This  observation  was  consistent  with  the 
finding that the L2000 siRNA complexes mediated higher gene silencing efficacy than 
the B-PEI siRNA complexes. Interestingly, the possible reason that the siRNA delivered 278
by the B-PEI siRNA complexes localised in the nucleus could be due to the nuclear 
localisation ability of the B-PEI itself (Godbey et al. 1999). 
The cell viability assay showed that the naked siRNA and other siRNA complexes used 
in the study were toxic to the cells. The toxicity of the naked siRNA or the complexes is
summarised as follows:
Naked siRNA > KBranch+siRNA > L-PEI+siRNA > B-PEI+siRNA > L2000+siRNA
Interestingly,  the  naked  siRNA,  the  Kbranch  siRNA  and  L-PEI  siRNA  complexes, 
which were not able to mediate gene silencing, were relatively toxic to the cells. The 
L2000 siRNA complexes, which were more effective in siRNA delivery than the B-PEI 
siRNA complexes, were less toxic to the cells. These results indicated that improved 
siRNA delivery may decrease the siRNA induced toxicity to the cells.  
5.3.7  The  relationship  between  the  biophysical  properties  and  the 
transfection efficiency of the complexes
In this  study,  only the  20:1  N/P  B-PEI siRNA  complexes  mediated  gene silencing. 
Table 5.4 summarises the biophysical properties of these complexes. As an effective 
siRNA delivery reagent, the B-PEI could encapsulate siRNA into a stable monodisperse
particle with a size less than 100 nm, and a positively charged complex. 279
Best 
transfection 
reagent
N/P 
ratio
Condensation 
of DNA
Amount of 
heparin 
necessary 
to initiate 
complex 
dissociation 
(U/ml)
Heparin 
concentration 
necessary to 
allow 
complete 
dissociation 
(U/ml)
Average 
hydrodynamic 
size (nm)
Zeta 
potential 
(mV)
B-PEI 20:1 Complete 0.33 5.3 60 +42
Table 5.4 A summary of the biophysical properties of the B-PEI siRNA complexes at an 
N/P ratio of 20:1.
Other  complex  reagents  such  as  the  Kbranch  peptide  and  L-PEI  formed  positively 
charged nano-sized particles with siRNA. However, the main difference between the B-
PEI siRNA complexes and the Kbranch siRNA and L-PEI siRNA complexes was that 
B-PEI had a higher affinity to siRNA than the other complex reagents. In other words, 
the B-PEI siRNA complexes were the most stable complexes in this study. 
   
5.3.8  Prediction  of  an  ideal  complex  reagent  for  effective  siRNA 
delivery
From this study, it was observed that three parameters were important for a successful 
siRNA delivery reagent; the physical structure and chemical composition of the reagent 
and the cellular toxicity mediated by the reagents. In terms of the physical structure, it
appeared that a branched structure was probably more effective than a linear structure 
for siRNA packaging. For instance, the Kbranch peptides were similar to the linear 280
lysine  peptides in  terms  of  size;  however,  the  Kbranch  peptides  packaged  siRNA 
whereas the linear lysine peptides could not.
Larger molecular sizes could also be beneficial for siRNA packaging. Despite L-PEI 
(22kDa) and the linear lysine peptides (1-4 kDa) being linear in structure, L-PEI was 
more effective in packaging siRNA. Since siRNA are a rigid rod like structure (Gary et 
al. 2007), they are not flexible in folding to other conformations. Therefore, larger sized 
reagents with a branched structure may be more efficient in packaging siRNA because 
they may provide the flexibility required for siRNA packaging (Grayson & Godbey 
2008).
This study showed that PEIs are more effective in packaging siRNA than the lysine 
peptides. This could also be due to the difference in the chemical composition between 
the PEI and the lysine peptides. PEIs are denser in amine groups than the lysine peptides
per  repeating  unit.  The  high  density  of  the  amine  groups enhances  the  electrostatic 
binding between the PEI and siRNA and increases the buffering capacity of PEI to 
improve endosomal escape of the siRNA complexes (Gary et al. 2007).
The siRNA delivery reagent should be non-toxic; otherwise, it will not be useful for 
basic research or clinical applications. In this study, it was found that B-PEI was the 
most effective siRNA delivery reagent apart from the L2000. However, B-PEI was toxic 
to the cells. To minimise PEI mediated toxicity, van Vliet and co-workers demonstrated 
that modifying the repeating unit of the PEI with varying proportions of methyl, benzyl, 
and n-dodecyl groups reduced the cellular toxicity (van Vliet et al. 2008).281
Overall, these results suggest that an ideal siRNA complex reagent should be branched 
and  large  in  molecular  size  to  provide  flexibility  for  siRNA  packaging.  Also,  the 
complex reagent should have a high charge density to enhance siRNA binding, cellular 
uptake and endosomal escape. Moreover, the complex reagent should not be toxic to the 
cells.
5.4 Conclusion
The linear lysine peptides, namely K8, K16, K24 and K32, are not able to encapsulate 
siRNA and mediate siRNA delivery. Despite the observation that the Kbranch peptide 
and L-PEI can package siRNA and form a nanoparticle with a positive surface charge, 
these complexes are not able to mediate siRNA transfer. Only B-PEI can be used to 
package  siRNA  into  a  positively  charged  nanoparticle  and  mediate  gene  silencing. 
These results suggest that the size and chemical composition of the cationic polymers 
play an important role in mediating effective siRNA delivery.282
Chapter 6
General discussion283
6.1 Introduction
Since successful delivery of nucleic acids such as plasmid DNA or siRNA to specific cells 
is a powerful tool to treat diseases, there have been studies exploiting different polymer 
systems to deliver nucleic acids to the cells. Examples of these polymer systems include 
PEI (Grayson et al. 2006), polyarginine, polylysine (El-Sayed et al. 2008; Kumar et al. 
2007), histidylated polylysine peptides (Leng et al. 2008), chitosan (Katas & Alpar 2006)
and dendrimers (Patil et al. 2008). Despite many reports showing that these polymers can 
deliver nucleic acids to the cells, systematic studies on the requirements for a good polymer 
based nucleic acid delivery system have been limited. Therefore, this study aimed to clarify 
the requirements of a successful nucleic acid delivery system. This information could be 
useful for the development of new kinds of nucleic acid delivery system and/or further 
improvement of the existing systems.       
There are two main cellular parameters limiting the efficiency of nucleic acid complex
delivery mediated by polymers. Firstly, the complexes need to be able to bind and be taken
up by the cells. Secondly, the complexes need to mediate endosomal escape and release the 
nucleic acids within the cells following cellular uptake. Complexes with positive charges 
and sizes on a nanometre scale would facilitate the cellular uptake processes. Positively
charged  complexes can  interact  with  the  negatively  charged  cell  membrane.  This 
interaction is believed to enhance cellular binding of the complex to the cell membrane 
which is rich in negatively charged molecules such as heparan sulfate proteoglycans and 
integrins (Gao et al. 2005; Grayson et al. 2006). Likewise, the size of the complex is crucial 284
for cellular uptake. Complexes with sizes larger than 50 nm could effectively be taken up 
by the cells through endocytosis (Gao et al. 2005). Once the complexes are taken up by the 
cells, they need to dissociate to release the plasmid DNA or siRNA from the vector system 
for their respective functions (Gary et al. 2007). The relative ability of DNA or siRNA 
unloading  can  be  estimated  through the  dissociation  properties  of  the  complex  system. 
Hence,  it  was  hypothesised  that  a  successful  nucleic  acid  delivery  system  would 
demonstrate biophysical properties that include condensation and dissociation of nucleic 
acids and formation of a positively charged monodisperse nanoparticle. 
   
In this study, the relationships between the biophysical and transfection properties of some 
well  known  polylysine  and  PEI  based  DNA  delivery  systems were  investigated.  The 
relationships  between  the  biophysical  and  transfection  properties  of  siRNA  complexes 
formed from these complex reagents were then studied and compared with the results of the 
respective DNA complexes. Through this comparative study, the outcome could be useful 
for developing nucleic acid delivery systems to effectively deliver other kinds of nucleic 
acids such as siRNA.
As mentioned, polylysine and PEI were used in this study. The polylysine used included
the  linear  lysine  K8,  K16,  K24  and  K32  and  the  Kbranch  peptides. The  linear  lysine 
peptides used only differ in their sizes so this may help determine the relationship between 
the  size  and  nucleic  acid  packaging  and  delivery  efficacy.  The  Kbranch  peptide  has  a 
similar size as the linear lysine peptides; therefore, the nucleic acid packaging properties of 
the Kbranch peptide can be used to compare with that of the linear lysines to find out the
effect of different structure on the nucleic acid packaging. L-PEI and B-PEI were also used 285
in this study since they have a similar size, allowing the relationship between the structure 
of the complex reagent and nucleic acid complex formation and transfer to be studied. PEIs 
are larger in size than the lysine based peptides; therefore, comparing the results from the 
PEI complexes with the lysine based complexes may allow clarification of the effect of the
complex reagent size and chemical composition on the nucleic acid complex formation and 
transfer.
6.2  Overall  summary  of  the  relationship  between  the  biophysical 
properties and the transfection efficacy of the DNA complexes
All the complex reagents except the K8 peptide were able to form complexes with DNA 
which  enabled  them  to  transfect  the  cells  with  different  efficiencies.  Those  complexes 
shared similar biophysical characteristics as expected. For instance, DNA was effectively 
packaged by the complex  reagents to form monodisperse nanoparticles (> 50 nm) with 
positive  surface  charges. Moreover,  all  the  complexes  formed  stable  complexes  which 
could withstand the challenge of different concentrations of heparin. 
Despite the similarity of the biophysical properties, there are differences in the transfection 
efficacies which could be due to the abilities of the complexes to mediate cellular uptake 
and/or endosomal escape. In this study, PEIs were better transfection reagents than the 
Kbranch DNA  complexes, and the  Kbranch peptide was more effective than the  linear 
lysine peptides. 286
In terms of cellular uptake, the Kbranch DNA and PEI DNA complexes were effectively 
taken up by the cells whereas the linear lysine DNA complexes were comparatively less 
effective in mediating cellular uptake. The Kbranch DNA complexes were expected to be 
more effective in cellular uptake than the linear lysine DNA complexes since the integrin 
targeting peptide on the Kbranch peptide could enhance the cellular binding and uptake of 
the complexes (Hart et al. 1995). Although the PEI DNA complexes behaved similarly in 
DNA condensation and nanoparticle formation as the linear lysine DNA complexes, they 
were more stable than the linear lysine DNA complexes as shown from the heparin induced 
complex dissociation assay. Gumbleton and Ramsay (2002) showed that complexes with 
higher stability resulted in higher cellular binding and uptake; the higher stability of the PEI 
DNA complexes could therefore improve cellular binding and uptake. 
In term of endosomal escape, PEI DNA complexes were more effective than peptide DNA 
complexes in escaping from the endosome via the proton sponge effect (Boussif et al. 1995)
whereas there are no such effective endosomal escape mechanisms for the lysine peptides
(Read et al. 2005). As the PEI DNA complexes were more superior in mediating cellular 
uptake  and  endosomal  escape  than  the  linear  lysine  DNA  complexes,  they  were  more 
effective in transfection. Although the Kbranch DNA complexes mediated effective cellular 
uptake, the lack of an endosomal escape capacity may have led to less efficient transfection 
than the PEI DNA complexes.
L-PEI is more effective in transfection than B-PEI. The main difference observed between 
these  complexes  was  the  dissociation  properties.  This  improved  transfection  capability 287
could be due to the fact that DNA is more easily dissociated from the L-PEI DNA complex 
than from the B-PEI DNA complex.
Overall, the most important characteristics of complexes for effective delivery of DNA to 
the cells would be the stability, size and surface charge of the complexes. The DNA should 
be stably condensed inside the complexes. The complexes needed to be able to withstand 
the heparin challenge to a certain level. With the hydrodynamic size larger than 50 nm and
with a positive surface charge, the complexes would be able to mediate cellular uptake. It is 
expected that a successful siRNA delivery system would demonstrate these characteristics.
   
6.3  Overall  summary  of  the  relationship  between  the  biophysical 
properties and the transfection efficacy of the siRNA complexes
The linear lysine and Kbranch peptides and PEI were used to form complexes with siRNA, 
and the biophysical properties of these complexes were examined. In the studies on the 
binding  between  the  complex  reagents  and  siRNA,  it  was  found  that  the  linear  lysine 
peptides could not package and form monodisperse complexes with siRNA. On the other 
hand, the Kbranch peptide could package siRNA in a positively charged nanoparticle. Since 
the Kbranch and the linear lysine peptides were similar in size, this suggested that the 
branched rather than the linear structure of the peptide could enhance the condensation of 
siRNA. 288
Despite complex reagents with a linear structure being less effective in packaging siRNA,
L-PEI was efficient in forming complexes with siRNA. The main differences between L-
PEI and the linear lysine peptides are the size and chemical composition. L-PEI (22 kDa) is 
larger than the linear lysine peptides (1-4 kDa). With one nitrogen atom in every three 
atoms in a repeating unit (von Harpe et al. 2000), the charge density of L-PEI is higher than 
that of the linear lysine peptides. Therefore, complex reagents with a large size and high 
charge density are more effective in siRNA complex formation. Being branched, large and 
high charge density, B-PEI was an effective reagent to form complexes with siRNA.
From the heparin induced complex dissociation assay, it was observed that the binding 
between L-PEI and siRNA was similar to that between the Kbranch peptide and siRNA at 
similar N/P  ratios.  On  the  contrary,  it  was  found  that  the  binding  between  B-PEI and 
siRNA was stronger than that between L-PEI and siRNA at the same N/P ratio. This means 
that the L-PEI siRNA complexes and the Kbranch siRNA complexes were less stable than 
the B-PEI siRNA complexes. Compared to the L-PEI, which is linear and contains mainly 
secondary amine group, B-PEI is branched and consists of primary, secondary and tertiary 
amine groups. The  branched structure and the  primary  amine  group could  enhance the 
binding between B-PEI and siRNA (Brissault et al 2006). The B-PEI siRNA complexes 
were  the  most  heparin-resistant  nanoparticle,  and  were  in  fact  the  most  stable  siRNA 
complexes compared in this study. 
Indeed, the B-PEI siRNA complexes were the only complexes that induced gene silencing 
in transfection studies apart from the positive control L2000 siRNA complexes. Although 
the  Kbranch  peptides  and  L-PEI  could  encapsulate  siRNA  in  a  positively  charged289
monodisperse nanoparticle, these siRNA complexes  did not mediate  gene silencing. As 
mentioned,  more  stable  complexes  mediate  better  cellular  binding  and  uptake  of  the 
complexes (Glumbleton and Ramsay 2002), which might explain the reason why the B-PEI 
siRNA complexes were more effective in mediating cellular uptake and siRNA delivery. 
A study on the cellular uptake of the siRNA complexes using flow cytometry analysis 
showed that the Kbranch siRNA and L–PEI siRNA complexes did not mediate cellular 
uptake in the cells. Interestingly, it was found that the Kbranch siRNA and L-PEI siRNA 
complexes  were  also  more  toxic  than  the  B-PEI  siRNA  and  L2000  siRNA  complexes
which were able to mediate cellular uptake. This observation could suggest that the poor 
siRNA transfection efficacies of the Kbranch siRNA and L-PEI siRNA complexes might be
related to the toxicity of these complexes.
Taken together, it was found that the physical structure and chemical composition of the 
complex reagents play an important role in forming complexes with siRNA. Large and 
branched  structures  with  higher  charge  densities  could  allow  the  formation  of  stable 
monodisperse complexes for effective siRNA delivery. The large and branched structures
could provide flexibility to encapsulate the small and rigid siRNA, which were inflexible in 
folding (Grayson & Godbey 2008). Higher charge density could enhance the binding to 
siRNA and improve the complex stability. 290
6.4 The biophysical properties of the best DNA transfection complexes 
were similar to those of the most effective siRNA transfection complexes
The best DNA transfection complexes, the L-PEI DNA complexes at N/P ratios of 10:1 and 
20:1,  shared  similar  biophysical  properties  with  the  most  effective  siRNA  delivery 
complexes, the B-PEI siRNA complexes with a 20:1 N/P ratio. Table 6.1 summarised their 
biophysical properties.
Best 
transfection 
performance
N/P 
ratio
Condensation 
of DNA or 
siRNA
Amount of 
heparin to 
initiate 
complex 
dissociation 
(U/ml)
Heparin 
concentration 
to allow 
complete 
dissociation 
(U/ml)
Average 
hydrodynamic 
size (nm)
Zeta 
potential 
(mV)
L-PEI + 
DNA
10:1 Complete 0.167 5.3 142 +37
L-PEI + 
DNA
20:1 Complete 0.33 5.3 79 +48
B-PEI + 
siRNA
20:1 Complete 0.33 5.3 60 +42
Table 6.1 A summary of the biophysical properties of the most effective DNA transfection and 
siRNA transfecion complexes. 
The L-PEI DNA and B-PEI siRNA complexes performed similarly in the formation of 
nanoparticles with positive surface charges. Moreover, these complexes behaved similarly 
under  the  heparin  challenge,  indicating  that  they  had  a  similar  complex  stability.  This 
observation  supported  the  notion  that  a  successful  nucleic  acid  delivery  system  shares 
similarity in biophysical properties which are important for cellular uptake and endosomal 
escape. To  take  it  further,  this  indicated  that  other  kinds  of  successful  self-assembly 291
polymer-based nucleic acid delivery systems would demonstrate biophysical characteristics 
similar to these properties. 
6.5 Different packaging requirements of DNA and siRNA because of the 
differences in their sizes and chemical compositions
siRNA is small in size, usually 21 base pair long. As a ribonucleotide,  the persistence 
length, which represents the tendency of a chain to persist in a given conformation and is 
directly proportional  to  the  helix  rigidity,  of  a  double  stranded RNA  is  around  70  nm 
(Kebbekus et al. 1995); therefore, siRNA, which is less than 30 nm in length, are a very 
rigid structure and are not flexible in folding. Comparatively, the plasmid DNA used in the 
study is around 5 kb. Since the persistence length of deoxyribonucleic acids is around 50 
nm (Hagerman 1997), this infers that the plasmid DNA is more flexible in folding and 
easier to condense. As a result, it is easier to form complexes with DNA. Since the siRNA 
is more rigid, the complex reagents used may need to be (1) more flexible in folding and (2) 
denser in charge to compromise the inflexibility of the siRNA.  
(1) Flexibility of the complex reagents
In  terms  of  flexibility  of  the  complex  reagents,  linear  structures  have  less  rotational 
freedom in folding than branched structures. Also, smaller sized complex reagents are more 
rigid than larger complex reagents (Grayson & Godbey 2008). Therefore, the flexibility of 
the complex reagents used in this study in an ascending order is as follows:292
Linear lysine peptides < Kbranch < L-PEI < B-PEI
In  this  study,  it  was  shown  that  all  the  complex  reagents  can  package  and  form 
nanoparticles with plasmid DNA but not siRNA. As discussed previously, the reasons for
this could be due to the fact that plasmid DNA is more flexible in folding and condensing 
within a complex. On the other hand, to form a nanoparticle with siRNA, it seems that a 
more flexible complex reagent is needed. 
The results shown in Chapter Five suggested that complex reagents with a larger size could 
be useful to package siRNA. For example, although both linear lysine peptides and L-PEI 
are linear in structure, L-PEI is able to encapsulate siRNA but not the linear lysine peptides, 
suggesting that the size of the reagents plays a role in siRNA packaging. 
The  structure  of  the  complex  reagents  such  as  a  linear  or  branched formation  is  also 
important  for  siRNA  complex  formation.  For  instance,  Kbranch, but  not  linear  lysine 
peptides, can package siRNA. Although both L-PEI and B-PEI can encapsulate siRNA, 
only the  B-PEI  siRNA  complex  mediated  gene  silencing.  This  again  indicates  that  the 
branched structure is superior for siRNA complex formation. As shown from an image 
from atomic force microscopy (Appendix III), it seems that a L-PEI siRNA complex is in 
a rod shape whereas a B-PEI siRNA complex is in a spherical shape. This indicates that 
different structures would lead to different ways of siRNA complex formation, which in 
turn affects the efficacy for siRNA delivery.293
Other studies have shown that large and branched polymers such as dendrimers, branched 
histidylated polylysine peptides, chitosan, which is a large branched structure, are all useful
for siRNA delivery. Howard and co-workers found that although high molecular weight 
chitosan  can  mediate  siRNA  delivery,  low  molecular  weight  chistosan  cannot  do  so 
(Howard et al. 2006). This again indicates that a flexible structure is needed to package 
siRNA. Similar to the findings in this study, Grayson and co-workers demonstrated that L-
PEI was not able to deliver siRNA in vitro whereas B-PEI was able to form complexes with 
siRNA and mediate gene silencing (Grayson et al. 2006). All in all, polymers with large 
and branched structures seem to be important features for siRNA packaging and delivery.    
(2) High charge density
Other than the size and structure of the complex reagent, the charge density of the repeating
unit within the complex reagent may play an important role in complex formation. One 
example is that the L-PEI, which has a higher charge density within a repeating unit than 
that of the lysine based peptides, package siRNA better. Another example was shown by 
Kumar and co-workers and in this study (Appendix IV) that a short arginine peptide (R9), 
which consists of 9 arginines in a row, can package siRNA and form a nanoparticle (Kumar 
et al. 2007). Indeed, the structure and size of the R9 peptide is similar to that of the K8 
peptide, except that the R9 peptide is denser in charge. 
In term of the  gene silencing ability of the R9 siRNA complexes, however, unlike the 
finding  from  Kumar  and  co-workers  which  used  a  similar  arginine  based  peptide  and 
showed  gene  silencing  efficacy,  the  results  from  this  study  showed  that  these  siRNA 294
arginine based peptide complexes were not able to mediate gene silencing (Appendix IV). 
Nevertheless,  it  seemed  that  a  higher  charge  density  would  facilitate  siRNA  complex 
formation.
6.6 Conclusion and future work
This study showed that complex reagents need to have different properties for efficient 
DNA or siRNA delivery. For DNA delivery, the complex reagents need to form a positive 
surface charge complex with DNA to mediate cellular binding and uptake. Within the cells, 
the complex reagents need to mediate endosomal escape to allow the plasmid DNA to 
traffick to the nucleus for transcription. On the other hand, siRNA delivery has proven to be 
more challenging. It was found that even though some of the complex regents can form 
siRNA nanoparticles with positive surface charges, not all of them can mediate cellular 
uptake. The data presented in this study suggested that a large and branched structure of a 
complex reagent is an important feature for siRNA complex formation and delivery. 
In the future, further studies could be done to establish the effect of different branched 
structures on siRNA packaging and the effect of modifying the backbone of the polymer to 
improve the siRNA delivery efficiency and decrease toxicity. To enhance cellular uptake of 
the complex, a ligand or antibody could be conjugated with the polymer.  295
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Appendix II
pCI-luc
5693 bp
Ampicillin
Luciferase
Intron
F1 origin
Polyadenylation signal
Primer Bind 1
CMV IE promoter
T7 Promoter
NotI (2786)
HindIII (749)
HindIII (1080)320
Appendix II
pEGFP-N1
4733 bp
Polyadenylation signal
Polyadenylation signal
hCMV promoter
SV40 ori
pUC ori
f1 ori
eGFP
Kanamycin/Neomycin resistance gene321
Appendix III
GAPDH knockdown model for NIH 3T3 and HT1080 
The  GAPDH  knockdown  model  can  be  used  to  investigate  endogenous  gene 
knockdown. In this model, the cells were seeded 24 hours prior to transfection. Having 
prepared the siRNA complexes with siRNA targeting GAPDH in Optimem, the cells 
were transfected and the GAPDH levels were analysed 48 hours post-transfection. The 
cells  treated  with  irrelevant  siRNA  complexes  could  indicate  the  non-specific  gene 
silencing although cell toxicity could also decrease GAPDH activity. 
Figure I shows the results of the GAPDH knockdown on NIH 3T3 and HT1080 cells. 
The  percentage  of  relative  fluorescent  unit  (RFU)  refers  to  the  GAPDH  activity 
normalised  to  the  untreated  cell  control.  The  siRNA  transfection  complexes  were 
formed  using  a  commercial  reagent,  siLentfect,  and  siRNA  targeting  GAPDH 
(siGAPDH) or irrelevant siRNA (irr). The amount of the siLentfect and siRNA used per 
well in the 96 well plate were as indicated.
It was observed that the same complex formulation mediated different levels of gene 
silencing in different cell lines. As shown in Figure IA, 0.1µg siLentfect with 20 nM 
siGAPDH per well mediated around 80% GAPDH silencing in HT 1080 cells whereas 
the same complexes did not mediate any gene silencing in NIH 3T3 cells (Figure IB). 
In fact, 0.4 µg siLentfect with 20nM siGAPDH per well was needed to mediate 60% of 
GAPDH knockdown in NIH 3T3 cells. This indicated that different cell types would 
have different optimal complex formations for gene silencing. 322
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Figure  I  The  GAPDH  knockdown  model. 5  ×  10
4 cells  were  seeded  24  hours  prior  to 
transfection. siRNA transfection complexes were made by mixing siLecfect with siRNA for 30 
minutes in  Optimem. The  complexes were then overlaid onto the  cells for 24 hours.  After 
removing  the  transfection  complexes,  full  growth  medium  was  added  to  the  cells.  The 
remaining  GAPDH  activity relative  to  the  untreated  control  was  analysed  2  days  post-
transfection. (A) remaining GAPDH activity within NIH 3T3  cells.  (B) remaining GAPDH 
activity within HT1080 cells. siGAPDH refers to siRNA targeting GAPDH; irr refers to siRNA 
not targeting any mRNA in the cells. Percentage of RFU: the relative fluorescence unit (RFU) 
of the samples normalised with the RFU of the untreated control.323
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Appendix V
Appendix IV consists of four pages which showed the sequence of the arginine based 
peptide, the sizes of the arginine based peptide siRNA complexes, the gene silencing 
efficiency  of  the  arginine  based  peptide  siRNA  complexes,  localisation  of  siRNA 
mediated by the arginine based peptide complexes and plasmid delivery efficiency of 
the arginine based peptide.  325
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